SEARCH:      Monitor Keywords |  Custom RSS

Drug, bio-affecting and body treating compositions April category listing, related patent applications 04/10

20100104502 - Compositions and methods for detecting and treating endothelial dysfunction: The present invention relates to endothelial dysfunction. In particular, the present invention provides biomarkers of endothelial dysfunction (e.g., vascular disease), and compositions and methods of using the same. Compositions and methods of the present invention find use in, among other things, research, clinical, diagnostic, drug discovery, and therapeutic applications.... Agent: Casimir Jones, S.c.

20100104504 - Materials and methods for diagnosis, prevention and/or treatment of stress disorders and conditions associated with abeta peptide aggregation: The subject invention concerns materials and methods for detecting and diagnosing conditions associated with accumulation of Aβ peptide in neural tissue, such as Alzheimer's disease and Parkinson's disease, using the chemical cotinine. In one embodiment, the method comprises administering cotinine labeled with a detectable label to a person or animal.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100104503 - Modular nanoparticles for adaptable vaccines: Modular nanoparticle vaccine compositions and methods of making and using the same have been developed. Modular nanoparticle vaccine compositions comprise an antigen encapsulated in a polymeric particle and adaptor elements which modularly couple functional elements to the particle. The modular design of these vaccine compositions, which involves flexible addition and... Agent: Pabst Patent Group LLP

20100104506 - Nanoparticle-coated medical devices and formulations for treating vascular disease: Nanoparticle-coated medical devices, nanoparticle-containing formulations and methods of using for treating a vascular disease are disclosed. The medical device includes a coating that comprises a plurality of nanoparticles, wherein the nanoparticles comprise one or more bioactive agents encapsulated within, adhered to a surface of or integrated into the structure of... Agent: Squire, Sanders & Dempsey LLP

20100104501 - Prss23 as a biomarker, therapeutic and diagnostic target: The invention provides PRSS23, which is associated with cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The... Agent: Banner & Witcoff, Ltd.

20100104505 - System and method for quantitative molecular breast imaging: A system and method for performing quantitative lesion analysis in molecular breast imaging (MBI) using the opposing images of a slightly compressed breast that are obtained from the dual-head gamma camera. The method uses the shape of the pixel intensity profiles through each tumor to determine tumor diameter. Also, the... Agent: Quarles & Brady LLP

20100104507 - Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivo: Sterically stabilized cationic liposomes (SSCL) encapsulating a K type oligodeoxynucleotide (ODN) including a CpG motif are disclosed. These SSCL encapuslating a K type ODN can be used to effectively deliver the ODN to a cell. A novel method is also disclosed for producing the SSCL encapsulating the K type ODN.... Agent: Klarquist Sparkman, LLP

20100104509 - Human antibodies that bind cd19 and uses thereof: Human monoclonal antibodies that specifically bind to CD19 with high affinity are disclosed The antibodies are capable of internalizing into CD19-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided... Agent: Baker Botts L.L.P.

20100104508 - Human antibodies that bind cxcr4 and uses thereof: The present disclosure provides isolated monoclonal antibodies that specifically bind to CXCR4 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions... Agent: Lahive & Cockfield, LLP/medarex Floor 30, Suite 3000

20100104510 - Selenocysteine mediated hybrid antibody molecules: The invention provides methods and compositions employing hybrid molecules of a synthetic molecule and antibody or antibody fragment comprising a selenocysteine residue, wherein the synthetic molecule is covalently linked to the antibody or antibody fragment at the selenocysteine residue. The invention also provides a composition comprising a hybrid molecule as... Agent: Leydig, Voit & Mayer, Ltd.

20100104511 - Methods and compositions using chelator-antibody conjugates: Disclosed are pharmaceutical compositions that include a chelator and an antibody directed against a phosphorylation site of a protein, wherein the antibody is conjugated to the chelator to form a chelator-antibody conjugate. For example, the antibody may recognize a phosphorylated tyrosine residue or a phosphorylated serine residue of a cell... Agent: Fulbright & Jaworski L.L.P.

20100104512 - Dendritic chelated compounds, methods for making the same and pharmaceutical compositions containing the same: The invention relates to dendritic chelated compounds, to methods for producing the same and to pharmaceutical compositions containing the same. The dendritic chelated complexes of the present invention have the following formula (I): [[MC]En-[D]m—X1p1X2p2X3p3X4p4]z− z B+ (I), where m is a magnetic or scintigraphic marker, C is a chelating agent... Agent: Morgan Lewis & Bockius LLP

20100104513 - Method and system for dye assessment: The present disclosure generally relates to systems and methods for identifying the boundaries of tumors and assessing quantitatively the ability of dyes to highlight a tumor's boundary. In accordance with these methods and systems, images are taken of subjects administered agents labeled with dyes. After accessing the images, tumors are... Agent: General Electric Company Global Research

20100104514 - Nanoparticle clusters and methods for forming same: A method for providing nanoparticle clusters of controlled dimensions is described. The method involves an activation of individual nanoparticles and the subsequent interaction between activated particles to form a cluster.... Agent: Seed Intellectual Property Law Group PLLC

20100104515 - Use of alpha-hydroxy carbonyl compounds as reducing agents: There is provided the use as reducing agents of alpha-hydroxycarbonyl compounds capable of forming cyclic dimers. There is also provided corresponding methods of reducing reducible compounds, particularly reduction-activated prodrugs. Examples of the alpha-hydroxycarbonyl compounds used are dihydroxyacetone, glycolaldehyde, glyceraldehyde, erythrose, xylulose, erythrulose or 3-hydroxy-2-butanone.... Agent: Morrison & Foerster LLP

20100104516 - Use of flagellin to prevent and treat gram negative bacterial infection: The disclosure describes use of flagellin polypeptides to induce tolerance to gram negative bacteria, such as Pseudomonas aeruginosa, in order to alleviate the effects of the inflammatory response to bacterial infection in a patient. Also described are methods and compositions for treating and preventing keratitis, cystic fibrosis, asthma, and other... Agent: Davis Wright Tremaine, LLP/seattle

20100104517 - Anhydrous antiperspirant compositions: An anhydrous aerosol antiperspirant composition comprising a concentrate comprising at least about 40%, by weight of the concentrate, of an alcohol; an antiperspirant active dissolved in the alcohol; and at least one volatile silicone oil that is miscible in the alcohol and antiperspirant active solution and that has a viscosity... Agent: The Procter & Gamble Company Global Legal Department - Ip

20100104518 - Chewing gum, confection, and other oral delivery vehicles containing a traditional chinese medicine or extract thereof: A method for producing a chewing gum with a controlled release traditional Chinese medicine active agent, as well as the chewing gum so produced, is obtained by physically modifying the release properties of the traditional Chinese medicine active agent by coating and drying. The traditional Chinese medicine active agent is... Agent: Wrigley & Dreyfus 28455 Brinks Hofer Gilson & Lione

20100104519 - Teeth whitening functional materials delivery system: The present invention relates to a tooth whitening agent delivery system, more particularly, to a tooth whitening composition comprising an adhesive polymer, a tooth whitening active material, a material for promoting penetration of the tooth whitening active material, a hydrophobic surfactant, a stabilizer, an antioxidant, an antihypersensitive agent, pyrophosphate and... Agent: Moore & Van Allen PLLC

20100104522 - Compostion for skin external use containing omega-3 fatty acid: Stable preparations containing omega-3 fatty acid as an effective ingredient are disclosed. Further, uses of omega-3 fatty acid in preventing or alleviating skin aging, moisturizing skin, improving skin roughness, restoring or strengthening skin barrier function, improving skin elasticity, recovering or preventing skin damage induced by UV are disclosed.... Agent: Merchant & Gould PC

20100104521 - Cosmetic and/or pharmaceutical composition comprising as an active principle at least one peptide and use of this peptide: A cosmetic and/or pharmaceutical composition contains, as an active ingredient, at least one peptide from SEQ ID No1 to SEQ ID No8. The use of this peptide as an active ingredient for preparing compositions for inducing, increasing or restoring melanin synthesis in melanocytes of the skin or dermal papilla is... Agent: Young & Thompson

20100104520 - Cosmetic or dermatological composition in the form of an oil-in-water or water-in-oil-in-water emulsion comprising a heat-induced gelling polymer, a water-miscible volatile organic solvent and an organic uv-screening agent: Cosmetic or dermatological composition in the form of an oil-in-water or water-in-oil-in-water emulsion comprising a heat-induced gelling polymer, a water-miscible volatile organic solvent and an organic UV-screening agent The present invention relates to a cosmetic or dermatological composition in the form of an oil-in-water emulsion or of water-in-oil-in-water multiple emulsion,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100104523 - Stabilization of uv-sensitive active ingredients: Disclosed is the use of merocyanine derivatives of formula (1) for stabilizing UV-sensitive active ingredients like dibenzoylmethane derivatives.... Agent: Ciba Corporation Patent Department

20100104524 - Cosmetic composition for skin whitening comprising arctiin, arctigenin or the mixture thereof as active: Present Invention relates to a skin whitening cosmetic composition comprising arctiin, arctigenin or a mixture thereof as an active ingredient. The disclosed composition can control or inhibit the synthesis of melanin by acting on a melanin synthesis route of α-MSH secreted by UV, and thus show an excellent whitening effect... Agent: Nixon & Vanderhye, PC

20100104526 - Deodorizing system: A deodorizing system capable of reducing malodors in confined spaces such as bathrooms, kitchens, cars and cellars. More specifically, it is provided a kit comprising a moisture-permeable, water-impervious sachet and a perfume composition, wherein said sachet comprises a solid composition comprising a hypohalite bleach and/or a peroxygen bleach.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20100104525 - Use of fragrance compositions for the prevention of the development of indole base malodours from fecal and urine based soils: The present invention relates to the use of fragrance compositions, said fragrance compositions comprising fragrance compounds selected among: aldehydes, α,β-unsaturated aldehydes, alcohols, ketones, and mixtures thereof in any home and personal care product, each fragrance compound being able to restrict the formation of indole to less than 0.01 ppm (wt/wt)... Agent: Merchant & Gould PC

20100104528 - Contact lens solution with a tertiary amine oxide: an antimicrobial component selected from the group consisting of biguanides, polymeric biguanides, quaternium ammonium compounds, hydrogen peroxide or a stabilized form of peroxide and any one mixture thereof. The solution has no anionic surfactant or less than 30 ppm of anionic surfactant. The invention is also directed to the use... Agent: Bausch & Lomb Incorporated

20100104527 - Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties: The present invention is directed to methods of removing potassium or treating hyperkalemia by administering pharmaceutical compositions of crosslinked cation exchange polymers having beneficial physical properties, including combinations of particle size, particle shape, particle size distribution, viscosity, yield stress, compressibility, surface morphology, and/or swelling ratio.... Agent: Senniger Powers LLP (rly)

20100104530 - Anti-vpac1 antibodies and their uses: Monoclonal antibodies, in particular monoclonal antibodies to the VPAC1 receptor protein, compositions containing them and nucleic acid sequences encoding them. Host cells expressing said monoclonal antibodies, recombinant (expression) vectors and methods for producing said antibodies. Prevention or treatment of thrombocytopenia with antibodies to the VPAC1 receptor.... Agent: Nixon & Vanderhye, PC

20100104531 - Homogeneous preparations of il-28 and il-29: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity... Agent: Zymogenetics, Inc. Intellectual Property Department

20100104529 - Tnf-alpha vaccine for treating disease conditions mediated by pathological tnf-alpha: The present invention provide TNFα-defensin/chemokine fusion polypeptides and polynucleotides and methods of treating, inhibiting or preventing disease conditions mediated by pathological TNFα, including chronic neuropathic pain, chronic inflammation, insulin resistance, diabetes, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia and artherosclerosis, by administering a therapeutically effective amount of the TNFα-defensin/chemokine fusion polypeptides and polynucleotides.... Agent: Townsend And Townsend And Crew, LLP

20100104532 - Nucleoside analogs for antiviral treatment: The invention provides unsaturated phosphonates of Formula I or a tautomer or pharmaceutically accepatble salt thereof, as described herein, as well as pharmaceutical compositions comprising the compounds, and therapeutic methods comprising administering the compounds. The compounds have anti-viral properties and are useful for treating viral infections (e.g. HCV) in animals... Agent: Gilead Sciences Inc

20100104533 - Early intervention of viral infection with immune activators: Symptoms of viral infection are mitigated by administering to a subject exposed to a virus a protective or symptom-mitigating amount of a dsRNA and continuing administration until the subject's symptoms have improved.... Agent: Nixon & Vanderhye, PC

20100104534 - Hydrazido-peptides as inhibitors of hcv ns3-protease: The present invention discloses novel compounds, which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.... Agent: Merck Patent Department (k-6-1, 1990)

20100104535 - Methods of treating anemia using recombinant adeno-associated virus virions: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue in the treatment of anemia is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the... Agent: Robins & Pasternak

20100104536 - P38 inhibitors: The invention relates to novel p38 MAPK inhibitor which involves Mycobacterium w and/or its constituents in pharmaceutically acceptable carriers and their uses. Mycobacterium w and/or its constituents when administered to mammal results in p38 inhibition The inhibition is found to last more than 28 days. It is also found to... Agent: Darby & Darby P.C.

20100104545 - Nutritional composition to promote healthy development and growth: A nutritional composition having a lipid or fat; a protein source; a source of long chain polyunsaturated fatty acids which comprises docosahexanoic acid; and up to about 2.5% by weight of a source of supplemental calcium which, when dissociated, provides a cation having prebiotic functionality.... Agent: Waddey & Patterson, P.C.

20100104538 - Beneficial effects of bacteriophage treatments: The invention relates to use of one or more bacteriophages in vivoin a human or animal in order to induce sensitivity to chemical antibiotics in bacterial cells, where such susceptibility is heritable, independent of continuing bacteriophage metabolism within those cells, and does not relate to the destruction of a biofilm... Agent: Evan Law Group LLC

20100104537 - Methods of treating parkinson's disease using viral vectors: Methods of delivering viral vectors, particularly recombinant AAV virions, to the CNS are provided. Also provided are methods of treating Parkinson's Disease.... Agent: Robins & Pasternak

20100104542 - Cell transplantation: The present invention provides polymers for use in preventing damage to the membranes of cells in fat grafts. Mixing of a triblock copolymer such as poloxymer P188 with adipocytes or adipose tissue to be transplanted into a subject is thought to stabilize the membranes of the cells leading to more... Agent: Wolf Greenfield & Sacks, P.C.

20100104543 - Cellular compositions and methods of making and using them: The invention relates to cellular compositions comprising hematopoietic cells with the potential or increased potential to form non-hematopoietic cells; methods for producing such cellular compositions; methods for differentiation of cells of cellular compositions of the invention into cells that exhibit morphological, physiological, functional, and/or immunological features of non-hematopoietic cells; and... Agent: Howson & Howson LLP

20100104541 - Method for preventing and treating cardiovascular diseases with brca1: Methods for inhibiting cardiomyocyte apoptosis and/or to improving cardiac function and inhibiting inflammation-induced apoptosis in endothelial cells by delivering BRCA1 are provided. Such methods are useful in treatment and prevention of cardiovascular diseases.... Agent: Licata & Tyrrell P.C.

20100104540 - Methods and compositions for treatment of fibrosis: Treatment methods and compositions for the treatment of fibrosis are provided. In some embodiments, these methods include augmentation of dendritic cells for treatment of fibrosis. In some embodiments, fms-like tyrosine kinase 3 ligand (Flt3L) is used for the treatment of fibrosis and/or the augmentation of dendritic cells. In certain embodiments,... Agent: Darby & Darby P.C.

20100104539 - Placental tissue grafts and improved methods of preparing and using the same: Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more... Agent: Gardner Groff Greenwald & Villanueva. PC

20100104544 - Selective cell therapy for the treatment of renal failure: Provided herein are isolated populations of kidney cells harvested from differentiated cells of the kidney, wherein the cells have been expanded in vitro. The kidney cells preferably produce erythropoietin (EPO). The kidney cells may also be selected based upon EPO production. Methods of producing an isolated population of EPO producing... Agent: Myers Bigel Sibley & Sajovec

20100104546 - Modulators of antigen-dependent t cell proliferation: The present invention relates to a method of inhibiting antigen-dependent proliferation of T-cells in a subject without substantially inhibiting mitogen-dependent proliferation of T-cells in the subject. The method includes administering to the subject an effective amount of a polyunsaturated fatty acid, or a salt or derivative of a polyunsaturated fatty... Agent: Brown & Michaels, PC 400 M & T Bank Building

20100104547 - Topical composition for the treatment of allergenic effects: A topical composition for treating stings and insect bites effectively significantly reducing pain and/or eliminating it (wiping away pain, or WAP) is disclosed comprising a stabilized proteonaise, antibacterial/anti-microbial, a cooling agent, an anti-inflammatory agent, a debriding agent and an exfoliating agent.... Agent: Stetina Brunda Garred & Brucker

20100104548 - Modulation of amino acid metabolism in the hypothalamus: Methods for reducing peripheral blood glucose levels, food intake, glucose production, gluconeogenesis, triglyceride levels, and low density lipoprotein (VLDL) levels in mammals are provided. Also provided are methods of increasing glucose production and food intake in mammals. Further provided are methods of treating a disorder selected from the group consisting... Agent: Amster, Rothstein & Ebenstein LLP

20100104549 - Glufosfamide combination therapy: The co-administration of glufosfamide and a glucose lowering drug other than insulin is efficacious in cancer treatment.... Agent: Townsend And Townsend And Crew, LLP

20100104550 - Cleavage of bip by subtilase cytotoxin: Cleavage of BIP (Immunoglobulin binding protein) by subtilase toxin and its application to inhibiting growth of or killing of cells. This has application to treatment of cancers and to conformational diseases and in particular to conformational diseases involving BiP that are influenced by cleavage by the subtilase cytotoxin. The invention... Agent: Coleman Sudol Sapone, P.C.

20100104551 - Method for prolonging activity of autodegradable enzymes and compositions thereof: A composition of a long-acting enzyme comprises the enzyme in a formulation comprising a buffer and an additive selected from the group consisting of tranexamic acid, ε-aminocaproic acid, and analogs of L-lysine other than tranexamic acid and ε-aminocaproic acid, combinations thereof, and mixtures thereof. The composition can further comprise another... Agent: Womble Carlyle Sandridge & Rice, PLLC

20100104552 - Antibiotic synergism: The present invention relates to antibiotic synergism of pharmaceutical compositions comprising a defensin and a beta-lactam antibiotic.... Agent: Novozymes North America, Inc.

20100104553 - Antibodies and methods for making and using them: The invention provides antibodies, including chimeric human antibodies, recombinant antibodies, synthetic antibodies, and the nucleic acids encoding them, and methods for making and using these immunoglobulins. The invention provides recombinant and synthetic polypeptide and nucleic acid embodiments of these polypeptides and/or antibodies. The invention also provides polypeptides comprising, or consisting... Agent: Mckee, Voorhees & Sease, P.L.C

20100104560 - Botulinum neurotoxin e receptors and uses thereof: An isolated polypeptide comprising an amino acid sequence selected from amino acids 506-582 of SV2A, wherein position 573 is N and is glycosylated, or amino acids 449-525 of SV2B, wherein position 516 is N and is glycosylated. The present invention also provides an antibody that binds specifically to the polypeptide,... Agent: Kening Li Pinsent Masons LLP

20100104556 - Epitope-tag for surface-expressed proteins and uses thereof: The present invention relates to a method for selecting a host cell population expressing a functional fusion protein comprising at least one epitope-providing amino acid sequence (epitope-tag) and the amino acid sequence of a protein that is expressed on the surface of said host cell. Preferably, the amino acid sequence... Agent: David S. Resnick

20100104555 - Hcv neutralizing epitopes: The invention relates to modified hepatitis C virus E2 polypeptides that are effective in eliciting the production of cross-neutralizing antibodies against hepatitis C virus. The invention provides modified hepatitis C virus E2 polypeptides, preparations and pharmaceutical compositions containing them, as well as methods for using these modified E2 polypeptides.... Agent: K&l Gates LLP

20100104557 - Optimized antibodies that target hm1.24: The present disclosure describes antibodies that target HM1.24. In various aspects, the antibodies have specific CDR, variable, or full length sequences, have modifications with the parent antibody, or include at least one one modification relative to a parent antibody that alters affinity to an FcγR or alters effector function as... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20100104554 - Peptide and uses thereof: A method of inhibiting activity of a cathepsin L-like protease in cells or tissue and the use of the method in the treatment of disease such as cancer and inflammatory diseases is described. The method comprises administration of a cathepsin propeptide or a nucleic acid encoding a cathepsin propeptide. In... Agent: Ip Group Of Dla Piper LLP (us)

20100104561 - Tyrosine-modified recombinant raav vector compositions and methods for use: Disclosed are tyrosine-modified rAAV vectors, as well as infectious virions, compositions, and pharmaceutical formulations that comprise them. Also disclosed are methods of preparing and methods for using the disclosed tyrosine-phosphorylated capsid protein mutant rAAV vectors in a variety of diagnostic and therapeutic applications including in vivo and ex vivo gene... Agent: Haynes And Boone, LLPIPSection

20100104559 - Us cip-compositions and methods for modulating responses mediated or associated with btla activity: Herpesvirus entry mediator (HVEM) is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and acts as a molecular switch that modulates T cell activation by propagating positive signals from the TNF related ligand, LIGHT (p30, TNFSF14), or inhibitory signals through the immunoglobulin superfamily member, B and T lymphocyte... Agent: Pillsbury Winthrop Shaw Pittman LLP

20100104558 - Use of an egfr antagonist for the treatment of glomerolonephritis: The present invention relates to uses, methods and compositions for treating immune-mediated glomerulonephritis, such as crescentic glomerulonephritis. More specifically, the invention relates to the use of an EFGR antagonist or of an inhibitor of EGFR or HB-EGF expression for the treatment of said diseases.... Agent: Mcandrews Held & Malloy, Ltd

20100104562 - Enhancing efficacy of vaccines administered via the respiratory tract: Disclosed herein are vaccine compositions comprising live attenuated virus with anti-antibody to improve efficacy. Specifically exemplified herein is a composition comprising live attenuated cold adapted influenza virus and an enhancing amount of IgG anti-IgA antibody to temporarily inactivate IgA defenses. Also disclosed herein are methods of immunizing a subject to... Agent: Beusse Wolter Sanks Mora & Maire

20100104564 - Altered antibody fc regions and uses thereof: The present invention relates to altered antibody Fc regions and uses thereof.... Agent: Baker Botts L.L.P.

20100104568 - Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders: The present invention relates to amino acid sequences that are directed against RANK-L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid... Agent: Wolf Greenfield & Sacks, P.C.

20100104563 - Antibodies that bind il-18 and methods of inhibiting il-18 activity: Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of... Agent: Abbott Bioresearch

20100104571 - Antibody-mediated modulation of allergy: The present invention is drawn to antibody-mediated modulation of allergy. In this regard, the present invention discloses a monoclonal antibody, antigen-binding fragment or mimic thereof directed against Group 1 pollen allergens or homologues thereof. Also disclosed herein is the mechanism by which the disclosed monoclonal antibody, antigen binding fragment or... Agent: Benjamin Aaron Adler Adler & Associates

20100104566 - Antitumor combination comprising a morpholinyl anthracycline and an antibody: The present invention provides the combined use of a morpholinyl anthracycline derivative of formula (I) or a pharmaceutically acceptable salt thereof, such as nemorubicin hydrochloride, and an antibody inhibiting a growth factor or its receptor, in the treatment of tumors. Also provided is the use of the said combinations in... Agent: Scully Scott Murphy & Presser, PC

20100104565 - Combinations comprising dmxaa for the treatment of cancer: The present invention relates to combinations of the xanthenone acetic acids class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and EGFR signalling pathway inhibitors. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations.... Agent: Foley & Lardner LLP

20100104569 - Humanized antibodies to interferon alpha receptor-1 (ifnar-1): Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.... Agent: Baker Botts L.L.P.

20100104567 - Pharmaceutical composition: [wherein —X—Y—Z— represents —O—CR17═N— (wherein R17 represents a hydrogen atom, lower alkyl, or the like), R15 represents —NR22aR22b (wherein R22a and R22b may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like), and R16 represents —NR24aR24b (wherein R24a and R24b... Agent: Fitzpatrick Cella Harper & Scinto

20100104570 - Semaphorin 7a plays a critical role in tgf-beta1-induced pulmonary fibrosis and alveolar destruction: The present invention provides methods of treating a subject diagnosed with, or at risk for developing, pathogenic fibrosis, particularly pulmonary fibrosis. The method of the invention comprises administering to the subject a compound or composition which inhibits semaphorin (SEMA) 7A, SEMA 7A receptors, or downstream effectors. A SEMA 7A inhibitor... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100104572 - Methods for screening for therapeutic molecules and use of the molecules therefrom: The present invention relates in general to the field of cancer diagnostics and treatment. In particular, the present invention provides methods for identifying diagnostic and therapeutic molecules that bind to a carbohydrate antigen on the surface of a cancer cell and induce cell death, to pharmaceutical compositions comprising the molecules... Agent: Fennemore Craig

20100104573 - Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable... Agent: Ropes & Gray LLP

20100104574 - Frizzled-binding agents and uses thereof: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100104576 - Mammalian genes; related reagents and methods: Nucleic acids encoding mammalian, e.g., primate or rodent, genes, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.... Agent: Merck C/o Schering-plough Biopharma

20100104575 - Polynucleotides and polypeptide sequences involved in the process of bone remodeling: This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling; variants and derivatives of the polynucleotides and corresponding polypeptides; uses of the polynucleotides, polypeptides, variants and derivatives; and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders.... Agent: Choate, Hall & Stewart LLP

20100104578 - Method and composition for treatment of neoplasms: The invention relates to methods of treating a neoplasm in an animal, in particular treating a neoplasm in a human, through the use of isolated nucleic acid sequence, including synthetic viral RNA and complementary DNA, derived from one or more Picornaviruses. The invention also relates to compositions of isolated nucleic... Agent: Seed Intellectual Property Law Group PLLC

20100104577 - Methods and materials related to anti-a (beta) antibodies: This document provides methods and materials related to anti-Aβ antibodies. For example, anti-Aβ antibodies, methods for making anti-Aβ antibodies, and methods for using an anti-Aβ antibody to treat or prevent an amyloid condition (e.g., AD).... Agent: Fish & Richardson P.C.

20100104579 - Trex1 as a marker for lupus erythematosus: The present invention relates a method of diagnosing lupus erythematosus or related autoimmune diseases in a human, said method comprising at least one of detecting a genetic variant, a mutation or polymorphism in the gene encoding for TREX1, detecting a change in the biochemical activity of TREX1, and detecting a... Agent: David S. Resnick

20100104580 - Altered immunogenic landscape in hiv-1 envelope proteins: The present invention provides compositions and methods useful in the prevention and treatment of HIV-1 infection in a host subject. High affinity binding of an allosteric dual antagonist to HIV-1 gp120 induces a conformational change in the gp 120 protein that traps the gp 120 protein in a three-dimensional structure... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100104582 - Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts: Disclosed are methods and compositions relating to CD200 and its receptor, CD200R which modulate bone mass via the differentiation of osteoclasts.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100104583 - Gene polymorphisms in vegf and vegf receptor 2 as markers for cancer therapy: The invention provides compositions and methods for determining the likelihood of successful treatment with anti-angiogenic antibodies or equivalent thereof, in combination with a pyrimidine based antimetabolite and a platinum-based alkylating agent based therapy. The methods comprise determining the genomic polymorphism present in a predetermined region of a gene of interest... Agent: Foley & Lardner LLP

20100104584 - Genes involved in mitochondrial biogenesis: The invention discloses suitable gene and polypeptide targets for the development of new therapeutics to treat, prevent or ameliorate conditions associated with mitochondrial dysfunction. The invention also relates to methods to treat, prevent or ameliorate said conditions and pharmaceutical compositions therefor, as well as to a method to identify compounds... Agent: Novartis Institutes For Biomedical Research, Inc.

20100104585 - Methods and reagents for regulation of cellular responses in biological systems: Multivalent ligands which carry or display at least one recognition element (RE), and preferably a plurality of recognition elements, for binding directly or indirectly to cells or other biological particles or more generally by binding to any biological molecule. The multivalent ligands provided can function for binding or targeting to... Agent: Greenlee Winner And Sullivan P C

20100104581 - Methods for diagnosing and treating graft rejection and inflammatory conditions: The present invention relates to a method of diagnosis and/or prognosis of an inflammatory condition, which method comprises determining the expression level of TRIB1 in a biological sample of a patient, in particular in peripheral blood or in a biopsy of a diseased tissue. Methods for treating inflammatory conditions by... Agent: Occhiuti Rohlicek & Tsao, LLP

20100104587 - Methods of modulating the negative chemotaxis of immune cells: The current invention is directed to methods of inducing migration of an immune cell toward a cancer cell comprising inhibiting the activity of a chemorepellant released from the cancer cell.... Agent: Elmore Patent Law Group, PC

20100104586 - Treatment of carcinomas with a combination of egf-pathway and telomerase inhibitors: A method and kit for inhibiting the proliferation of carcinoma cells are disclosed, based on a combination of an EGF pathway inhibitor and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with the antibody alone or the telomerase inhibitor... Agent: Geron Corporation Attn. David J. Earp

20100104588 - Serum albumin binding peptides for tumor targeting: Peptide ligands having affinity for serum albumin are useful for tumor targeting. Conjugate molecules comprising a serum albumin binding peptide fused to a biologically active molecule demonstrate modified pharmacokinetic properties as compared with the biologically active molecule alone, including tissue (e.g., tumor) uptake, infiltration, and diffusion.... Agent: Arnold & Porter LLP (24126) Attn:IPDocketing Dept.

20100104589 - Immunoconjugates with an intracellularly-cleavable linkage: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.... Agent: Immunomedics, Inc.

20100104590 - Alpha-galactosylceramide derivatives, pharmaceutically acceptable salts thereof, preparation method and pharmaceutical composition for the immune adjuvant containing the same as an active ingredient: Disclosed are novel α-galactosylceramide derivatives, pharmaceutically acceptable salts thereof, preparation methods thereof, and pharmaceutical compositions for use in an immune adjuvant containing the same as an active ingredient. The derivatives, in which the amide moiety of α-GalCer is bioisosterically replaced with a triazole moiety, direct cytokine secretion toward IL-4 rather... Agent: Greenlee Winner And Sullivan P C

20100104592 - Hepatitis c virus codon optimized non-structural ns3/4a fusion gene: Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions... Agent: Knobbe Martens Olson & Bear LLP

20100104591 - Polypeptides for inducing a protective immune response against staphylococcus epidermidis: The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1 and uses of such polypeptides. SEQ ID NO: 1 is a truncated derivative of a full-length S. epidermidis polypeptide. The full-length naturally occurring polypeptide is referred to herein as full-length ORF2695e. A His-tagged... Agent: Merck

20100104593 - Meningococcal conjugate vaccination: Conjugated meningococcal capsular saccharides will be introduced into immunisation schedules in the near future, but the phenomenon of “carrier suppression” must first be addressed, particularly where multiple conjugates are to be used. In the invention, tetanus toxoid is used as the carrier protein, even where multiple meningococcal conjugates are administered... Agent: Novartis Vaccines And Diagnostics Inc.

20100104594 - Pathogen for bacterial poultry disease: The invention belongs to the field of animal health and in particular the causative agent of a new bacterial poultry disease, Gallibacterium. The invention provides said Gallibacterium bacteria, vaccine comprising inactivated Gallibacterium, and a method of immunizing to prevent disease in poultry.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100104595 - Lyophilized preparation comprising influenza vaccine, and method for preparation thereof: e

20100104596 - Acutte transmitted hiv envelope signatures: The present invention relates, in general, to human immunodeficiency virus (HIV) and, in particular, to a method of inducing an immune response to HIV in a patient and to immunogens suitable for use in such a method. The invention also relates to diagnostic test kits and methods of using same.... Agent: Nixon & Vanderhye, PC

20100104598 - Development of dengue virus vaccine components: The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3′ untranslated region (3′-UTR) comprising a Δ30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the Δ30... Agent: Edwards Angell Palmer & Dodge LLP

20100104597 - N-linked glycosylation alteration in e0 and e2 glycoprotein of classical swine fever virus and novel classical swine fever virus vaccine: E2 is one of the three envelope glycoproteins of Classical Swine Fever Virus (CSFV). E2 is involved in several functions including virus attachment and entry to target cells, production of antibodies, induction of protective immune response in swine, and virulence. Seven putative glycosylation sites in E2 were modified by site... Agent: Usda, Ars, Ott

20100104599 - Compositions and methods for enhancing immune system of felines: Compositions and methods useful to enhance the development of the immune system of a growing animal are disclosed.... Agent: Colgate-palmolive Company

20100104600 - Methods and compositions for increasing tissue tropism of recombinant adenoviral vectors: Methods are provide to allow for the preparation of adenoviral vectors with altered tropism. Compositions comprising such vectors and methods of use thereof also are provided.... Agent: Mcandrews Held & Malloy, Ltd

20100104601 - Treatment of immune disease by mucosal delivery of antigents using genetically modified lactobacillus: The present invention relates to the treatment of autoimmune and allergic diseases by mucosal delivery by micro-organism, in particular Lactococcus lactis, of secreted immunodominant antigens.... Agent: Traskbritt, P.C.

20100104602 - Neurotoxin therapy for postprandial hyperglycemia: Botulinum toxin is increasingly being injected into visceral smooth muscle for a variety of indications. The present invention discloses intragastric administration of botulinum toxin to delay gastric emptying with the aim of inducing satiety and promoting weight-loss. The present invention also discloses the effects of intragastric administration of Botulinum toxin... Agent: Dr. Benjamin Adler Adler & Associates

20100104603 - Use of staphylococcal superantigen-like protein 5 (ssl5) in medicine: The present invention relates to Staphylococcal superantigen-like protein 5 (SSL5) or homologues or derivatives thereof for use in medicine, in particular for use in the treatment of indications involving an excessive recruitment of leukocytes, such as stroke, perfusion/ischemia, transplant rejection, rheumatoid arthritis. The invention further relates to a pharmaceutical composition... Agent: Bozicevic, Field & Francis LLP

20100104604 - Compositions and methods to elicit immune responses against pathogenic organisms using yeast based vaccines: Embodiments of the present invention illustrate methods of treating and preventing infection due to a pathogen such as a fungal pathogen. In particular, the present invention relates to compositions and methods for vaccinations against or treatment for a fungal organism in a non-immunocompromised or immunocompromised subject.... Agent: Sheridan Ross P.C.

20100104605 - Method for preventing and treating influenza: The present invention provides a method for making pressure-induced ganoderma spores, for using the pressure-induced ganoderma spores to ameliorate and/or prevent influenza in a mammal; and to stimulating the host immune system in a mammal. The method for making the pressure-induced ganoderma spores includes (1) soaking ganoderma spores in a... Agent: Andrews Kurth LLP

20100104606 - Allergen fragments: The present invention relates to a peptide derived from the ragweed pollen allergen Amb a (1) and comprising (6 to 50) amino acid residues and pharmaceutical preparations comprising said peptide and uses thereof.... Agent: Chalker Flores, LLP

20100104607 - Anti-bacterial peptides and methods of treating diseases using same: Isolated peptides comprising no more than ten amino acids and having anti-bacterial properties are disclosed. In one embodiment the peptides have a consensus amino acid sequence X1X2X3X4X5, wherein X1 and X5 comprise polar amino acids. In another embodiment, the peptides have a consensus amino acid sequence X1X2X3X4X5, wherein X2 and... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100104608 - Reactive surgical implant: Biocompatible implants include a polymer substrate and a reactive component selectively applied to the substrate. The reactive component in combination with the substrate creates crosslinked regions on a surface of the substrate. The crosslinked regions may provide a visual aid and/or stiffening element to the implant.... Agent: Tyco Healthcare Group Lp

20100104611 - Antiperspirant compositions: Anhydrous antiperspirant compositions comprising particulate antiperspirant active; capsules comprising a shear-sensitive shell which encapsulates perfume; and a carrier for the particulate antiperspirant active and capsules; wherein the capsules have a shell of cross-linked gelatin coacervate having a thickness of from 0.25 to 9 μm and providing from 10 to 40%... Agent: Unilever Patent Group

20100104612 - Antiperspirant compositions: Fragrance leaches rapidly from capsules having shells made from cross linked gelatin into volatile silicone oils. Unfortunately such oils are much favoured for anhydrous antiperspirant compositions. The rate and extent of leaching can be ameliorated greatly or nearly halted by employing as carrier oil, an ester oil or an ether... Agent: Unilever Patent Group

20100104613 - Antiperspirant or deodorant compositions: a

20100104610 - Color cosmetics comprising a random terpolymer:

20100104609 - Hair cosmetic composition:

20100104615 - Absorbent article comprising lactic acid producing bacteria: The present invention relates to absorbent articles comprising at least a liquid acquisition layer and an underlying liquid storage layer, said absorbent article comprising lactic acid producing bacteria. The lactic acid producing bacteria are dispersed in a hydrophobic carrier and the article further comprises at least one super-absorbent polymer. At... Agent: Birch Stewart Kolasch & Birch

20100104614 - Providone compositions for wound healing: Described here are wound dressings and kits. The wound dressings include povidone compositions that may be directly applied to wound surfaces or provided on substrates to form a composite material. The povidone compositions contain a povidone polymer, where the povidone polymer itself is capable of healing wounds. The povidone compositions... Agent: Morrison & Foerster LLP

20100104616 - Process: s

20100104618 - Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use: Surgically implantable drug delivery systems for long-term delivery of haloperidol containing a biodegradable polymer and haloperidol fabricated into the surgically implantable drug delivery systems via solvent casting and compression molding are provided. Also provided are methods for producing the surgically implantable drug delivery systems and methods for using these systems... Agent: Pearl Cohen Zedek Latzer, LLP

20100104617 - Graft prosthesis, materials and methods: A graft prostheses (11), materials and method for implanting, transplanting, replacing, or repairing a part of a patient. The graft prosthesis includes a purified, collagen-based matrix structure removed from a submucosa tissue source. The submucosa tissue source is purified by disinfection and removal steps to deactivate and remove contaminants, thereby... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20100104619 - Delivery system for a non-steroidal non-ionized hydrophilic drug: This invention relates to an extended release formulation comprising a solid non-steroidal non-ionized hydrophilic drug, having a molecular weight below 500 Dalton and having a solubility of at least 0.1 wt % in ethylene vinyl acetate copolymer having a vinyl acetate content of 28%, which formulation is a vaginal device... Agent: Organon Usa, Inc. C/o Merck

20100104620 - Over-coated product including tableted center and medicament: Methods and products for delivering a medicament or agent to an individual are provided as well as methods for producing the product. The product includes a coating having a medicament or agent. The medicament or agent is present within the coating that surrounds a tableted center. The tableted center is... Agent: K&l Gates LLP

20100104621 - Treating adhd and other diseases involving inflammation: The present disclosure relates to methods and drug delivery systems for treating diseases involving inflammation, including Attention Deficit Hyperactivity Disorder (ADHD) by administering a CNS stimulant to a patient in need thereof so as to maintain steady state serum drug levels that remain therapeutically effective for about 24 and ½... Agent: Overhauser & Lindman

20100104628 - method of treating neuroblastoma: The present invention relates, in general, to neuroblastoma and, in particular, to a method of treating neuroblastoma tumors, including refractory neuroblastoma tumors. The invention also relates to compounds and compositions suitable for use in such a method.... Agent: Banner & Witcoff, Ltd.

20100104623 - Agent for enhancing the resistance of liposome against biological component, and liposome modified with the agent: (b) A peptide comprising an amino acid sequence represented by SEQ ID No: 1 or 2, in which one or more amino acids are deleted, substituted or added, and having an activity for promoting lipid membrane fusion under acidic condition. An agent for enhancing the resistance of liposome against biological... Agent: Quinn Emanuel Koda & Androlia

20100104625 - Biodegradable compositions and materials: The present invention provides compounds of Formula I, materials comprising one or more compounds of Formula I and one or more biologically active agents, pharmaceutical compositions comprising an inventive material and a pharmaceutically acceptable excipient, methods of making compounds of Formula I, methods of making inventive materials, and methods of... Agent: Choate, Hall & Stewart LLP

20100104629 - Cationic lipids and uses thereof: Cationic lipids, cationic lipid based drug delivery systems, ways to make them and methods of treating diseases using them are disclosed.... Agent: Paul D. Yasger Abbott Laboratories

20100104624 - Combination therapy using phosphodiesterase inhibitors: Described here are compositions and methods for treating side-effects of vasodilator therapy. The compositions may include both a vasodilator and a side-effect alleviating agent in a single dosage form. Alternatively, the vasodilator and side-effect alleviating agent may be formulated separately, each in its own dosage form. The compositions may be... Agent: Goodwin Procter LLP

20100104632 - Drug having regulatory cell ligand contained in liposome: A liposome containing a regulatory cell ligand such as α-galactosyl ceramide or β-galactosyl ceramide is employed as the active ingredient of a drug for preventing or treating immune diseases etc.... Agent: Fitch, Even, Tabin & Flannery

20100104622 - Ligand targeted nanocapsules for the delivery of rnai and other agents: A carrier system for the delivery of therapeutic and/or diagnostic agents is described. The carrier system is comprised of ligands and a biodegradable polycation for complexing polyanionic molecules such as RNAi, said polycation forming a coating on the outer surface of anionic or neutral liposomes. Also disclosed is a method... Agent: Maurizio Cattaneo

20100104631 - Method of treatment for bladder dysfunction: Liposomes are used for intravesical drug delivery, especially delivery of botulinum toxin (BoNT) to help improve lower urinary tract symptoms by decreasing bladder irritation and frequency. The system uses a lower and safer dose of BoNT with lower risk of urinary retention. A simple instillation of liposome-BoNT as a liquid... Agent: Pabst Patent Group LLP

20100104626 - Methods and compositions for treating and diagnosing kidney disease: The invention relates to a method for diagnosing a kidney disease state. The method comprises the steps of administering to a patient a composition comprising a conjugate or complex of the general formula V-L-D where the group V comprises a vitamin receptor binding ligand that binds to kidney proximal tubule... Agent: Barnes & Thornburg LLP

20100104627 - Stable aqueous g-csf formulations: The invention relates to stable glutamate-buffered G-CSF formulations having a pH of from 3.5 to 4.8. The invention further concerns lyophilisates and powders obtainable from such formulations, and to pharmaceutical kits containing such lyophilisates and powders.... Agent: O''melveny & Myers LLP Ip&t Calendar Department La-13-a7

20100104633 - Topical terbinafine formulations and methods of administering same for the treatment of fungal infections: The present invention relates to topical antifungal formulations terbinafine or a pharmaceutically acceptable salt thereof, a lipid, and a surfactant, and uses thereof for the treatment of skin and nail fungal infections.... Agent: Jones Day

20100104630 - Water soluble statin microstructures and method of preparation: A method of preparing a water soluble microstructure includes the steps of providing a saturated solution of a payload with poor water solubility, providing a solution of helper molecules, and combining the saturated solution of the payload with the solution of helper molecules. The combined saturated solution of the payload... Agent: Robert A. Parsons

20100104634 - Pharmaceutical compositions of entacapone: The invention relates to pharmaceutical compositions comprising entacapone or pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparation of such compositions.... Agent: Bio Intellectual Property Services (bio Ips) LLC

20100104635 - Process for preparing granules of hydrophilic vitamins: The present invention relates to a process for preparing granules of a hydrophilic vitamin with polyvinylpyrrolidone as binder in a fluidized bed granulator, to the granules of a hydrophilic vitamin obtained by said process, to tablets made with said granules of a hydrophilic vitamin, to mixture of L-ascorbic acid for... Agent: Connolly Bove Lodge & Hutz, LLP

20100104636 - Pharmaceutical compound and composition: A pharmaceutical composition comprising rosiglitazone or a pharmaceutically acceptable salt thereof wherein said rosiglitazone has a median particle size diameter of about 5 microns to about 20 microns.... Agent: Summa, Additon & Ashe, P.A.

20100104637 - Tablet formulations containing 8-[-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom: Pharmaceutical formulations containing a salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, which are suitable for forming into a tablet dosage form, as well as tablet dosage forms are disclosed. Disclosed also are methods of treatment utilizing such dosage forms.... Agent: Monte Browder Opko Health Inc

20100104638 - Extended release oral acetaminophen/tramadol dosage form: An extended release oral administered dosage form of acetaminophen and tramadol. The dosage form includes a composition of acetaminophen together with a tramadol complex formed with an anionic polymer. The tramadol complex provides sustained release of tramadol for a synchronized (coordinated) release profile of acetaminophen and tramadol.... Agent: Philip S. Johnson Johnson & Johnson

20100104639 - Bupropion hydrobromide and therapeutic applications: Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100104640 - Pharmaceutical compositions comprising irbesartan: The present invention relates to a pharmaceutical composition comprising irbesartan.... Agent: Smith Patent Consulting, LLC

20100104641 - Therapeutic composition, and use of a cell-free substance: The invention relates to a therapeutic composition, a method for producing a therapeutic composition, and the use of a cell-free substance, especially a cell-free bone or cartilage matrix. The disclosed therapeutic composition comprises at least a cell-free substance obtained from stimulated stem cells and/or precursor cells. Immunogenic reactions during in... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20100104642 - Hydrophilic foam and pharmaceutical dosage form employing the same: Disclosed herein is a hydrophilic foam. The hydrophilic foam includes a polyurethane matrix having a plurality of cells. The cells are capable of retaining water in an amount of least about 8 grams of water per gram of the hydrophilic foam.... Agent: Muncy, Geissler, Olds & Lowe, PLLC

20100104643 - Pharmaceutical compositions: The present invention provides an orally deliverable pharmaceutical composition for the once-daily (OD) administration of trimipramine. The composition comprises a therapeutically effective amount of trimipramine and at least one pharmaceutically acceptable excipient. The compositions of the invention may exhibit one or more of the release profiles defined in this specification.... Agent: Panitch Schwarze Belisario & Nadel LLP

20100104650 - Charged mesoporous silica nanoparticle-based drug delivery system for controlled release and enhanced bioavailability: A charged mesoporous silica nanoparticle (MSN)-based drug delivery system for controlled release and enhanced bioavailability is disclosed. The system comprises a positively charged MSN, which has a silica matrix and an array of pores and/or nanochannels in the matrix. The entire substance of the matrix, all the surfaces and the... Agent: Ipc Intellectual Property Connections, Inc.

20100104644 - Compositions and methods for treating or preventing ophthalmic disease: Methods are disclosed for treating or preventing ophthalmic conditions related to a toxic visual cycle product. Compounds and compositions useful in these methods, either alone or in combination with other therapeutic agents, are also described, along with methods of screening for new agents useful in said the therapeutic and prophylactic... Agent: Edwards Angell Palmer & Dodge LLP

20100104647 - Hollow microparticles: The invention provides a process for making hollow microparticles. The process comprises providing a dispersion having a continuous aqueous phase and a discontinuous organic phase and polymerising a monomer in the dispersion to form hollow polymeric microparticles. The continuous aqueous phase of the dispersion comprises a stabiliser and the discontinuous... Agent: Townsend And Townsend And Crew, LLP

20100104649 - Lercanidipine hydrochloride polymorphs and an improved process for preparation of 1,1,n-trimethyl-n-(3,3-diphenylpropyl)-2-aminoethyl acetoacetate: Disclosed herein is an improved, commercially viable and industrially advantageous process for the preparation of substantially pure Lercanidipine intermediate, 1,1,N-trimethyl-N-(3,3-diphenylpropyl)-2-aminoethyl acetoacetate. The intermediate is useful for preparing Lercanidipine, or a pharmaceutically acceptable salt thereof, in high yield and purity. The present invention further provides a novel crystalline form of Lercanidipine... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100104645 - Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles: This application provides methods of making nanoparticles using pre-functionalized poly(ethylene glycol) (also referred to as PEG) as a macroinitiator for the synthesis of diblock copolymers. These diblock copolymers comprise a poly(ethylene glycol) block bearing a targeting agent at its terminus and a second biocompatible and biodegradable hydrophobic polymer block (e.g.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100104646 - Nanoparticle composition for prevention of hair loss and promotion of hair growth: A nanoparticle composition is provided for preventing hair loss and promoting hair growth. It is based on herbal materials and thus has no harmful side effects on the body. When applied to the scalp, the nanoparticle composition deeply infiltrates into the dermis to promote blood circulation therein and provide nutrients... Agent: Tarolli, Sundheim, Covell & Tummino L.L.P.

20100104651 - Pharmaceutical compositions containing diacerein: A once-daily controlled-release formulation of diacerein for treating inflammatory or autoimmune diseases or their complications, with reduced adverse side effects and methods of treating such diseases are disclosed.... Agent: Wood, Phillips, Katz, Clark & Mortimer

20100104648 - Treatment of inflammatory and/or bacterial conditions with particles of microstructure: The present invention refers to a method for treatment of an inflammatory and/or bacterial condition, wherein particles of microstructure comprising titanium, titanium alloy, at least one titanium oxide or a combination thereof, and having a surface with at least a substantial part consisting of at least one type of titanium... Agent: Smith, Gambrell & Russell

20100104653 - Nanoparticle-coated medical devices and formulations for treating vascular disease: Nanoparticle-coated medical devices, nanoparticle-containing formulations and methods of using for treating a vascular disease are disclosed. The method for treating a vascular disease includes providing a formulation comprising a plurality of nanoparticles having a density different from that of blood and further comprising one or more bioactive agents encapsulated within,... Agent: Squire, Sanders & Dempsey LLP

20100104652 - Use of advanced nanomaterials for increasing sepecific cell functions: Disclosed herein are methodologies and compositions for enhancing cellular functions, which can be used in a variety of biological applications.... Agent: Foley And Lardner LLP Suite 500

20100104656 - Meltable binder for melt granulation and/or pelletization: A low melting binder composition for preparation of pharmaceutical tablets and/or granules which comprises a polymer and a hydrophobic meltable binder.... Agent: International Specialty Products William J. Davis, Esq.

20100104654 - Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof: Biocompatible, bioerodible implants and microspheres include latanoprost and a biodegradable polymer effective, when placed intraocular (such as into the subtenon space) to treat glaucoma.... Agent: Allergan, Inc.

20100104655 - Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same: The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 1 to about 20 weight percent of a vinca alkaloid; and about 50 to about 99 weight percent biocompatible polymer.... Agent: Goodwin Procter LLP Patent Administrator

20100104657 - Pharmaceutical composition comprising a reduced concentration of cholesterol: The invention relates to a process for decreasing the amount of cholesterol in a mixture comprising a marine oil, the marine oil containing the cholesterol, which process comprises the steps of adding a volatile working fluid to the mixture, where the volatile working fluid comprises at least one of a... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100104658 - Graft prosthesis, materials and methods: A graft prostheses (11), materials and method for implanting, transplanting, replacing, or repairing a part of a patient. The graft prosthesis includes a purified, collagen-based matrix structure removed from a submucosa tissue source. The submucosa tissue source is purified by disinfection and removal steps to deactivate and remove contaminants, thereby... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20100104659 - Benzopyranopyrazoles: Compounds of a certain formula I, in which Ra, Rb and Rc have the meanings indicated in the description, are effective compounds with anti-proliferative and/or apoptosis inducing activity.... Agent: Millen, White, Zelano & Branigan, P.C.

20100104660 - Composition and method for treating tumor: Methods for treating neoplasm, tumors and cancers, using one or more tumor treating drug carriers, haptens and anticancer drugs, alone or in combination with other antineoplastic agents or treatments, are provided. Also provided are compositions, and kits containing the composition for affecting the therapy.... Agent: Knobbe Martens Olson & Bear LLP

20100104662 - Composition and methods for modulating cell proliferation and cell death: Described herein are compositions and methods for modulation of p53-dependent cell death and cell proliferation. The compositions are microRNAs and associated nucleic acids.... Agent: Rosetta-genomics C/o Polsinelli Shughart PC

20100104661 - Discontinuous methods of treating cancer: Disclosed are methods of treating taxane sensitive tumors (i.e., cancers treatable with taxanes) using a taxane and the discontinuous dosing of lonafarnib.... Agent: Merck Patent Department (k-6-1, 1990)

20100104663 - Rehydration composition for preparing a solute by reconstitution in water: s

20100104664 - Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods: The present invention generally concerns the management of age-related diseases in domestic animals. Specifically, the present invention is directed to combination therapies for the treatment of progressive renal diseases (e.g., Chronic Renal Failure) and their accompanying secondary disease states. In a composition aspect, the present invention provides a composition comprising... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20100104665 - Methods and apparatus for treating rhinitis: Apparatus and methods deliver treatment agents simultaneously with capnic gases. The capnic gases can enhance the effectiveness of the treatment agent for treating rhinitis, lower the dosage of drug or concentration of agent necessary to achieve a therapeutic result, or both. Exemplary capnic gases include carbon dioxide, nitric oxide, nitrous... Agent: Howrey LLP-ca

20100104666 - Animal repellant & method of use thereof: A new Animal Repellent & Method of Use Thereof which generally comprises a composition of materials or ingredients that combine to create a new and novel animal repellant that is embodied in liquid or granular form, and can be applied as a spray directly to plant parts or sprinkled on... Agent: Marilyn Cox

20100104667 - Conversation of nitrogen dioxide (no2) to nitric oxide (no): A nitric oxide delivery system, which includes a gas bottle having nitrogen dioxide in air, converts nitrogen dioxide to nitric oxide and employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid. A nitric oxide delivery system may be used to... Agent: Steptoe & Johnson LLP

20100104669 - Method for preparing an aqueous solution containing triterpenic acid, aqueous solution containing triterpenic acid, and use thereof: A method for preparing an aqueous solution containing triterpenic acid, an aqueous solution containing triterpenic acid, and use thereof, includes preparation of a basic aqueous solution containing triterpenic acid and reduction of the pH of the basic aqueous solution containing triterpenic acid by adding an acidic aqueous solution in the... Agent: Muirhead And Saturnelli, LLC

20100104668 - Nutritional supplement for honeybees: A nutritional supplement for honeybees includes plant material chosen from a group comprised of plants known to provide nutrients to the honeybees, a beverage brewed from the plant material and a sugar base upon which the beverage is applied where, when the beverage has dried, the nutritional supplement is formed... Agent: Marisha Tereszkiewicz

20100104670 - Use of chitosans for the treatment of nail inflammatory diseases: Chitosan-based nail formulations are useful to treat nail inflammatory diseases like psoriasis, atopic dermatitis and lichen planus. The chitosan is normally in the form of an amino-polysaccharide derivative, preferably water soluble, such as hydroxypropyl chitosan. The formulation may be a nail lacquer, a spray, a cream, an ointment, a gel,... Agent: The Firm Of Hueschen And Sage

20100104671 - Cosmetic and/or pharmaceutical compositions and their applications: Compositions are disclosed containing, as active ingredients, an extract of Allium species, an extract of Citrus species and either an extract of Paullinia species and an extract of Theobroma species, or an extract of Salix species and zinc sulphate, and the method of preparation of these compositions, and cosmetic and/or... Agent: Harness, Dickey & Pierce, P.L.C

20100104672 - Gel-type bird aversion compositions: A gel-type bird aversion composition consists of, on the basis of weight, 30 to 90% of a thickening agent, 0.01 to 4% of an ultraviolet ray absorbent, 0.1 to 20% of methyl anthranilate, 0.1 to 10% of cinnamon essential oil, 0.1 to 20% of mint essential oil; 5 to 40%... Agent: Ipla P.A.

20100104673 - Methods and compositions for treatment of skin conditions: Topical skin care compositions are described that include effective amounts of anti-inflammatory, antioxidant, silica and sugar compounds. In addition, methods of treating skin conditions are described, which include applying topically to a site of treatment a therapeutically effective amount of a composition comprising anti-inflammatory, antioxidant, silica and sugar compounds.... Agent: Winstead PC

20100104674 - Composition for the treatment of hypertension: p

20100104675 - Method of treating demyelinating central nervous system diseases: The invention provides a method of treating a subject afflicted with a disease associated with demyelination of the central nervous system comprising administering to the subject a therapeutically effective amount of any of a composition containing Tripterygium wilfordii Hook F. root extract or components thereof and a pharmaceutically effective carrier... Agent: Cozen O''connor

20100098624 - Method for using cdo antagonists to modulate hedgehog signaling: The present invention provides for a method of using BOC/CDO hedgehog antagonists to inhibit hedgehog signaling, as well as treating and diagnosing disorders relating to hedgehog signaling or overexpression of hedgehog, including cancer, cell proliferative disorders, and angiogenesis, neurological disorders, as well as other conditions affected by hedgehog signaling such... Agent: Genentech, Inc.

20100098625 - Icbp90 polypeptide and its fragments and polynucleotides coding for said polypeptides and applications for diagnosing and treating cancer: The invention concerns a novel ICBP90 (Inverted CCAAT box binding protein 90) and its fragments, polynucleotides coding for said polypeptides and specific antibodies directed against said polypeptides. The invention also concerns methods and kits for diagnosing cell proliferation and compounds useful as medicine for preventing and/or treating pathology involving cell... Agent: Foley And Lardner LLP Suite 500

20100098626 - Protein: The present invention provides methods and compositions for screening, diagnosis and prognosis of colorectal cancer, kidney cancer, liver cancer, lung cancer, lymphoid leukaemia (particularly chronic lymphocytic leukaemia), ovarian cancer or pancreatic cancer, for monitoring the effectiveness of colorectal cancer, kidney cancer, liver cancer, lung cancer, lymphoid leukaemia (particularly chronic lymphocytic... Agent: Klauber & Jackson

20100098627 - Proteins: The present invention provides methods and compositions for treatment, prevention, diagnosis and monitoring of colorectal cancer, kidney cancer, lung cancer and/or pancreatic cancer in particular relating to a polypeptide OGTA066.... Agent: Klauber & Jackson

20100098628 - Proteins: The present invention relates to the identification of membrane proteins associated with B-cell non-Hodgkin's lymphoma, breast cancer, cervical cancer, colorectal cancer, gastric cancer, glioblastoma, hepatocellular carcinoma, lung cancer, lymphoid leukaemia (particularly acute T-cell leukaemia and chronic lymphocytic leukaemia), melanoma, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer... Agent: Klauber & Jackson

20100098629 - Novel amides acting on the adenosine receptors: There are described Compounds of formula (I) in which R3 to R8 are independently selected from hydrogen, halogen, trihaloalkyl, alkyl having 1, 2, 3, 4 or 5 carbon atoms, electron donor groups selected from alkoxy having 1, 2, 3, 4 or 5 carbon atoms, trihaloalkoxy, hydroxy or amino, electron acceptor... Agent: Cantor Colburn, LLP

20100098631 - Novel-2-heteroaryl substituted indoles 695: The present invention relates to novel 2-heteroaryl substituted indole derivatives, precursors thereof, and therapeutic uses of such compounds, having the structural formula (Ia) below: and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel 2-heteroaryl substituted indole derivatives that are suitable for imaging... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100098630 - Phenazine and quinoxaline substituted amino acids and polypeptides: Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a phenazine or quinoxaline substituent. Also disclosed herein are... Agent: Attn: John W. Wallen, Iii Ambrx, Inc.

20100098632 - Hydroxyapatite particles: This document provides methods and materials related to hydroxyapatite particles. For example, hydroxyapatite particles, methods for making hydroxyapatite particles, and methods for using hydroxyapatite particles are provided herein.... Agent: Fish & Richardson P.C.

20100098633 - Selective seprase inhibitors: Novel radiopharmaceuticals that are useful in diagnostic imaging and therapeutic treatment of disease characterized by overexpression of seprase include complexes that contains a proline moiety and a radionuclide adapted for radioimaging and/or radiotherapy:... Agent: Foley And Lardner LLP Suite 500

20100098634 - Imaging agents useful for identifying ad pathology: Provided herein are compounds and compositions which comprise the formulae as disclosed herein, wherein the compound is an amyloid binding compound. An amyloid binding compound according to the invention may be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits, and distinguish between neurological tissue... Agent: Peter L. Kendall Siemans Corporation - Intellectual Property Dept.

20100098636 - Compositions for delivery of therapeutics and other materials: This disclosure relates to compositions for delivering agents to a subject, and in particular, to compositions for delivery of therapeutic agents or diagnostic agents in the presence or absence of targeting moieties. In part, this disclosure relates to compositions comprising a hydrophobic group with a first end and a second... Agent: Wilson Sonsini Goodrich And Rosati / Pharmain Ltd

20100098637 - Dye-loaded nanoparticle: The present invention generally relates to dye-loaded nanoparticles. In particular, the present invention provides methods for the staining and visualization of tumor and tumor boundaries using dye-loaded nanoparticles.... Agent: Casimir Jones, S.c.

20100098635 - Modular antigen transporter molecules (mat molecules) for modulating immune reactions, associated constructs, methods and uses: It is therefore the object of the invention to provide means for supplying any of a wide variety of antigens in a sufficiently targeted manner to their processing site that even better therapeutic and diagnostic use thereof is possible.... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20100098638 - Rip140 regulation of diabetes: Inhibition of RIP140 increases glucose transport. Compounds that inhibit RIP140 expression or activity are useful for treating disorders associated with aberrant glucose transport (e.g., diabetes), treating obesity, increasing metabolism (e.g., fatty acid metabolism), and increasing brown fat.... Agent: Fish & Richardson PC

20100098639 - Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics: A method of therapeutic treatment of CNS disorders using local convection enhanced delivery.... Agent: Bozicevic, Field & Francis LLP

20100098640 - Multidentate pyrone-derived chelators for medicinal imaging and chelation: Provided herein are chelating agents and metal chelates that are useful in diagnostic and therapeutic applications. The uses of metal chelates provided herein include their use as contrast agents in medical imaging modalities, such as magnetic resonance imaging (MRI).... Agent: Jones Day

20100098641 - Monophosphates as mutual prodrugs of anti-inflammatory signal transduction modulators (aistm's) and beta-agonists for the treatment of pulmonary inflammation and bronchoconstriction: A mutual prodrug of an AISTM and a β-agonist in formulation for delivery by aerosolization to inhibit pulmonary inflammation and bronchoconstriction is described. The mutual prodrug is preferably formulated in a small volume solution (10-500 μL) dissolved in a quarter normal saline having pH between about 5.0 and 7.0 for... Agent: Wood, Phillips, Katz, Clark & Mortimer

20100098642 - Optimised formulation of tobramycin for aerosolization: The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100098643 - Oral health composition: The present invention relates to Orthosiphon spicatus for use in oral health applications, an oral composition comprising Orthosiphon spicatus, and the use of Orthosiphon spicatus or the composition, in the improvement or maintenance of oral health in an animal, preferably through the reduction or control of dental plaque and/or alteration... Agent: Fulbright & Jaworski, LLP

20100098644 - Solubilizing systems for flavors and fragrances: The present invention provides compositions and clear oil-in-water microemulsion containing up to 80% w/w of an oil, a surfactant system, a w/w oil/surfactant system ratio between 1 and 3, and a solubilizing-aid ingredient which is not a surfactant neither a VOC compound, the latter being present in an amount sufficient... Agent: Winston & Strawn LLP Patent Department

20100098645 - Formulation and method for the treatment of fungal nail infections: The present invention relates to a formulation and method for the treatment of fungal nail infections, such as those caused by Trichophyton rubrum and/or Aspergillus niger. The formulation of the invention comprises glucose oxidase, D-glucose and hydrogen peroxide in an aqueous solution. Advantageously, the formulation of the invention provides a... Agent: Choate, Hall & Stewart LLP

20100098646 - Soap-based liquid wash formulations with enhanced deposition of conditioning and/or skin appearance enhancing agents: The invention relates to soap-based liquid body and facial wash compositions. Using high solvent, low water compositions and incompletely naturalized fatty acids to help structure the compositions, all in combination with modified benefit agents, enhanced deposition of conditioning and/or skin appearance and/or optical enhancing agents is achieved.... Agent: Unilever Patent Group

20100098647 - Soap-based liquid wash formulations with enhanced deposition of make-up agents: The invention relates to soap based liquid body and facial wash compositions. Using high solvent, low water compositions and incompletely neutralized fatty acid to help structure the compositions, all in combination with modified benefit agents, enhanced deposition of make-up agents is achieved.... Agent: Unilever Patent Group

20100098648 - Compositions containing at least one oil structured with at least one silicone-polyamide polymer, and at least one crystalline silicone compound and methods of using the same: The invention relates to a physiologically acceptable composition, in particular a cosmetic composition, containing at least one liquid fatty phase structured with at least one structuring polymer of the silicone-polyamide type, the polymer being solid at room temperature and soluble in the liquid fatty phase at a temperature of from... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100098650 - Controlled release of active aldehydes and ketones from equilibrated dynamic mixtures: The present invention concerns a dynamic mixture obtained by combining, in the presence of water, at least one diamine derivative that includes at least one benzylamine moiety, with at least one active aldehyde or ketone. The inventive mixture is capable of releasing in a controlled and prolonged manner the active... Agent: Winston & Strawn LLP Patent Department

20100098649 - Polymer conjugates for a controlled release of active molecules: The present invention relates to the field of perfumery. More particularly, it concerns co-polymers, derived from a maleic anhydride derivative and a ethylenic derivative, comprising at least one β-oxy or β-thio carbonyl moiety capable of liberating an active molecule such as, for example, an α,β-unsaturated ketone, aldehyde or carboxylic ester.... Agent: Winston & Strawn LLP Patent Department

20100098652 - Compositions and methods for treating hair: Compositions and methods for treating hair are disclosed. Such compositions and methods can be used to modify hair properties, such as imparting and/or maintaining a level of softness or a conditioning effect on hair. In general, such compositions can utilize a copolymer having a plurality of polycationic segments, which can... Agent: Nutter Mcclennen & Fish LLP

20100098651 - Hair transformation method: Disclosed is a method and composition for transforming hair. The composition is a dual composition that is useful to curl or straighten hair. The composition also repairs hair. The reducing solution includes monoethanolamine and thioglycolic acid and is essentially ammonium hydroxide free.... Agent: Greenberg Traurig (hou) Intellectual Property Department

20100098653 - Antioxidant polymers containing [1,2]-dithiolane moieties and uses thereof: The present invention describes polymers containing 1,2-dithiolanes capable of acting as scavengers of free radicals, metals and reactive oxygen species. Also described are methods of synthesizing the antioxidant 1,2-dithiolane derivatives and polymerization thereof to produce biodegradable antioxidant polymers. The antioxidant polymers of the present invention may be used to treat... Agent: Davis Wright Tremaine LLP/los Angeles

20100098654 - Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin: The present invention relates to methods of treatment of neuroblastoma. The present invention includes administering polymeric prodrugs of 7-ethyl-10-hydroxycamptothecin to patients in need thereof.... Agent: Lucas & Mercanti, LLP

20100098655 - Aqueous oligo- and polyester formulations: Aqueous formulations of soil release polyesters are claimed, which comprise from 50 to 90% by weight of soil release polyester and from 0.1 to 40% by weight of a phosphonic acid or of a phosphonate. The addition of the phosphonic acid or of the phosphonate allows the preparation of formulations... Agent: Clariant Corporation Intellectual Property Department

20100098658 - Biopolymer conjugates comprising an interleukin-11 analog: The present invention provides for biopolymer conjugates of an IL-11 analog (mIL-11) and a biocompatible polymer. The mIL-11 of the invention displays an enhanced resistance to acidolysis and shows increased stability as compared to rhIL-11. The conjugates of the present invention are characterized by a longer serum half-life and exhibit... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100098657 - Method of treating cancer with immunomodulatory compounds and igg: Provided herein relates to the field of cancer and its treatment by administering immunomodulatory compounds in combination with other compounds. In particular, a combination of an immunomodulatory compound and an antibody is provided.... Agent: Jones Day

20100098656 - Polyamino acids functionalized by hydrophobic grafts bearing an anionic charge and applications thereof, such as therapeutic applications: The present invention relates to novel materials based on biodegradable polyamino acids that are useful especially for the vectorization of active principle(s) (AP). The invention further relates to novel pharmaceutical, cosmetic, dietetic or phytosanitary compositions based on these polyamino acids. The object of the invention is to provide a novel... Agent: Patton Boggs LLP

20100098659 - Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions: Provided are methods for treating an MMP9-mediated condition or disease, comprising administration of an electrokinetically altered aqueous fluid comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures substantially having an average diameter of less than about 100 nanometers and stably configured in the ionic aqueous fluid in an amount sufficient... Agent: Davis Wright Tremaine, LLP/seattle

20100098660 - Method of treating tuberculosis with interferons: A method of treating tuberculosis comprising administering an aerosolized interferon such as interferon α, interferon β or interferon γ in a therapeutically effective amount is provided herein. Further, a method of reducing the infectivity of tuberculosis or reducing the number of infectious organisms present in the lungs of a patient... Agent: Klauber & Jackson

20100098661 - 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections: The present invention relates to 4,5-ring annulated indole derivatives, compositions comprising at least one 4,5-ring annulated indole derivatives, and methods of using the 4,5-ring annulated indole derivatives for treating or preventing a viral infection or a virus-related disorder in a patient. Wherein ring Z, of formula (I), is a cyclopentyl,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20100098662 - Treatment of liver diseases in which iron plays a role in pathogenesis: The invention relates to the use of 4-[3,5-Bis-(2-hydroxyphenyl)-[1,2,4]-triazol-1-yl]benzoic acid (hereinafter referred to as “Compound I”) for the manufacture of pharmaceutical compositions for the treatment of liver diseases in humans in which iron plays a role in pathogenesis, including viral diseases, such as chronic hepatitis C, optionally in conjunction with antiviral... Agent: Novartis Corporate Intellectual Property

20100098666 - Humanized viral vectors and methods of use thereof: The present invention provides humanized viral vectors and methods of use thereof for delivery of transgenes or therapeutic nucleic acids to human subjects. Humanized viral vectors are modified from known viral vectors such as those based on AAV by coating their surface with a human protein such as human serum... Agent: Dann, Dorfman, Herrell & Skillman

20100098664 - Lentiviral vectors allowing rnai mediated inhibition of gfap and vimentin expression: The present invention relates to method for preventing, treating or alleviating a central nervous system (CNS) disorder using a non replicative lentivirus comprising a lentiviral genome comprising a nucleic acid sequence producing at least one functional miRNA, at least one functional shRNA and/or at least one functional siRNA, preferably derived... Agent: Nixon & Vanderhye, PC

20100098665 - Method of cancer treatment: A method and composition for treating cancer comprising administering to a patient an effective amount of attenuated Salmonella typhimurium containing a plasmid carrying the coding sequence encoding a truncated human interleukin-2 and optionally an oil containing a high antioxidant concentration.... Agent: Briggs And Morgan P.A.

20100098663 - Methods of inhibiting tumor cell proliferation with foxm1 sirna: The invention provides methods for inhibiting tumor cell proliferation by inhibiting FoxM1B (also called FoxM1) activity in a tumor cell. The invention also provides FoxM1B siRNA molecules and pharmaceutical compositions comprising FoxM1B siRNA molecules, wherein the siRNA molecules can inhibit FoxM1B activity and can inhibit proliferation of tumor cells. The... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100098667 - Culture medium for bifidobacterium longum, composition comprising the same and preparation method: The present invention provides a triple vital bacteria composition, including: powder of Bifidobacterium longum, powder of Lactobacillus acidophilus, and powder of Streptococcus faecalis. The present invention further provides a method for preparing the above triple vital bacteria composition, as well as the protection agents, fermenting culture medium and seed culture... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20100098674 - Use of polypeptides as cocciostat and/or histomonastat: The present invention relates to the use of isolated polypeptides as a coccidiostat and/or as a histomonastat. An example of a polypeptide of the invention is the so-called L12 protein from Bacillus licheniformis ATCC 14580. The invention furthermore relates to the probiotic use of strains of Bacillus, which produce proteins... Agent: Nixon & Vanderhye, PC

20100098668 - Oncolytic adenoviruses and uses thereof: The disclosed subject matter provides methods and materials relating to viral vectors, such as adenoviral vectors, that effectively target cancer cells and that express a protein that specifically binds to Transforming Growth Factor-β.... Agent: Marshall, Gerstein & Borun LLP

20100098671 - composition for prevention or treatment of bone marrow damage: Substance-P stimulates proliferation of mesenchymal stem cells (MSCs) within the bone marrow to thereby facilitate protection and regeneration of bone marrow cells and hematopoietic stem cells. Therefore, the composition of the present invention can be therapeutically used for treatment and/or prevention of bone marrow damage. Further, the composition of the... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100098670 - Autologous dental pulp stem cell-based bone graft substitute: The invention features methods and compositions for promoting the growth and differentiation of dental pulp stem cells and the use of the differentiated cells for the treatment of orthopedic conditions.... Agent: Clark & Elbing LLP

20100098673 - Bone graft composites and methods of treating bone defects: Bone graft compositions comprising demineralized bone matrix, calcium phosphate, collagen and bioinductive cellular solution. Methods to repair and heal defective and missing bone using the bone graft compositions are also described.... Agent: Harness, Dickey & Pierce, P.L.C

20100098669 - Use of adipose tissue-derived stromal stem cells in treating fistula: Provided herein are novel methods and compositions utilizing adipose tissue-derived stromal stem cells for treating fistulae.... Agent: Moore & Van Allen PLLC

20100098672 - Use of mesenchymal stem cells for treating genetic diseases and disorders: A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal.... Agent: Mcandrews Held & Malloy, Ltd

20100098675 - Methods for reducing the side effects of ophthalmic laser surgery: A method for treating the side effects resulting from ophthalmic lasery surgery of the eye. The method administers stem cells as a means for treating the destruction of retinal and other tissues resulting from photocoagulation in the treatment of diabetic retinopathy and other eye disorders. Methods for using the invention... Agent: Stemedica Cell Technologies, Inc

20100098677 - Methods and devices for epithelial protection during photodynamic therapy: Methods for preventing damage to the epidermis during PDT induced using a pre-photosensitizing agent are provided. The methods of the present invention utilize spatial confinement to control formation of a photoactive species from a topically-applied pre-photosensitizing agent. In one embodiment, thermal inhibition is used to prevent the metabolism of a... Agent: Nutter Mcclennen & Fish LLP

20100098678 - Methods of treatment of mitochondrial disorders: In accordance with the present invention, there are provided methods for the treatment of mitochondrial disorders. Invention methods include the administration of a pyrimidine-based nucleoside such as triacetyluridine, or the like. Also provided are methods of reducing or eliminating symptoms associated with mitochondrial disorders. Mitochondrial disorders particularly appropriate for treatment... Agent: Dla Piper LLP (us)

20100098676 - Synergistic anti-inflammatory and antioxidant dietary supplement compositions: Disclosed herein are novel dietary supplement compositions comprising enriched 3-O-acetyl-11-keto-β-boswellic acid and enriched demethylated curcuminoids, wherein the composition exhibits anti-inflammatory, antiulcerogenic and antioxidant activities. Also disclosed are novel compositions comprising enriched 3-O-acetyl-11-keto-β-boswellic acid, enriched demethylated curcuminoids that have a synergistic effect on specific inhibition of—COX-2 and 5-LOX activity and optionally... Agent: Kramer & Amado, P.C.

20100098679 - Promotion of peroxisomal catalase function in cells: The molecular mechanisms of peroxisome biogenesis have begun to emerge; in contrast, relatively little is known about how the organelle functions as cells age. The present inventors characterized age-related changes in peroxisomes of human cells and showed that aging compromises peroxisomal targeting signal 1 (PTS1) protein import, with the critical... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100098680 - Anti-pathogen treatments: Chimeric molecules that contain at least one pathogen-detection domain and at least one effector domain, and their methods of use in preventing or treating a pathogen infection in a cell or organism are described. The pathogen-detection domain and effector domain of the chimeric molecules are domains not typically found in... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100098681 - Dimeric high affinity egfr constructs and uses thereof: Polypeptides comprising EGFR extracellular domains I-III capable of forming dimeric EGF-binding proteins are provided. The dimeric construct of the invention is useful in applications where high affinity EGF binding is desired and can be used to select agents capable of binding to native EGFR in the presence of EGF.... Agent: Philip S. Johnson Johnson & Johnson

20100098682 - Effect of bri proteins on ass production: Provided are methods for reducing inhibiting or preventing Aβ and/or AID production by a cell and methods of treating a subject having Alzheimer's disease. Also provided are methods of determining whether a compound is a mimic of a BRI2 or a BRI3. Additionally provided are pharmaceutical compositions of BRI2, BRI3... Agent: Amster, Rothstein & Ebenstein LLP

20100098684 - Biomarkers and methods for detecting and treating spinal and joint pain: Biomarkers, including isolated fibronectin-aggrecan complexes that correlate with spinal or joint pain and inflammation, and methods for their detection are provided. Also provided are methods for identifying treatment sites in the spine or joint for treatment of pain and inflammation by detecting the presence of, or increased levels of, fibronectin-aggrecan... Agent: Pabst Patent Group LLP

20100098687 - Compositions and methods for treating thymic stromal lymphopoietin (tslp)-mediated conditions: Provided are methods for treating a TSLP-mediated or TSLPR-mediated disease or condition, comprising administration of an electrokinetically altered aqueous fluid comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures substantially having an average diameter of less than about 100 nanometers and stably configured in the ionic aqueous fluid in an... Agent: Davis Wright Tremaine, LLP/seattle

20100098686 - Method for reducing levels of c-reactive protein: o

20100098683 - Muc1 and galectin-3: The invention provides methods of identifying and making compounds that inhibit the interaction between MUC1 and galectin-3. Also embraced by the invention are in vivo and in vitro methods of inhibiting such an interaction and of inhibiting the expression of galectin-3 by a cell.... Agent: Fulbright & Jaworski L.L.P.

20100098685 - Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto: The invention provides the use of TLR inhibitors or a pharmaceutically acceptable derivative thereof, optionally in combination with one or more lipid lowering composition, cholesterol lowering composition, diuretics, non-steroidal anti-inflammatory compounds (NSAIDs), antibodies, antisense oligonucleotides, TLR agonists, TLR antagonists, peptides, proteins or gene therapy vectors or combinations thereof for the... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100098688 - Method for diagnosis of a disease involving an anti-at1-receptor antibody: The present invention relates to a method for diagnosis of a disease selected from the group of diabetes, vasculitis, collagenosis, an inflammatory rheumatic disease and arteriosclerosis wherein, presence or absence of an anti-AT1-receptor antibody is determined in a sample from a patient to be diagnosed and wherein, the presence of... Agent: Millen, White, Zelano & Branigan, P.C.

20100098689 - 4-1 bb ligand in inflammatory diseases: The invention provides 4-IBBL blocking agents, as well as pharmaceutical compositions and articles of manufacture comprising such blocking agents as new therapeutic interventions for sustained inflammation. Thus, the invention also provides methods for reducing sustained production of tumor necrosis factor.... Agent: The Scripps Research Institute

20100098694 - Antibodies to cd40: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies... Agent: Ropes & Gray LLP

20100098691 - Combination of benzimidazole anti-cancer agent and a second anti-cancer agent: The present invention relates to a pharmaceutical composition for the treatment of cancer as well as methods of treatment of cancer that are based on the finding that certain benzimidazole based anti-cancer agents can be used in combination with a second anti-cancer agent to achieve desirable therapeutic outcomes. More specifically... Agent: Connolly Bove Lodge & Hutz LLP

20100098693 - Compositions and methods for blood-brain barrier delivery of organophosphatases: Provided herein are compositions and related methods for delivering an organophosphatase to the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a receptor expressed on the surface of the blood-brain barrier (BBB receptor) and an organophosphatase. In some embodiments, the compositions described herein... Agent: Wilson, Sonsini, Goodrich & Rosati

20100098692 - Humanized endoglin antibodies: The present application relates to compositions of humanized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100098690 - Pharmaceutical composition: e

20100098695 - Biomarker specific to brain/nerve or specific to neuronal differentiation: The invention provides a polypeptide and a specific partial peptide thereof, as well as a polynucleotide and a specific partial nucleotide thereof, that can be used as a biomarker specific for the brain/nerves or specific for nerve differentiation; an expression vector for such a polynucleotide and a specific partial peptide... Agent: Leydig Voit & Mayer, Ltd

20100098697 - Chlamydia trachomatis antigens: Proteins encoded by Chlamydia trachomatis which are immunogenic in humans as a consequence of infection have been identified using Western blots of two-dimensional electrophoretic maps. Several known immunogens were identified, as were proteins not previously known to be immunogens, and proteins not previously reported as expressed gene products.... Agent: Novartis Vaccines And Diagnostics Inc.

20100098696 - Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment: The present invention relates to an isolated antibody or fragment thereof, which specifically binds to human FGFR-3(IIIb) and FGFR-3(IIIc), or mutant forms thereof Further embodiments include pharmaceutical compositions comprising the antibody and methods of using the antibody to treat cancer.... Agent: Eli Lilly & Company

20100098698 - Targeted apheresis for the treatment of rheumatoid arthritis: This invention uses “targeted apheresis” to treat rheumatoid arthritis patients. “Targeted Apheresis” is a process whereby the RF and immune complexes responsible for causing the disease symptoms are selectively removed from the blood by passing the blood through a cartridge containing immobilized IgG. The RF and immune complexes are bound... Agent: Stetina Brunda Garred & Brucker

20100098701 - Combination of anti-ctla4 antibody with dasatinib for the treatment of proliferative diseases: Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.... Agent: Louis J. Wille Bristol-myers Squibb Company

20100098703 - Determination of am-binding proteins and the association of adrenomedullin (am) therewith: The present invention provides methods for the isolation, identification, and purification of adrenomedullin (AM)-binding proteins. Also, provided are methods for utilizing the purified AM-binding proteins, or functional portions thereof, to diagnose, treat, and monitor AM-related diseases, for example, diseases or disorders associated with abnormally elevated AM levels. In addition, the... Agent: Klarquist Sparkman, LLP

20100098702 - Method of treating androgen independent prostate cancer: The present invention is directed to a method treating prostate cancer. The method comprises administering to a patient in need thereof at least one compound selected from N-methyl-Δ3,3′-dihydroindole-2,2′ diketone; N-1-(β-D-O-triacetyl-xylopranosyl)-Δ3,3′-dihydroindole-2,2′ diketone; and N-1-(β-D-O-triacetyl-xylopranosyl)-N′-methyl-Δ3,3′-dihydroindole-2,2′ diketone. Preferably the compound is in an amount sufficient to inhibit growth, invasion, and/or metastasis of prostate... Agent: Fennemore Craig

20100098699 - Methods of using lrr superfamily genes and proteins: The instant application provides methods and compositions for the treatment of inflammation, for modulating the activity or expression of proinflammatory cytokines, for increasing the rate of wound healing, for treating infection, and for treating septic shock. The invention provides lumican, or modulators thereof, as a therapeutic composition for the treatment... Agent: Edwards Angell Palmer & Dodge LLP

20100098700 - Pharmaceutical compositions for binding sphingosine-1-phosphate: The present invention relates to compositions that comprise an anti-S1P monoclonal antibody, antibody fragment, or derivative in a carrier, particularly a buffered, hypertonic aqueous solution, as well as to kits containing such compositions, and methods for using such compositions for treatment of diseases and conditions associated with S1P.... Agent: Biotechnology Law Group 12707 High Bluff Drive

20100098704 - Antibodies that bind human dendritic and epithelial cell 205 (dec-205): Isolated monoclonal antibodies which bind to human DEC-205 and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100098705 - Method and tool for predicting cancer and other diseases: The invention concerns a marker for low-grade inflammation and metabolic syndrome (MS) and MS-related diseases and/or low-grade inflammation-related diseases such as cardiovasculardisease, ischemic heart disease and type 2 diabetes. More particularly it concerns the measurement of the concentration of soluble urokinase plasminogen activator receptor (suPAR) in human biological fluids (sputum,... Agent: Pabst Patent Group LLP

20100098706 - Monoclonal antibody directed against the human ldl receptor: The invention relates to a monoclonal antibody directed against the human LDL (Low Density Lipoprotein) receptor, in which the variable region of each of the light chains is coded by the murine nucleic acid sequence SEQ ID NO: 5, the variable region of each of the heavy chains is coded... Agent: Marsh, Fischmann & Breyfogle LLP

20100098707 - Monoclonal antibody: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The... Agent: Jones Day

20100098708 - Methods of preventing and treating rsv infections and related conditions: The present invention provides methods for preventing, managing, treating and/or ameliorating a Respiratory Syncytial Virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), otitis media (preferably, stemming from, caused by or associated with a RSV infection, such as... Agent: Jones Day

20100098710 - Anti-igf-1r antibodies and uses thereof: The invention relates to antibodies which bind to insulin like growth factor receptor-1 (IGF-1R) and uses thereof, in particular in the diagnosis and treatment of cancer. Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20100098709 - Antibodies specific for the complex of interleukin-6 and the interleukin-6 receptor: Binding members, especially antibody molecules that bind the IL-6:IL-6Ra complex formed by IL-6 and IL-6Ra, and do not bind either IL-6 or IL-6Ra alone. The binding members may have greater specificity for inhibiting pathological effects of IL-6 rather than beneficial effects of IL-6, as compared with binding members that bind... Agent: Medimmune, LLC Patrick Scott Alban

20100098715 - Annexin ii compositions for treating or monitoring inflammation or immune-mediated disorders: Methods and compositions for treating, detecting, diagnosing or assisting in the diagnosis of an inflammatory or immunological disorder are provided. The authors have made the novel discovery that anti-dsDNA antibodies are reactive to cell surface annexin II and through this interaction, anti-dsDNA antibodies are bound and then internalized and translocated... Agent: Pabst Patent Group LLP

20100098711 - Antagonist antibodies against ephb3: EphB 3-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating an EphB3-related disease or disorder.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100098714 - Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy: Methods are provided for the prevention and treatment of seizures and epilepsy. It is shown herein that leukocyte recruitment plays a key role in the pathogenesis of epilepsy. Treatment with an agent that inhibits leukocyte recruitment has therapeutic and preventative effects in blocking recurrent seizures and epilepsy.... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20100098713 - Novel 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 molecules and uses therefor: The invention provides isolated nucleic acids molecules, designated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules,... Agent: Millennium Pharmaceuticals, Inc.

20100098712 - Pharmaceutical formulation of an antibody against ox40l: Pharmaceutical formulations of an antibody against OX40L and processes for making the same.... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20100098716 - Recombinant human epo-fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo: A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo in comparison to naturally occurring or recombinant native human erythropoietin. In one embodiment of the invention, the protein has a half-life in vivo... Agent: Oyen, Wiggs, Green & Mutala LLP 480 - The Station

20100098717 - Polypeptides recognized by anti-trichinella antibodies, and uses thereof: The present invention relates to new polypeptides recognized by anti-Trichinella antibodies. The invention also relates to the use of said polypeptides for the detection of anti-Trichinella antibodies and for the prevention of trichinellosis.... Agent: Hunton & Williams LLP Intellectual Property Department

20100098718 - Nucleic acid vectors for immunization: A dimeric protein comprising a first fusion protein and a second fusion protein, wherein the first fusion protein comprises a targeting domain, a leucine zipper domain, and an antigen; and wherein the second fusion protein comprises a targeting domain, a leucine zipper domain, and optionally an antigen. Nucleic acid vectors... Agent: Novartis Vaccines And Diagnostics Inc.

20100098719 - Fusion proteins comprising two or more igg binding domains of streptococcal protein g: The invention is related to fusion proteins comprising two or more IgG binding domains of streptococcal protein G, linked to a polypeptide of interest. These fusion proteins can be complexed with IgG antibodies directed against surface receptors of target cells, allowing their delivery to said target cells.... Agent: Morgan Lewis & Bockius LLP

20100098720 - Substance preventing adverse actions of therapeutic agents for dyslipidemia: A substance preventing adverse actions of conventional fibrate-series drugs as therapeutic agents for the metabolic syndrome and dyslipidemia to enhance the therapeutic effects thereof comprises an extract from Dunaliella salina or Dunaliella bardawil, for administration in combination with the fibrate-series drugs. The substance suppresses liver hypertrophy caused by the fibrate-series... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100098721 - Methods and compositions for preparing a universal influenza vaccine: Compositions and methods for preventing and treating influenza virus infections are provided. Compositions include novel immunogenic compositions having at least one vector capable of expressing an antigenic component from four or more influenza viruses representative of the antigenic diversity of a target population of influenza virus strains. Compositions further include... Agent: Alston And Bird LLP St. Jude Children's Research Hospital

20100098722 - Packaging of immunostimulatory substances into virus-like particles: method of preparation and use: The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100098724 - Immunoenhacer-linked oligomeric hiv vaccines: Provided herein are immunogenic compositions comprising fusion proteins, the fusion proteins comprising lentivirus gp41 or a fragment thereof, a trimerization or oligomerization motif and an immunoenhancer that elicit potent and broad HIV neutralizing antibody responses in the immunized hosts. Also disclosed are methods of making and using the immunogenic compositions.... Agent: K&l Gates LLP

20100098723 - Vaccine compositions against infectious pathologies for mammals: The invention concerns immunogenic compositions prepared from preparations obtained by incubating first means expressing the target receptor(s) of an infectious pathogenic agent, with second means expressing at least the regions of the infectious pathogenic agent recognising said targets, in conditions enabling interaction between the first and second means so as... Agent: Nixon & Vanderhye, PC

20100098725 - Methods for cultivating cells, propagating and purifying viruses: The present invention provides novel serum-free cell culture medium and methods for cultivating MDCK cells. In particular, non-tumorigenic MDCK cells. The present invention also provides methods for producing influenza viruses (e.g., particularly cold-adapted, and/or temperature sensitive, and/or attenuated influenza viruses) that eliminate the need for a cell culture medium exchange... Agent: Medimmune, LLC Patrick Scott Alban

20100098726 - Virus-expressing host costimulation molecules: An antiviral vaccine that encodes costimulation molecules for increasing immune response to the particular virus at issue is provided herein. In an illustrative embodiment, in mice lacking both B7-1 and B7-2 (B7KO), the increased severity of HSV infection has confirmed the importance of these molecules in generation of HSV-specific immunity.... Agent: Husch Blackwell Sanders LLP

20100098727 - Methods for treating eye disorders: Methods of treating an eye disorder are disclosed. Particular methods comprise a step of locally administering a Clostridial toxin to the eye of a patient to treat the disorder.... Agent: Allergan, Inc.

20100098728 - Immunostimulating composition containing lactic acid bacteria: Producing an immunostimulating composition containing lactic acid bacteria having IL-12 production-inducing activity, by culturing lactic acid bacteria belonging to the genus Lactobacillus, immediately killing the bacteria at the point of time at which the pH of the culture medium substantially stops decreasing, and then adding the obtained killed cells to... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100098729 - Novel surface exposed immunoglobulin d-binding protein from foraxella catarrhalis: The present invention relates to a surface exposed protein, which can be detected in Moraxella catarrhalis, having an amino acid sequence as described in SEQ ID NO: 1, an apparent molecular weight of 200 kDa and a capacity of selectively binding membrane bound or soluble IgD, to an immunogenic or... Agent: Buchanan, Ingersoll & Rooney PC

20100098730 - Immunoglobulin variants and uses thereof: Variant immunoglobulins with one or more amino acid modifications in the Fc region that have increased in vivo half-lives, and methods of using the same are provided.... Agent: Genentech, Inc.

20100098731 - Hollow sphere from amphiphilic chitosan derivatives and method of preparing amiphiphilic chitosan derivative complex for medical use: r

20100098734 - Methods for preparation of a thixotropic microemulsion for skin care formulations: Methods for the preparation of a novel topical gel delivery system are disclosed. The delivery system is an oil-in-water (O/W) type thixotropic microemulsion especially useful as a vehicle for the delivery of botanical actives. The delivery system is comprised of natural starches emulsified with a cationic surfactant and utilizes both... Agent: William H. Dippert Eckert Seamans Cherin & Mellott, LLC

20100098732 - Methods, processes and compositions comprising the protein calmodulin (cam) for treatment of damaged or aging skin, and/or hair loss: The invention relates to compositions comprising the calcium binding protein, calmodulin (CaM), and the use of this protein additive in compositions suitable for topical application for the maintenance and development of healthy skin; for improving the aesthetic appearance of skin; for treating fine lines, and/or wrinkles, and/or age spots, and/or... Agent: Dorr Felt Tippens

20100098733 - Nitric oxide releasing particles for oral care applications: The present invention provides an oral care composition Comprising a nitric oxide releasing particle and an orally-acceptable carrier. The nitric oxide releasing particle comprises at least one nitric oxide donor. Another aspect of the present invention provides a device for oral care comprising a nitric oxide releasing particle, wherein the... Agent: Myers Bigel Sibley & Sajovec

20100098736 - Connective tissue repair: The invention concerns a human stem cell isolated from the full depth of human cartilage tissue and/or isolated from aged human cartilage; and uses thereof.... Agent: King & Schickli, PLLC

20100098735 - Injectable depot compositions and its process of preparation: Novel injectable compositions are provided comprising an active agent which is tamsulosin or letrozole or its pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof and one or more pharmaceutically acceptable excipient(s) wherein the compositions are preferably formulated as biodegradable microparticles or nanoparticles which... Agent: Ladas & Parry LLP

20100098737 - methods and compositions for delivery of glycopeptide antibiotics to medical device surfaces: The presently disclosed subject matter relates to peptides having binding affinity for glycopeptide antibiotics and methods and compositions for delivering glycopeptide antibiotic to the surface of medical devices. The peptide compositions can comprise a peptide having binding affinity for a surface material of a medical device that is coupled to... Agent: Laura L.kiefer Affinergy, Inc.

20100098739 - Compositions and methods for modular soft tissue repair: Adipose tissue-derived stromal cells induced to form multicellular aggregates can be formed reliably and consistently, they can be maintained for prolonged periods in adherent or suspension culture, and they are able to survive, grow, and/or differentiate in serum-free media conditions. The present invention provides compositions and methods for the use... Agent: University Of Virginia Patent Foundation

20100098740 - Method of controlling a drug release rate: A method of controlling the drug release rate of a drug coated endovascular stent by depositing a drug material layer on the stent and then modifying the drug material using gas cluster ion beam irradiation to create a carbon matrix with interstices containing the original drug. The rate at which... Agent: Burns & Levinson, LLP

20100098741 - Method of incorporating carbon nanotubes in a medical appliance, a carbon nanotube medical appliance, and a medical appliance coated using carbon nanotube technology: A method of coating an article is provided. The method includes: preparing a solution including a bioactive agent and a carbon nanotube precursor; treating the solution to form carbon nanotubes; and applying the solution to the article. A method of producing a medical device is provided. The method includes: forming... Agent: Kenyon & Kenyon LLP

20100098738 - Surface bound actives: An implantable metal device having an active biosurface, the device comprising a non-peptide polymer spacer having a plurality of target sites, at least one or more of the target sites binding a biologically active agent, wherein the target sites are derived from a plurality of carbonyl, epoxy, hydroxyl or thiol... Agent: Diana Houston Smith & Nephew, Inc.

20100098742 - Fabrication of tissue lamina using microfabricated two-dimensional molds: Methods and materials for making complex, living, vascularized tissues for organ and tissue replacement, especially complex and/or thick structures, such as liver tissue is provided. Tissue lamina is made in a system comprising an apparatus having (a) a first mold or polymer scaffold, a semi-permeable membrane, and a second mold... Agent: Edwards Angell Palmer & Dodge LLP

20100098743 - Medical substitute membrane, use thereof, and method for repair of membrane tissue in living body: An object is to overcome the disadvantages of a conventional lyophilized amniotic membrane or the like which causes damages in a cell membrane or an amniotic membrane tissue and is therefore not suitable for use as a substitute membrane for a membrane tissue in a living body, and to provide... Agent: Birch Stewart Kolasch & Birch

20100098744 - Reduction of infection associated with medical device: Anti-infective articles capable of preventing infection associated with implantation of medical devices include low levels of anti-infective agents, may cover only a fraction of the portion of the medical device and be effective, or may rapidly elute anti-infective agent, without sustained elution, and still be effective.... Agent: Medtronic, Inc.

20100098745 - Methods for delivery of medication using dissolvable devices: A method utilizing a dissolvable device for the internal delivery of medication and more particularly to the use of films, fibers or non-woven fabrics made of a safe polymer material incorporating a medication that is released by dissolution of the films, fibers or non-woven fabrics over time, and more particularly... Agent: Evelyn M. Sommer, Esq. 17th Floor

20100098746 - Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone: Effective treatments of periodontal disease for extended periods of time are provided. Through the administration of an effective amount of clonidine, sulindac, and/or fluocinolone at or near a target site, one can reduce, prevent, and/or treat periodontal disease. In some embodiments, when appropriate formulations are provided within biodegradable polymers, treatment... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20100098747 - Percutaneous administration device of bisoprolol: The present invention relates to a percutaneous administration device of bisoprolol, which includes a backing; and a pressure-sensitive adhesive layer containing bisoprolol, which is laminated on one surface of the backing, wherein the maximum value of a release rate of bisoprolol during a period of from immediately after the application... Agent: Sughrue-265550

20100098748 - Arg-gly-asp (rgd) sequence containing cyclic peptide and its active targeting liposomes: The present invention relates to the field of pharmaceutics and clinical pharmacy, involving the preparation method and application of a cyclic peptide containing Argnine-Glycine-Aspartate sequence and its active targeting liposomes. The cyclic peptide described here meets the requirement for ligand in that it forms ring by amide linkage with stable... Agent: Ware Fressola Van Der Sluys & Adolphson, LLP

20100098752 - Materials and methods for delivering antioxidants into the skin: Compositions and methods for administering one or more antioxidants to a human subject have been developed. The antioxidant-containing lipid vesicles of the invention provide a delivery system for antioxidants which can be applied topically to the skin.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100098749 - Methods for joint lubrication and cartilage wear prevention making use of glycerophospholipids: The present invention concerns methods of joint lubrication and/or prevention of cartilage wear making use of liposomes having membranes with at least one phospholipid (PL) of the group consisting of a glycerophospholipid (GPL) having two, being the same or different, C12-C16 hydrocarbon chain and a sphingolipid (SPL) having a C12-C15... Agent: Oliff & Berridge, PLC

20100098751 - Novel use of an extract of common mallow as an hydrating agent, and cosmetic composition containing it: The present invention relates to a novel use of an extract of common mallow for restoring, maintaining or reinforcing the state of moisturization of the skin; to a cosmetic composition containing it, and also to cosmetic care methods using said composition.... Agent: Woodcock Washburn LLP

20100098750 - Pharmaceutical composition comprising phenylamidine derivative and method of using the pharmaceutical composition in combination with antifungal agent: wherein R1 and R2 may be same or different, and represent an optionally substituted C3-4alkyl group; and one or more agents selected from azole antifungal agents, polyene antifungal agents, candin antifungal agents and fluoropyrimidine antifungal agents, and a method for combination use of the phenylamidine derivative or a salt thereof... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100098753 - Prophylactic and/or therapeutic agent for cardiac infarction: e

20100098754 - Processing of heat-sensitive active agents: The present disclosure relates to a method of melt processing an active agent. The method may include encapsulating an active agent in a first polymer material exhibiting a first processing temperature T1 and forming capsules including the active agent. The method may also include melt processing the capsules with a... Agent: Grossman, Tucker, Perreault & Pfleger, PLLC

20100098755 - Process of producing directly compressed tablets of sterols and/or stanols: A method of producing a tablet which comprises sterols and stanols includes the steps of forming the sterols and/or stanols, separately or together, into spherically-shaped, substantially uniform beads or prills and directly compressing the beads or prills into a tablet core.... Agent: Kirton And Mcconkie

20100098756 - Oral disintegrating tablet: An oral disintegrating tablet containing (1) D-mannitol, (2) an active ingredient, (3) one or more disintegrating agents selected from the group consisting of crospovidone and carmellose, and (4) one or more lubricants selected from the group consisting of sodium stearyl fumarate and sucrose esters of fatty acids. The oral disintegrating... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100098758 - Abuse-resistant dosage form: A solid pharmaceutical dosage form that is safeguarded against abuse, comprising at least one active substance that is susceptible to abuse and at least one emetic that is spatially separate from the at least one active substance. The active substance or substances are present in the form of at least... Agent: Crowell & Moring LLP Intellectual Property Group

20100098757 - Process for production of buprenorphine pharmaceutical preparation to be applied to mouth mucosa: The objective of the present invention is to provide a process for producing a buprenorphine pharmaceutical preparation to be applied to mouth mucosa. The process according to the present invention for producing a buprenorphine pharmaceutical preparation to be applied to mouth mucosa includes steps of: preparing a granule for an... Agent: Leydig Voit & Mayer, Ltd

20100098759 - Controlled-release preparation containing cilostazol and process for the preparation thereof: The present invention relates to a controlled-release formulation comprising cilostazol and a method for preparing said formulation. The inventive controlled-release formulation comprising cilostazol or a pharmaceutically acceptable salt thereof, a solubilizing agent, a swelling agent, a swell-controlling agent and a gas generating material has advantages in that it maintains a... Agent: Law Offices Of Khalilian Sira, LLC

20100098760 - Polypeptide for treating or preventing adhesions: The described invention provides compositions and methods for treating or preventing adhesions in a subject in need thereof, the method comprising the step of (a) administering an adhesion-reducing amount of a composition comprising a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA [SEQ ID NO: 1] or a functional equivalent thereof... Agent: Greenberg Traurig, LLP

20100098763 - Pharmaceutical formulation 514: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition,... Agent: Astrazeneca R&d Boston

20100098761 - Polymer compositions for biomedical and material applications: The invention relates to composite materials that contain a polymer matrix and aggregates, and in some embodiments, methods of making, and methods of using these materials. Preferably, the aggregates are calcium phosphate aggregates. Preferably, the material is resistant to fracture. In further embodiments, the materials are used in surgical procedures... Agent: Peter G. Carroll Medlen & Carroll, LLP

20100098762 - Thermosensitive pluronic derivative hydrogels with high biodegradability and biocompatibility for tissue regeneration and preparation method thereof: The present invention relates to a thermosensitive pluronic derivative hydrogel for tissue regeneration in which a biodegradable polymer is introduced at one end or both ends of a pluronic polymer, a methacryloxyethyl trimellitic acid anhydride is conjugated to the biodegradable polymer, and a physiologically active substance is fixed to the... Agent: Jones Day

20100098764 - Polysaccharide gel formulation having multi-stage bioactive agent delivery: Described herein are polysaccharide gel formulations including at least one inhibitor of polysaccharide degradation and methods of making the same. The methods described herein involve the steps of providing at least one polysaccharide and incorporating at least one inhibitor of degradation into the polysaccharide.... Agent: Allergan, Inc.

20100098767 - Convection enhanced delivery apparatus, method, and application: An embodiment of the invention is directed to a microfabrπcated, silicon-based, Convection Enhanced Delivery (CED) device The device comprises a silicon shank portion, at least one individual parylene channel disposed along at least a part of an entire length of the shank, wherein the channel has one or more dimensioned... Agent: Bond, Schoeneck & King, PLLC

20100098768 - Method of neuroprotection from oxidant injury using metal oxide nanoparticles: A metal oxide nanoparticle composition including a cerium oxide nanoparticle and a metal adapted to enhance the neuroprotective activity of the cerium oxide nanoparticle. The metal can include noble metals such as platinum, and rare earth metals such as gadolinium, samarium, titanium, yttrium, zirconium, and a combination thereof Another metal... Agent: Bond, Schoeneck & King, PLLC

20100098765 - Powder makeup compositions and methods: An anhydrous powder composition wherein the ratio of platelet to non-platelet particulates is greater than about 5 to 1 respectively, which is preferably talc-free, oil-free, paraben-free, and fragrance-free; and a method for preparing the powder composition of the invention.... Agent: The Estee Lauder Cos, Inc

20100098766 - Use of an aqueous micro-emulsion for the preparation of a formulation for the treatment of adipose diseases: Use of a micro-emulsion comprising at least one surfactant having a HLB value between 5 and 15, at least one lipophilic substance, and water for the preparation of a formulation for the treatment of adipose tissue disease and/or condition with improved bioavailability and good release behaviour of active substances.... Agent: The Firm Of Hueschen And Sage

20100098769 - Synthetic peptides reducing or removing bags formed under the lower eye contour and their use in cosmetic or dermopharmaceutical compositions: that can reduce or remove bags formed under the eyes, their stereoisomers and racemic or non-racemic mixtures thereof, and the cosmetically or dermopharmaceutically acceptable salts thereof, wherein X is cystenyl, seryl, threonyl or aminobutyryl; R1 is H or alkyl, aryl, aralkyl or acyl group; and R2 is amino, hydroxy or... Agent: Merchant & Gould PC

20100098770 - Sirolimus pharmaceutical formulations: Pharmaceutical formulations comprising sirolimus or its derivatives, processes for preparing formulations comprising sirolimus, and their methods of use, treatment, and administration.... Agent: Dr. Reddy''s Laboratories, Inc.

20100098771 - Abuse-resistant oral dosage forms and method of use thereof: An opioid-antagonist oral dosage form which does not release a therapeutically effective amount of the opioid antagonist when the oral dosage form is orally administered to a human being, but whereby a physical alteration of the oral dosage form results in a release of the therapeutically effective amount of the... Agent: Woodcock Washburn LLP

20100098772 - Drug delivery systems and methods for treating neovascularization: Anti-angiogenesis compositions, and methods of using such compositions, useful for intraocular to treat neovascularization. The compositions can have viscosities at about 25° C. of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity at 25° C. is in... Agent: Allergan, Inc.

20100098773 - Polymer vesicles for selective electromagnetic energy-induced delivery: Provided are polymer vesicles comprising polymersomes, a radiofrequency absorbing moiety, a protein or a polysaccharide associated with the inner leaflet of the membrane and a therapeutic or diagnostic cargo. The invention also concerns the use of these polymer vesicles for selective electromagnetic energy-induced delivery of therapeutic or diagnostic agents.... Agent: Woodcock Washburn LLP

20100098774 - Composition comprising crustacean gastrolith components and its use: Provided is a formulation containing amorphous or microcrystalline calcium carbonate finely interspersed with organic matter in a ratio of 10 parts of the carbonate per 1 to 3 parts of the organic matter, wherein the organic matter consists of chitin and polypeptide. The formulation is efficient in treating various pathological... Agent: Kevin D. Mccarthy Roach Brown Mccarthy & Gruber, P.C.

20100098775 - Detecting genetic predisposition to osteoarthritis associated conditions: This application relates to methods and kits for detecting predisposition to increased risk for osteoarthritis associated conditions.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100098776 - Soap-based liquid wash formulations with enhanced deposition of antimicrobial agents: The invention relates to soap-based liquid body and facial wash compositions using high solvent, low water compositions and incompletely neutralized fatty acids to help structure the compositions, all in combination with modified benefit agents, enhanced deposition of antimicrobial agents is obtained.... Agent: Unilever Patent Group

20100098777 - Copper containing algicidal compounds: The present application is directed to a coating composition comprising a ceramic binder and inorganic copper compound particles. Generally, the inorganic copper compound particles have a median particle size of less than 5 micrometers. In some embodiments, the particles have a median particle size of greater than 1 micrometer. The... Agent: 3m Innovative Properties Company

20100098778 - Compositions and methods for controlling the weight of animals: Compositions are provided comprising a balance between lysine and essential amino acids and metabolizable energy. The compositions are useful in methods to prevent or treat obesity in an animal without concomitant loss of lean muscle mass. The compositions may also be used in methods to preserve or to cause a... Agent: Colgate-palmolive Company

20100098779 - Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects: The present invention relates to compositions and methods for prophylactic nutritional supplementation and therapeutic nutritional supplementation. Specifically, the composition provides a nutritional supplement with a beneficial increased supplementation of vitamin D and the method involves administering to an individual a composition comprising carotenoids, vitamin E, vitamin D, vitamin C, thiamine,... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20100098780 - Flaky particle and cosmetic: The present invention has an object to provide a flaky particulate material giving skin an excellent smoothness, which is free from whitening problem upon use thereof owing to its high transparency. The present invention also has another object to provide a cosmetic composition containing the flaky particulate material. The present... Agent: Jordan And Hamburg LLP

20100098781 - Carbonate radical-containing magnesium hydroxide particle and manufacturing method thereof: e

20100098782 - Use of sodium acid sulfate as a disinfectant: Animal carcasses are disinfected by applying to the animal carcass an aqueous solution of sodium acid sulfate that does not include a chlorine-containing composition. The solution is maintained at from about pH 1.0 to about pH 2.5 and can optionally include a second acid such as citric acid, lactic acid,... Agent: Johnsondiversey, Inc.

20100098783 - Appetite suppressant composition: A chewable appetite suppressant composition includes a Hoodia extract, a 5-hydroxytryptophan, a Gymnema Slyvestris, and at least one amino acid derivative. The chewable appetite suppressant composition may further include flavorants.... Agent: Brooks Kushman P.C.

20100098784 - Capsule containing plant preparations: The invention relates to a composition containing a lipophilic extract of Vitellaria paradoxa and at least one amino sugar or a pharmaceutically acceptable salt thereof, in addition to a capsule containing said composition. The composition is used for the prophylaxis and treatment of inflammatory osteoarthritis.... Agent: The Nath Law Group

20100098785 - Composition of ashwagandha and indian gooseberry: A therapeutic composition comprising extracts of the plant species ashwagandha (Withania somnifera) and Indian gooseberry (Phyllanthus emblica). A composition of ashwagandha and Indian gooseberry may: (1) lower cortisol and increase DHEA, (2) prevents free radical-induced photoaging, (3) inhibit collagenase activity in vitro, (4) inhibit hyaluronidase activity in vitro, (5) display... Agent: Downs Rachlin Martin PLLC

20100098786 - Formulation containing a carboxylic acid or an ester thereof: A formulation comprising eicosapentaenoic acid, or an ester thereof, and a triterpene, or an ester thereof, and the use of such a formulation.... Agent: Gibson & Dernier LLP

20100098787 - Compositions comprising cinnamon oil (and/or its component cinnamaldehyde) and diallyl disulfide, their formulations, and methods of use: The invention relates to diallyl disulfide and cinnamon oil formulations, for protecting plants from nematodes and other plant pathogens. The invention provides a method for suppressing plant damage by nematodes and other plant pathogens, which comprises the concurrent administration, to the locus, soil or seeds of plants in need of... Agent: Wood, Phillips, Katz, Clark & Mortimer

20100098789 - Compositions of ground/powdered nuts/nut butters with curcuminoids/turmeric/mix having improved health benefits and oxidative stability: A turmeric, turmeric components, curcumin or curcuminoid modified nut or seed butter spread known as A which is resistant to oxidation with improved cu/co/tc/tu/mx solubility and possessing some human health benefits comprising: 0.2-70% of components selected from the group consisting of curcumin, curcuminoids, turmeric components and turmeric; and 30-99.8% of... Agent: Isaac A. Angres Suite 304b

20100098788 - Extracts of curcuma and methods of use thereof: The present invention relates in part to turmeric extracts that are useful for treating or preventing neurodegenerative disorders. Another aspect of the invention relates in part to turmeric extracts that are useful for treating or preventing inflammatory disorders. In some embodiments, the extracts comprise at least one compound selected from... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100098790 - Combination herbal product to benefit respiratory tract: An herbal composition for providing a beneficial effect to the respiratory tract. The composition includes Colt's Foot, Mangosteen, Thyme Leaf, Wild Cherry Bark, Quercitin, Sundew, Butterbur, and Grape Seed Extract. In particular, the composition may prevent or treat cough. Also described are methods of using the herbal composition.... Agent: Stetina Brunda Garred & Brucker

20100098791 - Composition for treating xerostomia or dry mouth: The present invention provides a composition comprising olive oil, trimethylglycine and xylitol for treating xerostomia and disorders associated thereto, with very good results in increasing the unstimulated salivary flow, in alleviating the symptoms of xerostomia, including the pain associated to xerostomia, as well as improving the quality of life of... Agent: Ostrolenk Faber Gerb & Soffen

20100098793 - Irvingia gabonensis to treat and prevent metabolic syndrome and reduce total cholesterol, ldl cholesterol, blood glucose, c-reactive protein, and leptin levels and increasing adiponectin levels: In one embodiment, a method is provided for lowering C-reactive protein levels in a mammal. The method comprises administering a composition containing an effective amount of Irvingia gabonensis seed to a mammal to reduce C-reactive protein levels in the mammal. Other embodiments include, among other things, lowering leptin levels, increasing... Agent: Greenberg Traurig LLP (la)

20100098792 - Methods and compositions using irvingia gabonensis to reduce weight, control obesity, effect adipogenesis, lower ppar-gamma, leptin, g3pdh and triglycerides levels and increase adiponectin levels: In one embodiment, a method is provided for lowering PPAR-Gamma in a mammal. The method comprises administering a composition containing an effective amount of Irvingia gabonensis seed to a mammal to reduce PPAR-Gamma levels in the mammal. In other embodiments, among other things, methods are provided for reducing triglyceride levels,... Agent: Greenberg Traurig LLP (la)

20100098794 - Topical anti-wrinkle and anti-aging moisturizing cream: The present invention relates to a topical anti-wrinkle and anti-aging moisturizing cream designed (formulated) to repair and restore human adult skin to its original youthful state. This has successfully been achieved by using a water based molecular mixture of high molecular weight (0.5 to 2.0 million Daltons) hyaluronic acid (HA)... Agent: Gerard Armand

20100098795 - Bacterial extract for digestive or urinary tract disorders and process for its preparation: The present invention relates to an extract from bacterial strains useful as a treatment for disorders such as digestive or urinary tract disorders, compositions comprising the extract, and processes of making the extract from media that do not pose a risk of prion diseases.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100092384 - Multifunctional nanoparticles and compositions and methods of use thereof: Provided is a multifunctional particle comprising: (a) an inner metallic core, (b) a biocompatible shell comprising an optical contrast agent embedded therein, and (c) a targeting biomolecule conjugated to the biocompatible shell through a multidentate ligand, wherein the multidentate ligand is chelated to an imaging agent. Also provided are compositions... Agent: Leydig, Voit & Mayer, Ltd.

20100092385 - Novel heteroaryl substituted imidazo [1,2-a] pyridine derivatives: The present invention relates to novel heteroaryl substituted imidazopyridine derivatives, precursors thereof, and therapeutic uses of such compounds, having the structural formula (Ia) and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel heteroaryl substituted imidazopyridine derivatives that are suitable for imaging amyloid... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100092386 - System for delivering therapeutic agents into living cells and cells nuclei: The present invention relates to a novel delivery system for delivering therapeutic agents into living cells, and more particularly, to novel chemical moieties that are designed capable of targeting and/or penetrating cells or other targets of interest and further capable of binding therapeutic agents to be delivered to these cells,... Agent: Pearl Cohen Zedek Latzer, LLP

20100092387 - Novel compound having affinity for amyloid: wherein R1 is a group selected from hydrogen, hydroxyl group, carboxyl group, sulfate group, amino group, nitro group, cyano group, an alkyl substituent with one to 4 carbon atoms or an alkoxy substituent with one to 4 carbon atoms; R2 is a radioactive halogen substituent; and m is an integer... Agent: Fitch, Even, Tabin & Flannery

20100092388 - Anthracycline derivatives: Anthracycline derivatives are suitable for use in cancer therapy and diagnosis. These anthracycline derivatives can be radiolabelled and used as an imaging agent in cancer diagnosis. The radiolabelled anthracycline derivatives can also be used together with a drug delivery system, in particular including a two-step targeting strategy, for treating solid... Agent: Porter Wright Morris & Arthur, LLP Intellectual Property Group

20100092389 - Detection of atherosclerosis using indocyanine green: Exemplary embodiments of apparatus and method can be provided for imaging a portion of an anatomical structure. According to an exemplary embodiment of the present invention, an indocyanine green (ICG) agent can be provided to at least one portion of an anatomical structure, and it can be determined whether at... Agent: Dorsey & Whitney LLP Intellectual Property Department

20100092391 - Imaging agents and methods of use thereof: Compositions and methods useful in connection with magnetic resonance imaging are provided. Metabolites hyperpolarized by dynamic nuclear polarization are used as reporter molecules in nuclear magnetic resonance (“NMR”) spectroscopy to study metabolic pathways and diagnose disease states. The reporter molecules include hyperpolarized glutamine and hyperpolarized acetate. The invention includes the... Agent: Davis Wright Tremaine LLP/los Angeles

20100092390 - Methods for making particles having long spin-lattice relaxation times: Methods for making collections of small particles having spin-lattice relaxation times greater than about 5 minutes are described. The long-T1 particles are useful as imaging agents for nuclear magnetic resonance imaging. In one embodiment, bulk silicon wafers are reduced to particles in a machining process, and the particles processed to... Agent: Patent Department Choate, Hall & Stewart LLP

20100092394 - Multimeric particles: The invention provides multimeric particle comprising metal-containing particles covalently bonded to one another by linker groups wherein at least some of said linker groups are cleavable. The invention further provides a contrast agent comprising said multimeric particles, along with a method of improving contrast of an image using said contrast... Agent: Townsend And Townsend And Crew, LLP

20100092396 - Hyperpolarized 89-yttrium and methods relating thereto: The present invention relates to the preparation of hyperpolarized 89Y. Hyperpolarized 89Y may be used as nuclear magnetic resonance (NMR) and magnetic resonance imaging (MRI) agents for sensitive detection and imaging.... Agent: Fulbright & Jaworski L.L.P.

20100092392 - Pet scanning determination of lymph nodes enriched in 124 i labeled antibodies for cancer patient prognostication: A method for detecting antigen associated with adenocarcinoma commences by forming a 124I conjugate of a preferential locator, such as an antibody, and introducing the conjugate into a patient suspected of having adenocarcinoma. Positron emission tomography (PET) scanning of the patient reveals sites of accumulated conjugate, such sites including lymph... Agent: Mueller And Smith, Lpa Mueller-smith Building

20100092395 - Acoustically delivering methods and compositons for remote treatment of a tumor: Disclosed herein is a method of acoustically delivering a therapeutic composition to a subject pre-diagnosed with a tumor. The method comprises the steps of: parenterally administering the composition from a site remote from a tumor location; and exposing the parenterally administering site to ultrasound waves to target the delivery of... Agent: Brian M. Mcinnis

20100092393 - Tunable hydrogel microparticles: Techniques are provided to produce and use non-spherical colloidal particles with independently tuned size, shape, flexibility, and chemical properties. A pre-polymer mixture for forming hydrogel particles includes a percentage of PEGDA selected to impart a target stiffness to the particles and includes, a percentage of acrylic acid selected to impart... Agent: Ditthavong Mori & Steiner, P.C.

20100092398 - Antimicrobial compositions and applications therefore: A composition derived from an essential oil obtained from one or more plants of the Melaleuca family in which at least 80% of the monoterpene content of the oil has been removed. Practical uses of the composition including antimicrobial, antiviral and therapeutic applications. Medical devices to which the composition has... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100092397 - Method for treatment of copd and other pulmonary diseases: A method for treatment of patients with pulmonary diseases by providing an aerosolized combination of a methylxanthine and a topical steroid administered into a patient's conducting and central airways. The method utilizes a specific treatment protocol and a nebulizing system providing an aerosol having particles of a predetermined mass medial... Agent: Peters Verny , L.L.P.

20100092399 - Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution: Provided is a method for preventing or treating inflammation and associated states (e.g. infection, hypersensitivity, pain) by administering a therapeutically effective amount of an oxidative reduction potential (ORP) water solution that is stable for at least about twenty-four hours. The ORP water solution administered in accordance with the invention can... Agent: Leydig Voit & Mayer, Ltd

20100092400 - Salicylic acid composition: Provided, among other things, is a delivery module for water-based salicylic acid composition comprising: an aerosol delivery system; within the aerosol delivery system, the salicylic acid composition comprising 0.5% or more salicylic acid by weight, lipophilic component(s), and a frothing agent, the salicylic acid composition having a viscosity low enough... Agent: MoserIPLaw Group

20100092403 - Buccal, polar and non-polar spray containing zolpidem: Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide zolpidem for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, zolpidem, and optional flavoring agent; formulation II:... Agent: Dickstein Shapiro LLP

20100092401 - Immune response modifier formulations: The present invention provides a pharmaceutical foam formulation. Generally, the formulation includes a therapeutically effective amount of imiquimod and a fatty acid.... Agent: Edwards Angell Palmer & Dodge LLP

20100092402 - Treatment of respiratory disease: The invention relates to the use of amidino compounds in the manufacture and formulation of medicaments for the treatment of respiratory diseases.... Agent: Ratnerprestia

20100092404 - Hydrogenation of caryophellene: A process for the hydrogenation of a mixture of caryophyllenes by contact with hydrogen in the presence of a supported catalyst. The resulting products are useful for the application to skin.... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20100092405 - Polyamino acid derivatives and use thereof in compositions for treating keratin fibers: The invention concerns the use in a cosmetic composition of at least a poly-aminoacid of general formula (1) in which X is —O—, —S— or —NR3; R represents in particular a hydrogen atom or a C1-C10 alkyl radical; R2 represents in particular a hydrogen atom or an optionally substituted alkyl... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100092406 - Systems, methods, and compositions for treatment and use of a palatal patch: Devices and methods for a palatal patch include a tablet or strip having a bioadhesive component and an active component. The bioadhesive component allows for the palatal patch to be attached to an upper palate, and for the active component to be released into the oral cavity and/or GI tract.... Agent: Yoram Tsivion

20100092407 - Tooth-bleaching material and method of bleaching tooth: A tooth bleaching material that is safe and has good operability and high bleaching effect and a tooth bleaching method using the tooth bleaching material are provided by bleaching and removing colored sediments (colored or discolored deposits) on a tooth with a tooth bleaching material containing hydrogen peroxide and/or a... Agent: Greenblum & Bernstein, P.L.C

20100092413 - Compositions and methods for alleviating skin disorders: The disclosure relates to the discovery that fractionated coconut oil is effective for alleviating existing skin disorders when applied topically to the skin of a person afflicted with such a disorder. The disclosure further relates to the discovery that fractionated coconut oil can be used to prevent or inhibit onset... Agent: Flaster/greenberg P.C. Four Penn Center

20100092411 - Hydrophobic zinc oxide powder: Hydrophobic zinc oxide powder in the form of partially or completely coated aggregates of zinc oxide primary particles having a carbon content of from 0.4 to 1.5% by weight, based on the hydrophobic zinc oxide powder, and a BET surface area of from 25 to 100 m2/g, where the coated... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100092409 - Personal care compositions comprising modified variant bowman birk protease inhibitors: The present invention relates to compositions that comprise modified variant Bowman Birk Protease Inhibitor proteins (BBPIs). The modified variant BBPIs comprise peptides that bind target proteins, and that are further modified to have greater protease inhibitory activity and/or be produced at greater yields than the unmodified BBPIs. The invention encompasses... Agent: Danisco US Inc. Attention: Legal Department

20100092408 - Resilient personal care composition comprising polyalkyl ether containing siloxane elastomers: A stable personal care composition in the form of a water-in-oil emulsion may comprise a silicone elastomer comprising a polyalkyl ether pendant or a polyalkyl ether crosslink, wherein the alkyl group contains three or more carbon atoms; a non-emulsifying silicone elastomer; an emulsifier; a polar oil; and water. The personal... Agent: The Procter & Gamble Company Global Legal Department - Ip

20100092412 - Self tanning compositions containing dihydroxyacetone, a retinoid and ascorbic acid glucoside as a stabilizer: The invention concerns a composition comprising dihydroxyacetone, a retinoid and a glycosylated ascorbic acid.... Agent: Philip S. Johnson Johnson & Johnson

20100092410 - Spf liquid cleansing compositions: The present application relates to a facial and/or body wash composition that after rinsing provides a sun protection factor of at least about 6 comprising (i) red petrolatum; (ii) at least one surface-treated metal oxide pigment that blocks ultraviolet radiation in the wavelength range of from about 290 nm to... Agent: Louis C. Paul

20100092414 - Guar protein extracts and compositions comprised thereof as surface treating and/or modifying agents: Surface treating and/or modifying compositions, for example cosmetic or pharmaceutical or plant protective compositions or domestic care compositions contain a guar protein extract, or derivative thereof, such guar protein extract containing at least 65% by weight of proteins and are particularly suitable as surface treating and/or modifying agents, wherein these... Agent: Buchanan, Ingersoll & Rooney PC

20100092415 - Hair frizziness reducing agent: Provided is a hair frizziness reducing agent containing a lower alcohol and water, having a viscosity of from 1 to 90,000 mPa·s and used by leaving, after application to the scalp, the agent as is without washing it away.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100092416 - Method for the cosmetic treatment of keratin materials: The present invention relates to a cosmetic treatment method for keratin materials, especially the hair, comprising the application of a cosmetic composition which comprises a polymer having a polymer backbone comprising amino acid monomer units with cationic function, and comprising hydrophilic grafts bonded covalently to said backbone, over all or... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100092417 - Mascara composition comprising an ethylene/vinyl acetate copolymer: The present invention relates to a mascara composition including a cosmetically acceptable aqueous medium, characterized in that it includes an oily phase including at least one ethylene/vinyl acetate copolymer, and at least one wax or a mixture of waxes in a certain weight ratio. The present invention also relates to... Agent: Young & Thompson

20100092418 - Isomers of bicyclo[2.2.1]hept-5-ene-2-carboxylic acid, ethyl ester and their use in perfume compositions: e

20100092419 - Magnetic fluids and their use: Disclosed are magnetic fluids containing ionic liquids and containing no stabilisation agents or containing selected stabilisation agents. These magnetic fluids can be used in different fields of industry, for example as an ink, as a damping fluid, as a sealing fluid, in imaging applications, in sink flotation techniques, in biomedical... Agent: Ferrells, PLLC

20100092420 - Preservative systems comprising cationic surfactants: Preservative systems on the basis of cationic surfactants are known i n the art, a typical example of such cationic surfactants is the ethyl ester of the lauramide of arginine monohydrochloride (LAE) (2). Besides the chloride form the corresponding bromide and sulphate salts are known. It was found that other... Agent: Rankin, Hill & Clark LLP

20100092421 - Process for the preparation of sevelamer hydrochloride and formulation thereof: Disclosed herein is an improved process for preparation of Sevelamer hydrochloride having phosphate binding capacity of 4.7 to 6.4 mmol/g. Further, the invention discloses Sevelamer hydrochloride compositions and a novel process for preparation of said compositions comprising high shear non-aqueous granulation.... Agent: Pharmaceutical Patent Attorneys, LLC

20100092422 - Poly (ß-hydroxy short-medium chain fatty acid): The present invention provides a composition comprising a polymer of a β-hydroxy short-medium chain fatty acid, which is used for delivering the β-hydroxy short-medium chain fatty acid or an oligomer thereof to the large intestine. In case the composition is administrated orally, the composition will be delivered to the large... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100092423 - Pharmaceutical composition comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis: The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen CD6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-CD6 monoclonal antibody... Agent: Moore & Van Allen PLLC

20100092424 - Method of diagnosis and treatment of tumors using high intensity focused ultrasound: A method of diagnosis and treatment of tumors using High Intensity Focused Ultrasound is provided. The method of diagnosing the presence of a tumor in a patient comprises the steps of subjecting a tumor to high intensity focused ultrasound (HIFU) to cause the tumor cells to release cellular material and... Agent: Reed Smith LLP

20100092425 - Nicotine immunonanotherapeutics: The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface having a plurality of nicotine moieties. The... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100092426 - 2-substituted benzimidazoles: Inhibitors of RSV replication of formula (I) the addition salts and stereochemically isomeric forms thereof, wherein Q is hydrogen, C1-6alkyl optionally substituted with a heterocycle or Q is C1-6alkyl substituted with both —OR4 and a heterocycle; wherein said heterocycle is oxazolidine, thiazolidine, 1-oxo-thiazolidine, 1,1-dioxothiazolidine, morpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxothiomorpholinyl, hexahydrooxazepine, hexahydro-thiazepine,... Agent: Philip S. Johnson Johnson & Johnson

20100092427 - Pyridinone diketo acids: inhibitors of hiv replication in combination therapy: A new class of diketo acids constructed on pyridinone scaffolds, designed as inhibitors of HTV replication through inhibition of HIV integrase, is described. These compounds are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS and ARC, either as the compounds, or as... Agent: Coleman Sudol Sapone, P.C.

20100092428 - Method for using a bacillus subtilis strain to enhance animal health: The present invention relates to a method for enhancing the health of an animal comprising administering to the animal a composition comprising Bacillus subtilis QST 713 or a mutant thereof.... Agent: Agraquest, Inc.

20100092438 - Bacteria mediated gene silencing: Methods are described for the delivery of one or more small interfering RNAs (siRNAs) to a eukaryotic cell using a bacterium or BTP. Methods are also described for using this bacterium to regulate gene expression in eukaryotic cells using RNA interference, and methods for treating viral diseases and disorders. The... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100092437 - Radiation inducible promoter: The present invention relates to a radiation inducible promoter, more particularly to a radiation inducible promoter including a base sequence represented by SEQ ID NO: 3 derived from Salmonella typhimurium, an expression vector including the promoter, a transformant including the expression vector, and a method for inhibiting and treating cancer... Agent: Greenlee Winner And Sullivan P C

20100092429 - Composition: The present invention provides a composition comprising: (a) one or more live Bifidobacterium lactis strains; and (b) a saccharide component; wherein the saccharide component comprises xylo-oligosaccharides with a degree of polymerisation of from 2 to 100.... Agent: Steptoe & Johnson LLP

20100092439 - Antimicrobially-primed medicinal maggot therapy: Antimicrobially-primed medicinal maggots and therapy methods are described for the treatment of a variety of indications including, without limitation, infected or non-healing wounds, soft tissue infection and the like (e.g., gangrenous or infected wound).... Agent: Grant Anderson LLP C/o Portfolioip

20100092440 - composition for the administration of biologically active principles in gynaecologic and rectal field and uses thereof: The present invention relates to a composition for the administration of biologically active substances in a gynaecologic and rectal ambit, as well as the uses of said composition. Said composition presents particularly favourable technological and stability characteristics of the end product, above all with regard to the viscosity after the... Agent: Pearne & Gordon LLP

20100092441 - Use of nitrites and nitrates and compositions containing these: Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a drop in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an... Agent: Morrison & Foerster LLP

20100092442 - Bacillus isolates and methods of their use to protect against plant pathogens: Methods of inducing systemic acquired resistance to infection in a plant by applying a composition comprising a Bacillus control agent to said plant wherein said plant is capable of producing defense proteins.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20100092443 - Novel combinations of nitrogenated heterocyclic antibacterial compounds with other antibacterial compounds and the use of same as drugs: The other antibacterial compound is selected among the group comprised of beta-lactams, monobactams or penicillins, if needed combined with a beta lactamases inhibitor, aminoglycosides, glycylcyclines, tetracyclines, quinolones, glycopeptides, lipopeptides, macrolides, ketolides, lincosamides, streptogramins, oxazolidinones, polymyxins and other compounds known to have therapeutic activity on Pseudomonas aeruginosa and Enterobacteriaceae.... Agent: Harness, Dickey & Pierce, P.L.C

20100092430 - Attenuated oncolytic paramyxoviruses encoding avian cytokines: The invention refers to a recombinant oncolytic RNA Newcastle Disease Virus for the treatment of a proliferative disease, comprising at least one transgene coding for an avian cytokine, wherein the recombinant oncolytic RNA Newcastle Disease Virus is obtainable from a velogenic or mesogenic oncolytic RNA Newcastle Disease Virus. Virus-mediated expression... Agent: Millen, White, Zelano & Branigan, P.C.

20100092431 - Edwardsiella ictaluri bacteriophage and uses thereof: Disclosed are isolated bacteriophage that have lytic activity for species of Edwardsiella bacteria including Edwardsiella ictaluri. The disclosed bacteriophage have been designated “ΦeiAU” and “ΦeiDWF.” Also disclosed are variant bacteriophage of ΦeiAU and ΦeiDWF bacteriophage, which variant bacteriophage have lytic activity against Edw. ictaluri. Also disclosed are isolated Edwardsiella ictaluri... Agent: Andrus, Sceales, Starke & Sawall, LLP

20100092432 - Cell preparation containing multipotential stem cells originating in fat tissue: [Means for Solving Problems] It is intended to provide a cell preparation which contains multipotential stem cells originating in a fat tissue and is usable for an ischemic disease, impairment of renal function, wound, urinary incontinence or osteoporosis. As the multipotential stem cells originating in a fat tissue, use is... Agent: Edwards Angell Palmer & Dodge LLP

20100092436 - Compositions and methods for restoring immune responsiveness in patients with immunological defects: The present invention relates generally to methods for stimulating, activating, and maintaining or increasing the polyclonality of expressed TCRs in a population of T cells. In the various embodiments, cells are stimulated with a surface, wherein the surface has attached thereto one or more agents that ligate a cell surface... Agent: Invitrogen Corporation C/o Intellevate

20100092434 - Thrombopoietic activity of tyrosyl-trna synthetase polypeptides: Thrombopoietic compositions are provided comprising tyrosyl tRNA synthetase polypeptides, including truncations and/or variants thereof. Also provided are methods of using such compositions in the treatment of conditions that benefit from increased thrombopoiesis, such as thrombocytopenia.... Agent: Seed Intellectual Property Law Group PLLC

20100092435 - Use of a varicellovirus tap-inhibitor for the induction of tumor-or virus-specific immunity against teipp: The present invention provides a novel approach to the modulation of the immune response, directing it towards specific antigens, away from antigens against which no response is desired. The invention is based on the use of viral immune evasion proteins, such as UL49.5, which block antigen presentation to CD8+ T... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100092433 - Vascularized islets and methods of producing same: An isolated composition of matter is provided comprising a heterogeneous population of cells seeded on a surface of a scaffold, wherein the heterogeneous population of cells comprises at least one pancreatic islet, endothelial cells and fibroblast cells. Methods of generating same and uses thereof are also provided.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100092445 - Adoptive immune cells for tumor vaccines: Adoptive immune cells obtained by a method including (a) obtaining mammalian antigen-presenting associated cells; (b) culturing the resulting cells from step (a) in a culture liquid contained in a culture vessel coated with a sugar chain-containing polymer; and (c) detaching the cells from step (b) by shaking the culture vessel... Agent: Frishauf, Holtz, Goodman & Chick, PC

20100092444 - Platelet rich plasma formulations for cardiac treatments: Compositions for platelet rich plasma (PRP) are provided. Generally, these compositions comprise a higher concentration of platelets and white blood cells than whole blood. The concentrations of the platelets and/or the white blood cells may be two to eight times the respective concentrations in whole blood. These compositions may have... Agent: Knobbe Martens Olson & Bear LLP

20100092446 - Drug solution having reduced dissolved oxygen content, method of producing the same and drug solution containing unit having reduced dissolved oxygen content: It is an object of the present invention to provide a drug solution which has a reduced dissolved oxygen content and is less susceptible to oxidative degradation and highly stable over time, a production method therefor, and a drug solution containing pack which is capable of maintaining the dissolved oxygen... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100092447 - Methods and compositions for the treatment of symptoms of prion diseases: A therapeutic composition for the treatment of the symptoms of prion diseases and the method for preparing the therapeutic agents is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies.... Agent: Kristina M. Grasso Kristina M. Grasso, Esq. PLLC

20100092448 - Local control of inflammation: A medical device includes a carrier and an agent. The agent is formulated to control inflammation of biological tissue, such as heart tissue, and is releasably coupled to the carrier. The carrier is configured to be disposed in operative proximity to the biological tissue to be treated by the agent.... Agent: Kenyon & Kenyon LLP

20100092449 - Treatment of pompe's disease: The invention provides methods of treating Pompe's disease using human acid alpha glucosidase. A preferred treatment regime comprises administering greater than 10 mg/kg body weight per week to a patient.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100092450 - Use of hyaluronidase for the prevention or treatment of arterial hypertension or cardiac insufficiency: The present invention relates to the use of hyaluronidase for the prevention and/or treatment of arterial hypertension or cardiac insufficiency. In addition, the present invention provides a composition and a combined preparation each comprising hyaluronidase and at least one further antihypertensive, and a method of prevention and/or treating arterial hypertension... Agent: Bozicevic, Field & Francis LLP

20100092451 - Combination enzyme therapy for digestion of dietary gluten: A combination enzyme product consisting of a glutamine specific endoprotease and a prolyl endopeptidase is provided. Both enzymes are active and stable in the stomach and can therefore be administered as lyophilized powders or simple capsules/tablets. A ratio of the two enzymes is used to maximize their synergy.... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20100092452 - Replenishment and enrichment of ocular surface lubrication: An ophthalmic composition, and methods of use thereof, including for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface or for the treatment or care of ophthalmic devices. The ophthalmic composition comprises a human PRG4 protein,... Agent: Sutherland Asbill & Brennan LLP

20100092453 - Method of producing porous microparticles: A method of preparing porous microparticles comprises the steps of combining one or more organic compounds with a volatile solvent system, and spray drying the system thus formed to provide porous microparticles of the organic compound or composite porous microparticles of combinations of organic compounds. Organic compounds used in the... Agent: Jacobson Holman PLLC

20100092454 - novel use of antidepressant compounds and related compositions: What is described is a use of an antidepressant compound, preferably belonging to the class of selective serotonin reuptake inhibitors (SSRI), for regenerating the integumentary system and/or for stimulating the growth, the original trophism and/or original pigmentation of the corresponding cutaneous appendages, particularly body hair and/or head hair, in mammals.... Agent: Steinfl & Bruno

20100092460 - Amino acid sequences directed against chemokines and polypeptides comprising the same for the treatment of chemokine-related diseases and disorders: The present invention relates to amino acid sequences that are directed against chemokines, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid... Agent: Wolf Greenfield & Sacks, P.C.

20100092457 - Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies: Methods that involve detection of a DSG3 protein for diagnosing cancer are disclosed. In lung cancer, the expression of DSG3 was found to be enhanced at very high frequency at the gene level and protein level. Methods of the present invention can be carried out using an antibody that recognizes... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100092463 - Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject: A method is described for treating or preventing a bone loss disease or a bone loss disorder in a mammalian subject or reducing the incidence of a bone loss disease or a bone loss disorder or alleviating the symptoms thereof. The method includes providing to the mammalian subject at least... Agent: Searete LLC Clarence T. Tegreene

20100092462 - Methods for suppressing toll-like receptor activity: Agents interfering with translocation of Toll-like receptor 3 (TLR3), methods of making and using the foregoing are disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20100092456 - Methods of treatment: Methods for modulating apoptosis and neurite outgrowth in cells by modulating levels of PtdIns(4,5)P2. Agents for such modulation, including agents which inhibit or activate type I and type II PIP kinases, and methods for identifying such agents. Methods for treating or preventing hyperproliferative disorders and neurodegenerative diseases using such agents.... Agent: Dann, Dorfman, Herrell & Skillman

20100092455 - Novel anti-proliferation antibodies: t

20100092459 - Protein complex and uses: The present invention relates to a complex comprising two or more of the proteins S6K2, PKCε and B-Raf. The invention also relates to antibodies that specifically bind to the complex, inhibitors of the complex and uses of the antibodies, inhibitors and complex in diagnosing and preventing chemoresistance in a patient.... Agent: Sullivan & Worcester LLP

20100092458 - Regulation of apg8 phosphorylation and uses thereof: The invention relates to proteins and peptides of the alpha isoform of light chain 3 (APG8) and antibodies to the APG8 protein, particularly antibodies that specifically bind to the alpha isoform of APG8 when either phosphorylated or not phosphorylated at serine-12 and antibodies that bind to the gamma isoform of... Agent: Morrison & Foerster LLP

20100092461 - Remedy for chemotherapy-resistant cancer containing hla class i-recognizing antibody as the active ingredient and use of the same: The present invention describes therapeutic agents for chemotherapeutic agent-resistant cancers that include an HLA class I-recognizing antibody as an active ingredient. A further objective of the present invention is to provide methods for treating chemotherapeutic agent-resistant cancers that include the step of administering an HLA class I-recognizing antibody to a... Agent: Fish & Richardson PC

20100092469 - Antagonists of a non-selective cation channel in neural cells: The present invention is directed to a combination of therapeutic compounds and treatment methods and kits using the combination. In particular, one of the combination affects the NCca-ATP channel of neural tissue, including neurons, glia and blood vessels within the nervous system. Exemplary SUR1 and/or TRPM4 antagonists that inhibit the... Agent: Fulbright & Jaworski, LLP

20100092470 - Antibodies, analogs and uses thereof: Camelid and shark heavy chain only antibodies and their analogs are disclosed. Methods of making such antibodies and their analogs are also provided. Also provided are kits, and methods of using such antibodies and their analogs in diagnostics, prognostics, therapy, and simultaneous diagnosis and therapy.... Agent: Foley And Lardner LLP Suite 500

20100092466 - Combination of zd6474 and bevacizumab for cancer therapy: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour,... Agent: Morgan Lewis & Bockius LLP

20100092464 - M-csf-specific monoclonal antibody and uses thereof: M-CSF-specific RX1-based or RX-I derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in or remodeling in a subject afflicted with an osteoblastic or osteolytic disease.... Agent: Marshall, Gerstein & Borun LLP

20100092468 - Method for predicting therapeutic responsiveness to tnf-alpha blocking agents: The present invention relates to a method for predicting the responsiveness of a patient to a treatment with a TNF-alpha blocking agent, said method comprising determining the presence or absence of a guanine at position −238, a guanine at position −308, and a cytosine at position −857 of the TNF-alpha... Agent: Stites & Harbison PLLC

20100092467 - Prevention of tissue ischemia, related methods and compositions: Provided herein are compositions and methods for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by... Agent: Klarquist Sparkman, LLP

20100092465 - Treatment of graft-versus-host disease: Methods for treating graft-versus-host disease, methods for reducing symptoms of graft-versus-host disease, and methods of reducing the severity of graft-versus-host disease in a patient are disclosed. The methods comprise administering to the patient a therapeutically effective amount of an IL-27 antagonist in combination with a pharmaceutically acceptable vehicle. IL-27 antagonists... Agent: Woodcock Washburn LLP

20100092473 - Anti-phospho-akt antibodies: The present invention relates to antibodies that immunospecifically bind to phospho-Akt and certain p-Akt substrates. The invention encompasses human and humanized forms of the antibodies and their use in treating cancers and other proliferative disorders. The invention also relates to p-Akt-derived peptides useful for preparing the antibodies. Methods and compositions... Agent: Nuclea Biotechnologies, LLC

20100092472 - Compounds and methods for the modulation of beta-1 integrin function to mediate tissue repair: The present invention provides methods and compositions which modulate beta 1 integrin activity by functioning as allosteric antagonists. In particular, the present invention provides methods for mediating tissue repair where insult or injury has occurred by antagonising the allosteric function of beta 1 integrin.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20100092471 - Porphyromonas gingivalis polypeptides useful in the prevention of periodontal disease: The invention is directed to vaccine compositions and methods based on P. gingivalis proteins identified to be regulated by haem availability that can be used in the prevention and treatment of periodontal disease. In particular, two specific internalin-like P. gingivalis proteins, namely PG0350 and PG1374 involved in the internalization of... Agent: Dla Piper LLP (us)

20100092479 - Compositions and methods for treatment of viral diseases: The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B,... Agent: Gearhart Law LLC

20100092478 - Materials and methods for evaluating and treating neuromyelitis optica (nmo): The invention provides prognostic methods for evaluating the severity of NMO and NMO-associated diseases as well as methods of treating NMO and NMO-associated diseases.... Agent: Fish & Richardson P.C.

20100092477 - Methods and compositions for treating prostate cancer: A polypeptide comprising an androgen binding region, the androgen binding region capable of binding to an androgen at a sufficient affinity or avidity such that upon administration of the polypeptide to a mammalian subject the level of biologically available androgen is decreased. Specifically disclosed is an AR IgG1 Fc fusion... Agent: Winston & Strawn LLP Patent Department

20100092476 - Pancreatic cancer biomarkers: The present invention provides a method of diagnosing, prognosing or screening for pancreatic cancer in a subject. The method may be carried out on a sample such as a blood or tissue sample collected from the subject. The is carried out by (a) detecting one or more markers in a... Agent: Myers Bigel Sibley & Sajovec

20100092474 - Pharmaceutical combinations: or salts, tautomers, solvates and N-oxides thereof; wherein R1 is hydroxy or hydrogen; R2 is hydroxy; methoxy or hydrogen; provided that at least one of R1 and R2 is hydroxy; R3 is selected from hydrogen; halogen; cyano; optionally substituted C1-5 hydrocarbyl and optionally substituted C1-5 hydrocarbyloxy; R4 is selected from... Agent: Frommer Lawrence & Haug

20100092475 - Treatment method using egfr antibodies and src inhibitors and related formulations: The present invention relates to the treatment of EGFR-mediated disease, particularly cancer by inhibiting or blocking EGFR and src in combination or simultaneously. The invention relates to treatment, prevention, or modulation of cancer, particularly EGFR-mediated disease, with one or more EGFR modulator and src inhibitor in combination. The invention further... Agent: Klauber & Jackson

20100092480 - Modulators of protein phosphatase 2a: Atomic coordinates for human serine/threonine protein phosphotase 2A (PP2A) core, as well as methods for using these atomic coordinates to prepare inhibitors of PP2A and inhibitors prepared using such methods are provided herein. A biochemical analysis of the interactions of PP2A core is also provided. Compositions including mimetics and small... Agent: Pepper Hamilton LLP

20100092481 - Human cytomegalovirus neutralising antibodies and use thereof: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes... Agent: Global Patent Group - Hmb

20100092484 - Cd44 antibodies: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to CD44, and that function to inhibit CD44. The invention also relates to heavy and light chain immunoglobulins derived from human CD44 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates... Agent: Dickstein Shapiro LLP

20100092482 - Compositions monovalent for cd40l binding and methods of use: The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of DC40L. in one aspect, a monovalent anti-CD40L antibody polypeptide consists... Agent: Edwards Angell Palmer & Dodge LLP

20100092483 - Compositions monovalent for cd40l binding and methods of use: The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of DC40L. in one aspect, a monovalent anti-CD40L antibody polypeptide consists... Agent: Edwards Angell Palmer & Dodge LLP

20100092485 - Genetic markers for predicting responsiveness to combination therapy: The invention provides compositions and methods for determining the likelihood of successful treatment with an effective amount of an anti-VEGF antibody or equivalent thereof, in combination with anti-EGFR antibody or equivalent thereof, and, in some aspects in combination with a topoisomerase inhibitor. The methods comprise determining the identity of a... Agent: Foley & Lardner LLP

20100092486 - Modulation of myeloid differentation primary response gene 88 (myd88) expression by antisense oligonucleotides: Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of MyD88. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding MyD88. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding MyD88 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100092487 - Toxic detection method: According to the present invention, an antibody against a Panton-Valentine leukocidin toxin contained in Staphylococcus aureus, a method and a kit for detecting the toxin with the use of the antibody, and a pharmaceutical composition containing an antibody against a Panton-Valentine leukocidin toxin for treating PVL infection caused by Staphylococcus... Agent: Foley And Lardner LLP Suite 500

20100092489 - Combination treatment of cd38-expressing tumors: The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non- corticosteroid chemotherapeutic agent.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100092488 - Method for treatment or prevention of disease associated wtih functional disorder of regulatory t cell: The inventors examined the role of MK in experimental autoimmune encephalomyelitis, which is a human model for multiple sclerosis. As a result, they discovered that MK has the effect of inhibiting regulatory T cells, and that the autoimmune mechanism induced by type 1 helper T cells can be suppressed by... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100092491 - Anti-epcam antibody and uses thereof: An anti-EpCAM antibody, designated ST3232/10, of marine origin exhibits properties suitable for both therapeutic and diagnostic applications. It shows high affinity for the native antigen and good tumour selectivity.... Agent: Steinfl & Bruno

20100092490 - Method for assay on the effect of vascularization inhibitor: The present invention provides a method of predicting the antitumor effect of an angiogenesis inhibitor. It is possible to predict the antitumor effect of an angiogenesis inhibitor by evaluating the EGF dependency of a tumor cell for proliferation and/or survival and using the EGF dependency as an indicator. Since the... Agent: Dickstein Shapiro LLP

20100092492 - Vascular endothelial cell growth factor antagonists: The present invention provides vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that inhibit the mitogenic, angiogenic, or other biological activity of hVEGF. The antagonists thus are useful for the treatment of diseases and disorders characterized by undesirable or excessive endothelial cell proliferation... Agent: Genentech, Inc.

20100092493 - Modulation of complement system activation for treatment of bleeding-related inflammation: This invention provides, inter alia, methods and compositions for treating, reducing the incidence of, reducing the severity of, or delaying onset or advancement, of synovitis and/or bleeding-associated inflammation in a subject in need thereof. The compositions comprise, and methods make use of, an effective amount of an agent, which abrogates... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100092494 - Composition and method for facilitating the internalization of a therapeutic agent into a cell: The present invention is a composition and method for facilitating the internalization of a therapeutic agent into a cell. Specifically, the invention relates to the use of the extracellular domain of basigin-2, cyclophilin, or anti-basigin-2 antibody or antibody fragment as a delivery moiety for internalization of a therape.... Agent: Jane Massey Licata Licata & Tyrrell P. C.

20100092496 - Chemical linkers and conjugates thereof: The present disclosure provides drug-ligand conjugates that are potent cytotoxins, wherein the drug is linked to the ligand through either a peptidyl, hydrazine, or disulfide linker. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.... Agent: Medarex C/o Darby & Darby P.C.

20100092495 - Potent cell-binding agent drug conjugates: The present invention relates to the use of about 2 to about 8 drug molecules, for example, maytansinoid, per cell binding agent, such as an antibody, and maximal efficacy as compared to a drug load of lesser or higher number of drugs linked to such a cell binding agent.... Agent: Sughrue Mion, PLLC

20100092498 - Anti-tumour vaccine derived from normal chemically modified cells: A composition for inducing an immune response in a mammal, comprises lymphoid cells in which expression of tumor antigens has been chemically induced. The tumor antigens are induced in proliferating normal lymphoid cells, especially during the log phase of proliferation. The proliferation of the normal lymphoid cells is stimulated by... Agent: Occhiuti Rohlicek & Tsao, LLP

20100092497 - Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer: Use of lactoferrin or metal ion lactoferrin, preferably iron lactoferrin, preferably bovine lactoferrin, preferably iron bovine lactoferrin, or a metal ion functional variant or functional fragment thereof and at least one anti-tumour food factor selected from soy protein and vitamin D inhibits tumour formation or growth, maintains or improves one... Agent: Knobbe Martens Olson & Bear LLP

20100092499 - Alpha thymosin peptides as cancer vaccine adjuvants: A pharmaceutical combination and method for enhancing cancer vaccine effectiveness in a subject, utilize an immune response-triggering cancer vaccine capable of eliciting an immune system response in a subject; and a vaccine effectiveness-enhancing amount of an alpha thymosin peptide, which enhances the immune system response in the subject, wherein the... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100092501 - Foxp3 peptide vaccine: The present invention provides Foxp3 peptides comprising the amino acid sequence of SEQ ID NOs: 3-5, 7-9, 12, 15-19, 22, 24, 27-30, 37, 67 or 74, and Foxp3 peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted or added, and having cytotoxic... Agent: Townsend And Townsend And Crew, LLP

20100092500 - Novel immunogenic lipopeptides comprising t-helper and b-cell epitopes: The present invention provides synthetic immunogenic lipopeptide molecules comprising co-linear T-helper and B cell epitopes, and methods for their production and use in the generation of primary and secondary immune responses, and for the vaccination of animal subjects against particular antigens. More particularly, the present invention provides highly soluble lipopeptides... Agent: Fenwick & West LLP

20100092502 - Modified hiv env polypeptides: Polynucleotide encoding modified HIV Env polypeptides are disclosed. The Env polypeptides are modified so as to expose at least part of the CD4 binding region. Methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided.... Agent: Novartis Vaccines And Diagnostics Inc.

20100092503 - Hcv fusion polypeptideds: The invention provides HCV fusion polypeptides including truncated or full-length HCV NS5 polypeptides, and a portion of the HCV NS2 polypeptide, fused to at least one other HCV epitope derived from another region of the HCV polyprotein. The fusions can be used in methods of stimulating an immune response to... Agent: Novartis Vaccines And Diagnostics Inc.

20100092504 - Combined human papillomavirus vlp/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors: The present invention relates to compositions that contain a chimeric papillomavirus virus-like particle (VLP) in combination with a DNA molecule encoding a protein or polypeptide epitope. The chimeric papillomavirus VLP is assembled from an L1 protein or polypeptide and a chimeric protein or polypeptide containing at least a portion of... Agent: Nixon Peabody LLP - Patent Group

20100092505 - Method for shielding functional sites or epitopes on proteins: Methods of site-specifically shielding one or more binding sites within a polypeptide are disclosed, comprising attaching at least one small molecular weight, water-soluble polymer to said polypeptide such that the binding site is masked by said polymer. The shielding of a binding site (e.g., epitope) as per the disclosed methods... Agent: Merck And Co., Inc

20100092507 - Purified component of blue-green algae and method of use: Disclosed herein are extracts of blue green algae, such as Aphanizomenon flos aquae, that are enriched for a selectin ligand, such as an L-selectin ligand. Selectin ligands isolated from blue-green algae cells are disclosed herein. Methods are described for isolating these selectin ligands. The purified selectin ligands are of use... Agent: Klarquist Sparkman, LLP

20100092506 - Use of phaeodactylum algae extract for depigmenting the skin: The invention relates to the use in a cosmetic composition of an extract of the alga Phaeodactylum tricornutum, as a depigmenting active agent intended in particular for attenuating or eliminating skin pigmentation marks or for lightening the complexion or bodily hairs or head hair. The extract is preferably a lipid... Agent: Woodcock Washburn LLP

20100092508 - Molecular antigen arrays: The present invention provides a composition comprising an AP205 virus like particle (VLP) and an antigen. The invention also provides a process for producing an antigen or antigenic determinant bound to AP205 VLP. AP205 VLP bound to an antigen is useful in the production of compositions for inducing immune responses... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100092509 - Hypo- and hyper- acetylated meningococcal capsular saccharides: Capsular saccharides derived from serogroups W135 and Y of Neisseria meningitidis have altered levels of O-acetylation at the 7 and 9 positions of their sialic acid residues, and can be used to make immunogenic compositions. Relative to unmodifed native saccharides, derivatives of the invention are preferentially selected during conjugation to... Agent: Novartis Vaccines And Diagnostics Inc.

20100092510 - Turkey herpesvirus vectored recombinant containing avian influenza genes: The present invention provides a recombinant turkey herpesvirus modified by the presence of the cDNA encoding the hemagglutinin protein of avian influenza virus under a promoter. A poultry vaccine comprising the recombinant turkey herpesvirus described in the present invention can induce serological responses that may be easily detected by the... Agent: Kratz, Quintos & Hanson, LLP

20100092511 - Escherichia coli mutants and methods of use thereof: The present invention provides methods and compositions for production of gram-negative bacterial mutants that are defective in intestinal colonization capacity and sensitive to infection by bacteriophage P1. Thus the present invention provides immunogenic compositions for the prevention or attenuation of food- and water-borne illnesses associated with ingestion of bacteria such... Agent: Lawson & Weitzen, LLP

20100092512 - Methods for preventing and ameiliorating porcine respiratory and reproductive syndrome virus-associated disease by immunizing against porcine ttv infection: Compositions and methods for preventing and ameliorating Porcine respiratory and reproductive syndrome virus (PRRSV)-associated diseases in pigs by immunizing against Torque teno virus (TTV) are disclosed. Also described are methods of identifying compounds for the treatment and prevention of PRRSV-associated diseases.... Agent: Robins & Pasternak

20100092513 - Methods and compositions for inducing an immune response to hiv and models for testing: The invention provides methods and compositions for raising an immune response in a subject by administering an HIV antigen. The HIV antigens include HIV clade C polynucleotides and polypeptides. The invention also provides for recombinant HIV viral particles and compositions.... Agent: Edwards Angell Palmer & Dodge LLP

20100092514 - Method and device for producing vaccine: A method of making a vaccine using animal derived component free (ADCF) cell culture technology, including the steps of attaching ADCF-adapted cells to a microcarrier including an attachment mechanism for attaching filipodia of the cells, the microcarrier being in a culture, growing the cells in ADCF maintenance media, infecting the... Agent: Shook, Hardy & Bacon LLP Intellectual Property Department

20100092515 - Herpes simplex viruses and methods of viral replication: A herpes simplex virus is disclosed in which the herpes simplex virus genome comprises a nucleic acid sequence encoding an ING4 polypeptide.... Agent: Swanson & Bratschun, L.L.C.

20100092516 - Bacterial ghost (bg) production process using betapropiolactone (bpl) for final inactivation: The invention relates to bacterial ghost preparation using betapropiolactone for final inactivation of bacteria.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100092517 - Dose and localization of botulinum toxins in skin and muscle: A novel dosing regimen for the administration of botulinum toxin based on the pattern, quantity, and location of neuromuscular junctions in the target tissue. Because the number of neuromuscular junctions in a target tissue remains generally stable throughout life and because the pharmacological effect of botulinum toxin is localized at... Agent: John S. Hale Gipple & Hale

20100092518 - Recombinant intracellular pathogen immunogenic compositions and methods of use: Immunogenic compositions comprising recombinant attenuated intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens are provided. Exemplary immunogenic compositions include, but are not limited to attenuated recombinant Mycobacteria expressing the major extracellular non-fusion proteins of Mycobacteria and/or other intracellular pathogens. Other... Agent: K&l Gates LLP

20100092519 - Compositions comprising polysaccharide conjugates and their use as vaccines: The present invention is in the field of combination therapies, including vaccine compositions, which comprise polysaccharide-protein conjugates and outer membrane vesicles (OMVs) from commensal bacteria, particularly commensal Neisseria.... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20100092520 - Recombinant plasmodium falciparum merozoite surface proteins 4 and 5 and their use: Accordingly, the invention provides constructs in which the nucleic acids encoding Plasmodium falciparum MSP4 and MSP5, and the resulting polypeptides, have been modified. More particularly, this invention provides constructs encoding recombinant MSP4 and MSP5 polypeptides, which are expressed as soluble, secreted polypeptides in a baculovirus-insect cell expression system. It was... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100092521 - Antigenicity of infectious pancreatic necrosis virus vp2 sub-viral particles expressed in yeast: Infectious pancreatic necrosis virus (IPNV), the etiologic agent of infectious pancreatic necrosis in salmonid fish, causes significant losses to the aquaculture industry. The gene for the viral capsid protein (VP2) was cloned into a yeast expression vector and expressed in Saccharomyces cerevisae. Expression of the capsid gene in yeast resulted... Agent: Moore & Van Allen PLLC

20100092522 - Immunogenic wt-1 peptides and methods of use thereof: This invention provides peptides, immunogenic compositions and vaccines comprising same, and methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, comprising same.... Agent: Pearl Cohen Zedek Latzer, LLP

20100092524 - Modification of exosomal components for use as a vaccine: The presently disclosed subject matter provides modified cell-derived exosomes substantially lacking one or more immunosuppressive polypeptides. The presently-disclosed subject matter further provides methods of producing the modified exosomes and methods of using the modified exosomes for treating cancers.... Agent: Stites & Harbison, PLLC

20100092523 - Molecules and methods for treatment and detection of cancer: The invention provides a method for inhibiting proliferation of cancer cells, as well as methods for detecting and treating various cancers, including cancer of the ovary, breast, prostate and colon. The method comprises contacting a cancer cell with an IGF-related molecule of the invention or administering an IGF-related vaccine to... Agent: Karen S. Canady Canady & Lortz LLP

20100092525 - Medical device: A medical device for delivery of a therapeutic agent to a physiological target site includes a flexible receptacle containing said therapeutic agent, wherein at least a part of the receptacle is formed of a water-soluble or water-dispersible material. The therapeutic agent may include a haemostatic agent and the physiological target... Agent: Barlow, Josephs & Holmes, Ltd.

20100092526 - Nanoemulsion therapeutic compositions and methods of using the same: The present invention relates to therapeutic nanoemulsion compositions and to methods of utilizing the same. In particular, nanoemulsion compositions are described herein that find use in the treatment and/or prevention of infection (e.g., respiratory infection (e.g., associated with cystic fibrosis)), in burn wound management, and in immunogenic compositions (e.g., comprising... Agent: Foley And Lardner LLP Suite 500

20100092527 - Glass flakes, and cosmetic containing the same: The glass flakes of the present invention each include a glass flake substrate and a coating layer coating the surface of the glass flake substrate. The glass flake substrates have an average thickness of 0.1 to 1.0 μm, and an average particle size of 1 to 100 μm. The coating... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20100092528 - Fructan-based epilatory compositions: The invention relates to an epilatory mixture comprising a fructan, preferably inulin. Furthermore, an epilatory composition is disclosed comprising said epilatory effective mixture. Also a method of use of said epilatory composition of the invention for the removal of unwanted hair from the skin is disclosed, as well as a... Agent: Hayes Soloway P.C.

20100092529 - Method for acaricidal and microbicidal treatment of textile materials: The present invention concerns a method of agaricidal and microbicidal treatment of textile materials, a Neem oil microcapsule composition specifically for said treatment and a bioactive textile material obtained. More particularly, the present invention concerns the industrial and commercial areas of the treatment of fabrics and like products and is... Agent: Dennison, Schultz & Macdonald

20100092530 - Novel triclosan salts: Novel silver-triclosan salts are provided which have antimicrobial properties and may be used as pharmaceutical compositions or to treat articles such as medical devices, packaging materials, and textiles.... Agent: Tyco Healthcare Group Lp

20100092531 - Textile implant of sheath-core construction and method of forming it: A textile implant includes at least one thread having a polymeric core and a polymeric sheath which surrounds the polymeric core at least partly, wherein the sheath includes a composition including at least one silica-supported antimicrobial active agent.... Agent: Ip Group Of Dla Piper LLP (us)

20100092533 - Bioabsorbable surgical composition: Bioabsorbable macromer compositions are provided including a polymeric component possessing a hydroxamate segment and a polymer segment. The polymeric component can be used by itself, or in some embodiments, combined with a second component, to form a macromer composition of the present disclosure. The resulting bioabsorbable macromer composition can be... Agent: Tyco Healthcare Group Lp

20100092532 - Materials and methods for treating and managing angiogenesis-mediated diseases: Disclosed herein are materials and methods suitable for treating sites of pathological angiogenesis and abnormal neovascularization. Sites of pathological angiogenesis or abnormal neovascularization can be treated by contacting a surface at or adjacent or in the vicinity of an area of pathological angiogenesis or abnormal neovascularization with an implantable material.... Agent: K&l Gates LLP

20100092534 - Combination local delivery using a stent: Described herein are implantable medical devices useful in treating vascular conditions such as restenosis. In one embodiment, stents are described in which a combination of bioactive agents is described for local delivery in the vasculature. The combination of bioactive agents comprises at least one compound capable of inhibiting smooth muscle... Agent: Medtronic Vascular, Inc.IPLegal Department

20100092540 - Drug delivery compositions and medical devices containing block copolymer: A composition for delivery of a therapeutic agent is provided. The composition comprises: (a) a biocompatible block copolymer comprising one or more elastomeric blocks and one or more thermoplastic blocks and (b) a therapeutic agent, wherein the block copolymer is loaded with the therapeutic agent. The block copolymer is preferably... Agent: Mayer & Williams PC

20100092539 - Fluorinated ghrh antagonists: Novel fluorinated synthetic analogs of hGH-RH(1-30)NH2 that inhibit the release of growth hormone from the pituitary in mammals as well as inhibit the proliferation of human cancers through a direct effect on the cancer cells, and to therapeutic compositions containing these novel peptides and their use.... Agent: Omri M. Behr

20100092536 - Implantable sensors and implantable pumps and anti-scarring agents: Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.... Agent: Seed Intellectual Property Law Group PLLC

20100092535 - Nanoporous drug delivery system: Disclosed herein are controlled release drug delivery systems. The systems comprise a medical device at least one nonoporous surface, at least one bioactive agent and optionally a biodegradable polymer. The nanoporous surfaces of the medical devices contain nanopores capable of acting as reservoirs for drugs that are controllably released.... Agent: Medtronic Vascular, Inc.IPLegal Department

20100092538 - Nucleic acids encoding spider glue proteins and methods of use thereof: Nucleic acids encoding spider glue proteins and methods of use thereof are disclosed.... Agent: Dann, Dorfman, Herrell & Skillman

20100092537 - Surgical implant composite materials and kits and methods of manufacture: A surgical implant composite material comprises a surgical implant substrate and a thin film coating deposited on the substrate, the thin film coating comprising TiO2-xMy, wherein M is one or more elements which does not adversely effect adherence of the coating to the substrate, y is the sum of the... Agent: Drinker Biddle & Reath (dc)

20100092541 - Compositions and methods for treatment of eye disorders: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a... Agent: Wilson, Sonsini, Goodrich & Rosati

20100092542 - Compositions and methods for treatment of eye disorders: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a... Agent: Wilson, Sonsini, Goodrich & Rosati

20100092543 - Dimpled adhering troche for use on teeth or orthodontic braces: A dissolving oral adhering disc with a dimple on at least one side to improve adhesion to hard convex surfaces in the mouth, including teeth, orthodontic braces, and gums (keratinized gingiva). The disc may be designed to prevent or treat a sore in the mouth opposite a tooth or brace... Agent: Jeffrey T. Haley

20100092544 - Adhesive composition for patch and use thereof: The present invention provides an adhesive composition for patch, containing a rubber elastomer and a tackifier having a weight average molecular weight of 1200-2500, a patch having a support and an adhesive layer containing the composition, which is provided on at least one surface of the support, and a patch... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100092545 - Polyethylene-oxide based films and drug delivery systems made therefrom: The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. The films contain a polymer component,... Agent: Hoffmann & Baron, LLP

20100092546 - Topical and transdermal delivery of hif-1 modulators to prevent and treat chronic wounds: Compositions and methods are provided for the treatment of chronic wounds, including, without limitation, pressure ulcers and diabetic ulcers, by transdermal delivery of an agent that increases activity of HIF-1α in the wound. Agents that increase HIF-1α activity include, without limitation, agents that stabilize HIF-1α, e.g. deferoxamine, deferiprone, deferasirox, etc.;... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20100092547 - Compositions and methods for preventing and treating mucositis and weight loss: A method for prophylaxis and/or treatment of mucositis comprising the steps of providing a therapeutically effective amount of a composition comprising either (1) at least one compound selected from the group consisting of 5-[2-pyrazinyl]-4-methyl-1,2-3-thione or an analogue, derivative, metabolite, prodrug, solvate or a pharmaceutically acceptable salt thereof; or (2) a... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100092548 - Chewable softgel capsules: A chewable softgel capsule configured for encasing orally ingestible articles. The chewable soft capsule is provided with an outer shell composition which comprises at least one gelatin in a range of 20% to 60% of the total weight of the shell composition, at least one plasticizer in an amount selected... Agent: Fasken Martineau Dumoulin LLP

20100092549 - Dosage form containing two or more active pharmaceutical ingredients in different physical forms: A dosage form for administration of two or more active pharmaceutical ingredients to a subject, comprising a first pharmaceutical composition comprising a first active pharmaceutical ingredient and optionally one or more pharmaceutically acceptable excipients in a first physical form selected from the group consisting of powder, granule, pellet, bead or... Agent: Summa, Additon & Ashe, P.A.

20100092550 - Alka-eeze: A composition for providing relief from acidity. The composition comprises sodium bicarbonate for use in neutralizing acids. There is one of a capsule and a tablet for enclosing the sodium bicarbonate therein, such one of such capsule and such tablet being a delayed release and a timed release system so... Agent: James Ray & Associates

20100092553 - anti-misuse microparticulate oral pharmaceutical form: The invention relates to a solid oral pharmaceutical form which is characterized in that it contains anti-misuse means, in that at least part of the AP it comprises is contained in coated microparticles for modified release of the AP, and in that the coated microparticles of AP have a coating... Agent: Patton Boggs LLP

20100092552 - Low dose controlled release tablet: Low dose pharmaceuticals can be delivered for a prolonged period using a tablet-in-tablet design wherein the drug is contained in a controlled release matrix in the outer compression coating layer but not in the inner tablet core.... Agent: SynthonIPInc

20100092551 - Solid preparation comprising alogliptin and pioglitazone: w

20100092554 - Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof: The present invention is directed to a combination of an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof with a conventional treatment option of Parkinson's Disease.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100092555 - Soft tablet containing high molecular weight cellulosics: The invention relates to an immediate release tablet capable of being chewed or disintegrated in the oral cavity, which comprises a pharmaceutically active ingredient having an optional tastemasking coating, and a matrix comprising hydroxyalkylcellulose having a weight average molecular weight of from about 60,000 to about 5,000,000. The tablet possesses... Agent: Philip S. Johnson Johnson & Johnson

20100092556 - Alfuzosin formulations, methods of making, and methods of use: Alfuzosin compositions comprising a tablet core of alfuzosin and a release-retarding matrix comprising about 40 to about 80% (by weight) hydroxypropyl methyl cellulose with a maximum apparent viscosity of about 5600 cP, based on the total weight of the tablet core; and an extended-release coating substantially surrounding the tablet core... Agent: Cantor Colburn, LLP

20100092557 - Dosage form comprising immediate release naproxen and sustained release opioid analgesic: A dosage form adapted for twice-a-day administration comprising a naproxen species in an immediate release phase and an opioid analgesic in a sustained release phase. The dosage form is useful in the treatment of pain.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100092559 - Boldine compounds for promoting bone growth: The present invention provides a method of promoting bone growth in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I. The present invention also provides methods for the treatment of renal disease and cancer.... Agent: Townsend And Townsend And Crew, LLP

20100092558 - Method for producing a product having a polymer matrix, implants made thereof and use thereof: The invention concerns a method for the production of a product having a polymer matrix, products which can be produced in accordance therewith and the use thereof.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100092560 - Reduced coenzyme q10-containing particulate composition and method for producing the same: The present invention aims to propose a particulate composition containing reduced coenzyme Q10, which simultaneously shows high oxidative stability and high absorbability in the body and a production method thereof, as well as a stabilizing method thereof, to be used in the fields of foods, foods with nutrient function claims,... Agent: Sughrue Mion, PLLC

20100092561 - Methods and compositions using substance p to promote wound healing: Healing of wounds in mammalian tissue may be enhanced by the application of certain neuropeptides, optionally in combination with known growth promoting hormones. Exemplary neuropeptides include tachykinins, such as Substance P, Substance K, and the like, as well as calcitonin gene-related peptides. The compositions may further include a polymeric delivery... Agent: Dunlap Codding, P.C.

20100092562 - Sustained-release drug delivery compositions and methods: The present invention relates to liquid sustained release suspension dosage forms. In particular, the invention encompasses sustained release compositions comprising a dispersed phase, which contains an ion-exchange matrix drug complex, a diffusion controlling membrane coating and a dispersion medium comprising an excipient capable of impeding water activity such that drug... Agent: Jones Day

20100092564 - Composition of and method for preparing orally disintegrating tablets: An improved orally dissolving tablet (ODT) and method of manufacture is provided. The improved ODT disclosed herein are prepared by direct compression of a mixture of pharmaceutical excipients including at least one water-insoluble hydrophobic inorganic salt in combination with at least one water-insoluble inorganic salt with less hydrophobicity compared to... Agent: Mallinckrodt Inc.

20100092568 - Drug microparticles: Provided are microparticles of active pharmaceutical ingredients, drug delivery vehicles comprising same, and methods for making them.... Agent: Kenyon & Kenyon LLP

20100092566 - Highly concentrated drug particles, formulations, suspensions and uses thereof: Highly concentrated drug particle formulations are described, wherein the drug comprises between about 25 wt % and 80 wt % of the particle formulation. The particle formulations of the present invention comprise, for example, macromolecules, such as proteins and/or small molecules (such as steroid hormones). The particle formulation typically further... Agent: Intarcia Therapeutics, Inc. Attn: Barbara G. Mcclung

20100092567 - Immunostimulatory nanoparticles and related compositions, methods and systems: Provided herein are immunostimulatory nanolipoprotein particles and related compositions methods and systems.... Agent: Llnl/steinfl & Bruno John H. Lee, Assistant Laboratory Counsel

20100092563 - Methods for the preparation of biologically active compounds in nanoparticulate form: A method for producing a composition comprising nanoparticles of a biologically active compound.... Agent: Mark J. Rosen P.C.

20100092565 - Pharmaceutical composition comprising microparticle oily suspension: A pharmaceutical composition comprising a suspension of medicinally-active ingredient microparticles having a mean particle diameter of 20 μm or smaller in a base oil which can achieve extremely high intestinal absorption and bioavailability especially when the medicinally-active ingredient is hardly water-soluble.... Agent: Greenblum & Bernstein, P.L.C

20100092570 - Controlled release oxycodone compositions: A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation... Agent: Jones Day

20100092571 - Microcapsules having multiple shells and method for the preparation thereof: Single-core and multi-core microcapsules are provided, having multiple shells, at least one of which is formed of a complex coacervate of two components of shell materials. The complex coacervate may be the same or different for each shell. Also provided are methods for making the microcapsules.... Agent: Ballard Spahr LLP

20100092569 - Product based on conjugated linoleic acid and a method for the manufacture thereof: A product based on conjugated linoleic acid (CLA) comprises an inner core in which the conjugated linoleic acid is substantially concentrated as well as a coating for covering and protecting the inner core; the coating in turn comprises a fraction greater than 80% by weight relative to the coating of... Agent: Castellano PLLC

20100092572 - Chitosan-based colloidal particles for rna delivery: The present invention provides new colloidal particles of negative zeta potential comprising a ribonucleic acid, a chitosan and a polyanion, and compositions comprising such particles. The compositions are useful for delivery of ribonucleic acids into mammalian cells in vitro, ex vivo and in vivo.... Agent: Richard Voellmy

20100092573 - Hemostatic bio-material composition and method: The present invention relates to a haemostatic bio-material composition and method for achieving hemostasis. The method for providing hemostasis generally comprises: supplying a dry potassium phosphate based hemostat mixture comprising: monobasic potassium phosphate, a metal oxide, and a tertiary calcium phosphate, wherein the weight percent ratio of monobasic potassium phosphate... Agent: Thomas Lally

20100092575 - Method of making treatment materials and using same to treat algae and/or pests: The present invention is directed to a composition for treating algae and pests in water or soil. The compositions of the present invention include an oxidizing agent, a thickener, and water. It is preferable to further include a stabilizer for the oxidizing agent. The components of the composition are preferably... Agent: Gregor Neff, Esq.

20100092574 - Synergistic peroxide based biocidal compositions: Disclosed is a method for controlling microbial growth in an aqueous system containing sulfite and/or bisulfite residues by addition of a peroxy compound at a pH of greater than 5. Also disclosed is a method for stabilizing an active halogen biocide in an aqueous system containing peroxide residues by addition... Agent: Hoffmann & Baron, LLP

20100092576 - Pharmaceutical compositions containing lanthanum hydroxycarbonate: An assay for analytically determining the amount of an impurity in a solid sample is provided. This X-ray diffraction method preferably uses the Rietveld refinement.... Agent: Darby & Darby P.C.

20100092577 - Topical compositions containing magaldrate: Disclosed are topical compositions containing the active ingredient magaldrate mixed with suitable vehicles and excipients.... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20100092579 - Medicament for treating lung cancer: Lung cancer can be treated effectively by combination of amrubicin or a pharmaceutically acceptable salt thereof with cisplatin.... Agent: Birch Stewart Kolasch & Birch

20100092578 - Protein kinase c iota: The invention involves PKCι signaling. The invention provides, for example, transgenic animals, inhibitors of PKCι signaling, methods for inhibiting PKCι signaling, methods for identifying inhibitors of PKCι signaling, and methods for diagnosing cancer.... Agent: Fish & Richardson P.C.

20100092580 - Weight reducing composition: The invention relates to soft drink industry, in particular, to dietetic nutrition. The inventive weight reducing composition comprises 0.01-10 mg/l of sodium and 25-150 mg/l of magnesium, the rest being water. Said composition (drinking water) makes it possible to reduce weight without altering the usual eating habits. In addition, consumption... Agent: Patent, Copyright & Trademark Law Group

20100092581 - Antibacterial compositions comprising an extract from arceuthobium: This application relates to an antibacterial composition comprising an extract from a plant belonging to the genus Arceuthobium, such as Arceuthobium americanum. The composition may be used in a pharmaceutical composition or a disinfectant. The invention also relates to a method of treating or preventing a bacterial infection, the method... Agent: Berliner & Associates

20100092582 - Topical hair care formulation and method of making: A topical hair care formulation and method of making includes combining generally equal amounts of eclipta alba herbal powder and embelica officinalis herbal powder to form a herbal powder mixture. The herbal powder mixture is steeped in an amount of base oil for a period of time to form a... Agent: Lavonda D. Anderson

20100092583 - Antioxidant-enriched fruit extracts and uses thereof in the treatment and prevention of diabetes and obesity: A method of treating or preventing diabetes or obesity that comprises administering an antioxidant-enriched composition produced by fermenting fruit extracts with the bacteria Serratia vaccinii. The antioxidant-enriched composition is capable of decreasing plasma glucose levels, increasing circulating adiponectin levels and decreasing hyperphagia in a subject.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100092584 - Composition comprising the extract of combined herbs for preventing and treating liver disease: The present invention is related to a combined herb composition comprising herbs of Coriolus versicolor, Astragalus membranaceus Bunge, and additionally comprising at least one herb selected from group consisting of Schisandra chinensis, and Artemisia capillaris, according to the need for the prevention and treatment of liver disease and methods of... Agent: Kirk Hahn

20100092585 - Plant extraction method and compositions: The present invention pertains to methods of extracting cardiac glycosides from cardiac glycoside containing plant material, such as Nerium oleander, through use of aloe. It further provides for compositions resulting from such extractions, pharmaceutical compositions, cosmetic compositions, and methods of treating skin conditions.... Agent: Knobbe Martens Olson & Bear LLP

20100092586 - Natural water soluble extracts for the inhibition of alpha-1-adrenergic receptors: The present invention discloses therapeutic natural products, in particular plant extracts effective in treating and preventing urinary tract disorders, and method for obtaining said extracts. In particular, the present invention discloses a water-soluble alcoholic extract of Opuntia ficus-indica flower (NABIA extract), a component thereof (NABIA fraction) or any mixture of... Agent: Nixon & Vanderhye, PC

20100086480 - Low radiocarbon dietary supplements and methods of making same: Methods for significantly lowering the carbon-14 content, particularly of DNA and histones in vertebrates, especially humans, to significantly below normal background levels and thereby reduce chromosomal damage using dietary supplements based on low radiocarbon DNA and histone precursors optionally including selected low radiocarbon amino acids, preferably including those which contribute... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20100086481 - Differential expression of molecules associated with intra-cerebral hemorrhage: Methods are provided for evaluating a stroke, for example for determining whether a subject has had a hemorrhagic stroke, determining the severity or likely neurological recovery of a subject who has had a hemorrhagic stroke, and determining a treatment regimen for a subject who has had a hemorrhagic stroke, as... Agent: Klarquist Sparkman, LLP

20100086482 - Divergent synthesis of looped poly(ester)-and poly(ether)-substituted dendrons and dendrimers: The present invention describes a process for preparing new looped dendrimer and dendron compounds by controlling the molar amount of branch cell reagent monomer that is combined with various cores bearing core-XR functionalities (e.g., primary, or secondary amines, thiol, or epoxy functionalities). These looped, macrocyclic structures are more robust to... Agent: Technology Law, PLLC

20100086484 - In vivo drug concentration distribution measuring device, variable-wavelength filter used for the same, and in vivo drug concentration distribution measuring method: An in vivo drug concentration distribution measuring device for measuring, when a drug having an imaging function is administered, in vivo concentration distribution of the drug is disclosed. The device includes: a light source which casts light to a living body as a measuring target; a variable-wavelength filter which, when... Agent: Harness, Dickey & Pierce, P.L.C

20100086483 - Method of multidetector computed tomagraphy: This invention relates to methods for multidetector computed tomography myocardial perfusion imaging comprising administering doses of a rate-control agent and one or more adenosine A2A receptor agonists to a mammal.... Agent: Swiss Tanner, P.C. P.o. Box 1749

20100086486 - Genetically modified human natural killer cell lines: The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (FcγRIII-A), or other Fcγ or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as FcεRI-γ, TCR-ζ,... Agent: Cohen & Grigsby, P.C.

20100086485 - Influenza vaccine: The present invention relates to a live-attenuated bacterial cell comprising a heterologous nucleotide sequence encoding at least one influenza virus antigen in operative linkage to an expression system.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100086487 - Papio cynocephalus toll-like receptor 3: Isolated polynucleotides encoding Papio cynocephalus Toll-Like Receptor 3 (Baboon TLR3), polypeptides obtainable from expression of these polynucleotides, recombinant cells, and methods of use are disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20100086488 - Hydrophilic nanoparticles with functional surface groups, production and use thereof: The present invention relates to nanoparticles having a hydrophilic surface coating, to methods of production thereof and to the use thereof in biological, molecular biological, biochemical and medical applications.... Agent: Gerstenzang, William C. Norris Mclaughlin & Marcus, Pa

20100086489 - Osteopenia animal model: Also, a method for producing an osteopenia animal model, comprising administering soluble RANKL or a fused protein of soluble RANKL with an epitope tag to a non-human animal so as to promote vivo osteoclast differentiation and activation in the non-human animal, and an osteopenia animal model produced by the method... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20100086491 - Capsule used for measuring flow information using x-rays and method of measuring flow information using the same: The present invention relates to a capsule used for measuring flow information using X-rays and a method of measuring flow information using the same. More particularly, the present invention relates to a capsule used for measuring flow information using X-rays including a biocompatible polymer, an organic contrast agent or deionized... Agent: Marshall, Gerstein & Borun LLP

20100086490 - Gas-filled microvesicles with targeting ligand or therapeutic agent: Gas-filled microvesicles comprising a boundary envelope containing a gas, wherein said microvesicles comprise: —a first component, bound to said envelope, having binding affinity for an Fc-region of an antibody; and—a second component comprising a Fc-region of an antibody, bound to said first component through said Fc-region, said second component comprising... Agent: Bracco Research Usa Inc.

20100086492 - Methods and devices for sonographic imaging: The present invention comprises methods and devices for providing contrast medium for sonography of structures such as ducts and cavities. The invention provides for creation of detectable acoustic variations between two generated phases of a gas and a liquid to make a contrast medium. Sonography is the primary means of... Agent: Ballard Spahr LLP

20100086493 - Pure chlorine dioxide solution, and gel-like composition and foaming composition each comprising the same: A pure chlorine dioxide solution includes a chlorine dioxide gas dissolved therein, a chlorite, and a pH adjuster which is an acid or a salt thereof having a buffering property whose pH is 2.5 to 6.8 as a 5% aqueous solution at 25° C.... Agent: Buchanan, Ingersoll & Rooney PC

20100086494 - Skin treatments containing carboxylic acid-substituted idebenone derivatives and methods of preparation and use thereof: The present invention relates to novel carboxylic acid-substituted idebenone derivatives, skin treatment compositions containing these carboxylic acid-substituted idebenone derivatives, methods of treating skin changes by topical application of these carboxylic acid-substituted idebenone derivatives, and their methods of synthesis. The carboxylic acid-substituted idebenone derivatives of the present invention are unexpectedly effective... Agent: Darby & Darby P.C.

20100086495 - Compositions and methods for enhancing transmucosal delivery: The present invention provides transmucosal pharmaceutical or nutraceutical compositions and methods for enhancing transmucosal delivery of pharmaceutical and nutraceutical ingredients through use of methylsulfonylmethane (MSM) as a transmucosal delivery enhancer. In particular, the invention provides transmucosal compositions comprising an active agent selected from a non-steroid anti-inflammatory drug (NSAID); an analgesic;... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100086496 - Oral care package: An oral care package includes a package wrapping a tooth pick (or preferably a combined pick and flossing device) impressed within or adjacent to a stick of chewing gum in such manner that the pick (or pick/floss device) may be easily removed from the package first and used to dislodge... Agent: A Patent Lawyer Corp, PLC R William Graham

20100086498 - Personal care compositions providing enhanced cooling sensation:

20100086497 - Tooth remineralisation: There is herein described a film and a method of using a film for tooth remineralisation. More particularly, there is described a film comprising a bioactive glass and a water soluble polymer and a method of using such a film for tooth remineralisation.... Agent: Intellectual Property / Technology Law

20100086499 - Tooth whitening composition: The present invention provides an effective tooth whitening composition comprising a chlorine dioxide precursor, an organic acid anhydride and an orally acceptable carrier.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100086501 - Determining age ranges of skin samples: The present invention provides methods for characterizing a skin sample of a subject as belonging to an age range by analyzing nucleic acid or protein molecules obtained from the subject. The methods include analyzing expression or mutations in epidermal samples, of one or more skin markers. The methods can include... Agent: Dla Piper LLP (us)

20100086500 - Ultraviolet light absorbing ketones of 2-(2-hydroxyphenyl) benzotriazole: where R1 is hydrogen atom, or a halogen atom, or a straight-chain or branched lower alkyl or lower alkoxy of 1 to 4 carbon atoms; R2 is an unsubtituted or substituted aryl group or an unsubstituted or substituted straight-chain or branched alkyl having 1 to 18 carbon atoms or a... Agent: Michael P. Aronson

20100086502 - Cosmetic/sunscreen compositions containing dibenzoylmethane compounds and dithiolane compound photostabilizers therefor: Cosmetic/sunscreen compositions contain a combination of at least one dibenzoylmethane sunscreen compound and a photostabilizing amount of at least one dithiolane compound of formula (I) below:... Agent: Buchanan, Ingersoll & Rooney PC

20100086504 - Methods of administering topical antifungal formulations for the treatment of fungal infections: The present invention relates to topical antifungal formulations comprising one or more antifungal (e.g., terbinafine), a lipid and a surfactant, and uses thereof for the treatment of skin and nail fungal infections.... Agent: Jones Day

20100086505 - Nail enamel compositions having a decorative color effect: A base coat nail enamel composition that forms a decorative color effect over natural or synthetic nails. The base coat nail enamel composition includes at least one dye in a sufficient amount, such that when a clear, tinted or pigmented top coat nail enamel composition is formed thereon, the combined... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20100086503 - Prodissolve: The solution formula is for nail enhancements in the beauty industry. The formula is formulated to remove nail enhancements such as acrylics, gel and plastic artificial nails in a timely and safer manner for both the professional and individual. Within the formula of ProDissolve, is a fast acting natural product;... Agent: Rosemary Martin

20100086506 - Cholesteric liquid crystal composition: A cholesteric liquid crystal composition containing at least one esterified product selected from the group consisting of (1) an esterified product of a hydrolysate of (A) a γ-oryzanol and (B1) a carboxylic acid compound, (2) an esterified product of a hydrogenated product of a hydrolysate of (A) a γ-oryzanol and... Agent: J C Patents

20100086508 - Pump-dispenser bottle device containing a polycondensate comprising at least one polyurethane and/or polyurea unit: The invention concerns aerosol devices comprising a reservoir containing, in a cosmetically suitable medium, a multiple-block polymer (A) comprising at least a polyurethane and/or polyurea unit and a film-forming polymer (B), the polymers (A) and (B) and the device being selected so as to obtain, at the device outlet, droplets... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100086509 - Self-heating shaving compositions: Non-pressurized shaving compositions are described that provide a warm/hot sensation during use as the result of an exothermic redox reaction. The compositions are post-foaming via nascent gas release in situ due to the generation of carbon dioxide. The carbon dioxide induced foam is maintained for several minutes after the compositions... Agent: The Procter & Gamble Company Global Legal Department - Ip

20100086507 - Make-up method and set for carrying out said method: n

20100086510 - Enzymatic peracid generation formulation: Disclosed herein are multi-component formulations for enzymatically producing aqueous solutions of peroxycarboxylic acids suitable for use in, e.g., disinfectant and/or bleaching applications. The multi-component peroxycarboxylic acid formulations comprise at least one carbohydrate esterase family 7 enzyme having perhydrolytic activity.... Agent: Potter Anderson & Corroon LLP Attn: Janet E. Reed, Ph.d.

20100086511 - Antibacterial and deodorant fiber, fiber formed article, and fiber product: s

20100086512 - Mucomimetic compositions and uses therefore: The present invention relates to mucomimetic and ophthalmic solutions comprising a cationic multimeric antimicrobial agent such as polyaminopropyl biguanide and a magnesium, calcium or magnesium/calcium complex of an anionic polymer such as hyaluronate, alginate, carboxymethyl cellulose, chondroitin sulfate or mixtures thereof. In specific embodiments, the solutions include additional components such... Agent: Richard Voellmy

20100086514 - Contact lens care solutions with a low molecular weight oligomer: A contact lens care solution comprising: a cationic antimicrobial component having an average molecular weight (MNA), and a cationic oligomer or nitrogen/amine oligomer having a number average molecular weight (MNO) from 500 daltons to 15,000 daltons. The lens care solutions are used to clean and disinfect contact lenses, and in... Agent: Bausch & Lomb Incorporated

20100086513 - Method for effecting antimicrobial activity using polyamine analogues: A method for using polyamine analogues containing bulky hydrophobic groups against antimicrobial agents is disclosed. The antimicrobial method works by the mechanical action of disrupting the protective outer member of a bacterial cell.... Agent: Strasburger & Price, LLP

20100086516 - Cytokine receptor chain: Polynucleotides encoding the IL-13 receptor and fragments thereof are disclosed. IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor and methods for their identification are also disclosed. Methods of medical treatment using such molecules and antagonists of the IL-13/IL-13R interaction are also provided.... Agent: Lando & Anastasi, LLP

20100086517 - Enhancement of b cell proliferation by il-15: Compositions and methods for modulating the growth, proliferation, and/or differentiation of B-cells in the germinal center are disclosed, and include use of IL-15 inhibitors, antagonists, and agonists. The compositions and methods find use in treating B-cell-related disorders, including neoplasms of the B-cell lineage.... Agent: Amgen Inc.

20100086515 - Human il-4 muteins in cancer therapy: The present invention relates to the use of a combination of human interleukin-4 muteins and chemotherapeutic or pro-apoptotic agents for the prevention and/or treatment of cancer disease.... Agent: Townsend And Townsend And Crew, LLP

20100086518 - Treatment of melanoma: Methods of treating melanoma include administering a compound of Structure I, a tautomer of the compound, a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt or the tautomer, or a mixture thereof to a subject. The compound, tautomer, salt of the compound, salt of the tautomer, or mixture... Agent: Novartis Corporate Intellectual Property

20100086519 - Treatment of hepatitis c infection with metalloporphyrins: The present invention is directed to the treatment of hepatitis C infection with a metalloporphyrin. In particular, the present invention is based on the discovery that the NS5A protein plays a key role in HCV RNA replication by participating in polyprotein cleavage, interferon response and cellular signaling pathways. It has... Agent: Alston & Bird LLP

20100086526 - Nucleic acid constructs and methods for specific silencing of h19: The present invention is directed to recombinant constructs and methods for treating pathological conditions associated with H19 expression, such as tumors characterized by up-regulated expression of H19 RNA. Specifically, the recombinant constructs of the invention comprise at least one nucleic acid sequence encoding a small interfering RNA (siRNA) molecule directed... Agent: Winston & Strawn LLP Patent Department

20100086520 - Compositions, kits and uses for protecting the skin against pathogenic microorganisms: Described are compositions and kits comprising: (i) microorganisms which are able to stimulate the growth of microorganisms of the resident skin microbial flora and which do not stimulate the growth of microorganisms of the transient pathogenic micro flora and (ii) microorganisms which are able to inhibit the growth of one... Agent: Connolly Bove Lodge & Hutz, LLP

20100086521 - Means for regulating the cosmetic appearance and/or health of human keratinous tissue: Regulating human keratinous tissue (e.g., skin, hair, and/or nails). More particularly, the invention relates to regulating the cosmetic appearance and/or health of human keratinous tissue by orally administering a dietary supplement comprising a probiotic to a human. In another aspect, the invention also relates to a method of marketing, an... Agent: The Procter & Gamble Company Global Legal Department - Ip

20100086528 - Novel bacteria isolated from fresh honey or the honey producing tract of honey bees: The invention relates to new isolated Lactobacillus and Bifidobacterium strains which have been isolated from fresh honey having a water content above 18% by weight or from the honey producing tract of at least one bee. The bacterial strains have unique properties rendering them useful in many products such as... Agent: Volpe And Koenig, P.C.

20100086527 - Synbiotic to improve gut microbiota: The use of a probiotic strain of Lactobacillus rhamnosus and an oligosaccharide mixture which comprises 5-70 wt % of at least one N-acetylated oligosaccharide selected from the group comprising GalNAcα1,3Galβ1,4Glc and Galβ1,6GalNAcα1,3Galβ1,4Glc, 20-90 wt % of at least one neutral oligosaccharide selected from the group comprising Galβ1,6Gal, Galβ1,6Galβ1,4Glc Galβ1,6Galβ1,6Glc, Galβ1,3Galβ1,3Glc,... Agent: K&l Gates LLP

20100086522 - Disparate suicide carrier cells for tumor targeting of promiscuous oncolytic viruses: The invention provides compositions and methods for treating neoplastic disease, such as cancer, with an oncolytic virus, such as VSV. A carrier cell is used to target a diseased tissue, and to cloak the oncolytic virus from surveillance by the subject's immune system during a targeting interval. Following delivery of... Agent: Fulbright & Jaworski L.L.P.

20100086524 - Cellular preparations for use as a revascularization stimulating agent: The invention relates to a cellular preparation containing endothelial cell precursors (EPCs) and smooth muscular cell precursors (SMCs), as a combination product for simultaneous, separated or time-spread administration, used as a revascularisation stimulating agent. The invention also relates to the use of such a cellular preparation.... Agent: Ostrolenk Faber Gerb & Soffen

20100086525 - Compositions and methods for altering pancreas or liver function: Methods for altering pancreatic and liver cell function are provided, wherein the compositions and methods are based on use of osteopontin or on altering the activity of osteopontin.... Agent: Licata & Tyrrell P.C.

20100086523 - Method for generating pluripotent stem cells: The present invention relates to a method for generating pluripotent stem cells and to pluripotent stem cells generated from human testis.... Agent: Morrison & Foerster LLP

20100086530 - Cancer-tumor necrosis by artery nutrient-oxygen blocking: This is a new, novel, natural, relatively non-invasive and non-toxic method for the shrinkage and necrosis of cancerous cells, tumors, glands, organs, metastases processes or unwanted growths in human or animal patients. A patient's or other donor's blood is aged and processed which results in the loss of its blood... Agent: Norman P. Martinov

20100086529 - Methods of making concentrated fibrinogen- and platelet-containing compositions: The present invention is drawn to methods of making concentrated fibrinogen- and platelet-containing compositions. The concentrated compositions can be produced by adding a sufficient amount of a fibrinogen precipitating agent, such as protamine or other similar acting agent(s), and a platelet aggregating agent, such as ADP or other similar acting... Agent: Thorpe North & Western, LLP.

20100086531 - Methods of modulating protein homeostasis, metabolic syndrome, heavy metal intoxication and nrf2 transcription factors: Phthalazinediones that function as intracellular redox modulators in the redox therapy of certain stressed cells are provided. By buffering aberrant redox states, phthalazinediones enable cellular processes essential for survival and augment medical treatments. The phthalazinediones of the invention can modulate functions related to cell growth, differentiation, activity, or death, to... Agent: Mccarter & English, LLP Boston

20100086532 - Chimeric zinc finger recombinases optimized for catalysis by directed evolution: The present invention is directed to chimeric recombinases comprising a serine recombinase operatively linked to a zinc finger nucleotide binding domain such that the chimeric recombinase protein catalyzes site-specific recombination at a DNA site specifically bound by the zinc finger nucleotide binding domain. The serine recombinase can be one of... Agent: Dla Piper LLP (us)

20100086533 - Laglidadg homing endonuclease variants having novel substrate specificity and use thereof: A LAGLIDADG homing endonuclease variant having novel substrate specificity, said variant being obtainable by a method comprising: (a) the mutation of at least one amino acid residue of the final C-terminal loop of a parent LAGLIDADG homing endonuclease, with the exclusion of the threonine 140 of I-CreI, b) the selection... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100086534 - Stabilization of perhydrolases: Disclosed herein are enzyme powders comprising a spray-dried formulation of at least one CE-7 esterase, at least one oligosaccharide excipient, and optionally at least one surfactant. Also disclosed herein is a process for producing peroxycarboxylic acids from carboxylic acid esters using the aforementioned enzyme powders. Further, disinfectant and laundry care... Agent: Potter Anderson & Corroon LLP Attn: Janet E. Reed, Ph.d.

20100086535 - Stabilization of perhydrolases: Disclosed herein is a method for stabilization of the perhydrolase activity of the CE-7 esterase in a formulation with a carboxylic acid ester that employs the addition of a buffering agent, substantially undissolved, to the mixture of the CE-7 esterase and the carboxylic acid ester. Further, disinfectant and laundry care... Agent: Potter Anderson & Corroon LLP Attn: Janet E. Reed, Ph.d.

20100086536 - Method of increasing plasmin activity through antiplasmin conversion: Methods for increasing plasmin activity in a patient in need thereof are provided, comprising administering to the patient a therapeutic amount of an agent which binds to α2-antiplasmin at a binding site to increase conversion of cc2-antiplasmin from an inhibitor to a plasmin substrate, thereby increasing plasmin activity in the... Agent: Sutherland Asbill & Brennan LLP

20100086538 - Antibody molecules which bind to human il-17: The invention relates to antibody molecules having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100086540 - Co-crystal of antibody 11f8fab fragment and egfr extracellular domain and uses thereof: The present invention relates to co-crystals of antibody 11F8 Fab fragments and the complete extracellular domain of EGFR or isolated domain III of EGFR, and structural coordinates obtained from such crystals. Such coordinates are useful for identifying mimetics that bind to the extracellular domain of EGFR. Such mimetics may, for... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100086543 - Compositions and methods for treating conditions associated with ceramide biosynthesis: Provided are a pharmaceutical composition and a method for reducing, preventing, or delaying the development of a biological condition associated with administration of an opioid drug, in particular, tolerance to and/or physical dependence on an opioid drug. The pharmaceutical composition includes an opioid drug, a ceramide biosynthesis inhibitor and a... Agent: Spencer Fane Britt & Browne LLP

20100086539 - Method and preparations for the diagnosis and therapy of multiple sclerosis and immune demyelinating polyneuropathy: The subject of the present invention is a method of diagnosing or treatment multiple sclerosis and immune demyelinating polyneuropathy as well as preparations used in these methods. The present invention is applicable in medicine.... Agent: Cooper & Dunham, LLP

20100086537 - Polynucleotides and polypeptide sequences involved in cancer: The present invention relates to polynucleotide and polypeptide sequences which are differentially expressed in cancer cells compared to normal cells. The present invention more particularly relates to the use of these sequences in the diagnosis, prognosis or treatment of cancer and in the detection of cancer cells.... Agent: Choate, Hall & Stewart LLP

20100086542 - Potentiation of erythropoietin (epo) action by membrane steroid receptor agonists: The present invention relates to the use of membrane steroid receptor agonists as potentiators of the action of erythropoietin (EPO). The present invention also relates to the combined use of membrane steroid receptor agonists and erythropoietin to control apoptosis, proliferation, differentiation, migration and regeneration of cells, in different organs and... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20100086541 - Regulation of autophagy pathway phosphorylation and uses thereof: The invention relates to polypeptides and proteins known to function in the autophagy pathway that have novel phosphorylation sites. The invention also relates to antibodies specific to these polypeptides and proteins that are phosphorylated or not phosphorylated at novel phosphorylated sites. The invention also relates to methods of producing these... Agent: Morrison & Foerster LLP

20100086544 - Compositions and methods for treating a neoplasm: The present invention relates to compositions and methods for treating neoplasms, including refractory or relapsed neoplasms, using VEGF antagonists. Furthermore, the present invention provides therapy regimens for treating those diseases.... Agent: Genentech, Inc.

20100086547 - Methods for administering anti-il-5 antibodies: The present invention relates generally to the methods for the treatment and diagnosis of conditions mediated by IL-5 and excess eosinophil production, and more specifically to mAbs, Fabs, chimeric and humanized antibodies. More particularly, methods are provided for reducing eosinophils in a human in need thereof, which method comprises administering... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100086545 - Prevention and treatment of synucleinopathic and amyloidogenic disease: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic... Agent: Townsend And Townsend And Crew LLP

20100086546 - Toll-like receptor 4 deficiency and downstream effectors cause pulmonary emphysema: The present invention provides compositions and methods for the detection, treatment, and prevention of emphysema/COPD. Compositions of the present invention comprise TLR4 activators, Nox3 inhibitors, and Cathepsin E inhibitors useful in the treatment or prevention of emphysema/COPD. Cathepsin E is a downstream effector of TLR4, wherein when cathepsin E is... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100086548 - Use of anti-il-20 antibody for treating rheumatoid arthritis and osteoporosis: Treatment of rheumatoid arthritis and osteoporosis using an anti-IL-20 antibody 7E, and optionally, in combination with an etanercept polypeptide.... Agent: Morrison & Foerster LLP

20100086549 - Use of anti-il-20 antibody for treating stroke: Treatment of stroke with an antibody specific to IL-20, e.g., monoclonal antibody 7E.... Agent: Occhiuti Rohlicek & Tsao, LLP

20100086550 - Anticancer agent comprising anti-pd-1 antibody or anti-pd-l1 antibody: Provided is an anticancer agent which comprises an anti-PD-1 antibody or an anti-PD-L1 antibody as an active ingredient, functioning to reverse the unresponsiveness of iNKT cells in which anergy has been induced by administration with an iNKT cell ligand. The anti-PD-1 or anti-PD-L1 antibody blocks the PD-1/PD-L1-mediated signaling pathway not... Agent: Merchant & Gould PC

20100086552 - Allergen-binding ige monoclonal antibodies and method for preparing hypoallergens: The present invention relates to human IgE antibodies and derivatives thereof, which bind non-continuous planar allergenic epitope, such as in β-lactoglobulin, with high affinity and specificity. The present invention also relates to processes for making and engineering such allergen binding monoclonal antibodies and to methods for using these antibodies and... Agent: Birch Stewart Kolasch & Birch

20100086551 - Antibody and uses thereof: A method of inhibiting angiogenesis in a group of cells, a tissue or an organ includes administering an antibody molecule or nucleic acid encoding an antibody molecule to the cells, tissue or organ, wherein the antibody molecule specifically binds cathepsin S, but does not inhibit proteolytic activity of cathepsin S.... Agent: Ip Group Of Dla Piper LLP (us)

20100086553 - Antitumor agent: m

20100086554 - Methods for administering anti-il-5 antibodies: The present invention relates to methods of treating nasal polyposis, in a human, comprising the step of administering to said human in need thereof an effective amount of a composition comprising at least one anti-11-5 antibody wherein said antibody comprises a heavy chain and a light chain.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100086555 - Neutralizing anti-influenza a virus antibodies and uses thereof: The invention relates to antibodies and antigen binding fragments thereof, that bind to hemagglutinin and neutralize infection of at least two different group 1 subtypes or at least two different group 2 subtypes of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and... Agent: Global Patent Group - Hmb

20100086556 - Use of hemagglutinin of the african swine fever virus as an adjuvant: The invention generally relates to the use of the hemagglutinin (HA) of African swine fever virus (ASFV) as an adjuvant to enhance the immune response against an antigen in a subject. The invention provides a gene construct comprising all or part of the encoding sequence of said HA fused to... Agent: Moore & Van Allen PLLC

20100086557 - Pharmaceutical composition for tumor treatment: The present invention provides pharmaceutical compositions for use in tumor therapy as well as a medical treatment in tumor therapy. The compositions comprise a leukocyte diminishing and/or leukocyte inactivating agent for use in bacterial tumor therapy in combination. Preferably, the leukocyte inactivating or diminishing agents are expressed by the bacteria... Agent: Greer, Burns & Crain

20100086559 - Polypeptide formulation: The present invention relates to an aqueous pharmaceutical composition suitable for long-term storage of polypeptides containing an Fc domain of an immunoglobulin, methods of manufacture, methods of administration and kits containing same.... Agent: Immunex Corporation Law Department

20100086558 - Protein having prolyl oligopeptidase activity, nucleic acid encoding same and method for producing and using same: Proteins isolated from Coprinus clastophyllus having prolyl oligopeptidase activity, nucleic acids encoding the protein and methods for producing and using the protein, wherein SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:9 and SEQ ID NO:10 must be contained therein to at least 60% similarity. The proteins and nucleic acids... Agent: Frenkel & Associates

20100086560 - Chemokines as adjuvants of immune response: Dendritic cells play a critical role in antigen-specific immune responses. Materials and Methods are provided for treating disease states, including cancer, infectious diseases, autoimmune diseases, transplantation, and allergy by facilitating or inhibiting the migration or activation of a specific subset of antigen-presenting dendritic cells known as plasmacytoid dendritic cells (pDC).... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20100086561 - Th1 vaccination priming for active immunotherapy: The present invention includes vaccine compositions and methods for using these vaccine compositions in active immunotherapy. The vaccine compositions include allogeneic activated Th1 memory cells. The compositions can also include one or more disease-related antigens. The methods include administering the vaccine compositions to provide a Th1 footprint in normal individuals... Agent: Westman Champlin & Kelly, P.A.

20100086563 - Compositions and methods for detection of antibodies specific for anaplasma phagocytophilum (aph) and anaplasma platys (apl): The invention provides methods and compositions for the detection and treatment of Anaplasma phagocytophilum and Anaplasma platys infection.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100086562 - Use of platelet glycopeptide iiia epitopes in the treatment of immune thrombocytopenic purpura: The present invention relates to a composition for treating diseases associated with autoantibodies specific for platelet proteins, in particular autoimmune thrombocytopenic purpura. The composition, comprising an epitope of a platelet protein, treats diseases by tolerisation.... Agent: Licata & Tyrrell P.C.

20100086564 - West nile virus vaccine: The invention provides chimeric flavivirus vaccines against West Nile virus and methods of using these vaccines to prevent or treat West Nile virus infection.... Agent: Clark & Elbing LLP

20100086565 - Vectors for expression of hml-2 polypeptides: A nucleic acid vector comprising: (i) a promoter; (ii) a sequence encoding a HML-2 polypeptide operably linked to said promoter; and (iii) a selectable marker. Preferred vectors comprise: (I) a eukaryotic promoter; (ii) a sequence encoding a HML-2 polypeptide downstream of and operably linked to said promoter, (iii) a prokaryotic... Agent: Novartis Vaccines And Diagnostics Inc.

20100086566 - Hiv administration protocols: Administration protocols for a fusion protein, matrix protein and psoralen inactivated HIV based immunogenic composition that induces an immune response to HIV. The immunogenic compositions are based on HIV biologically active fusion peptide, matrix peptide, or psoralen inactivated HIV. The number of doses is 3X. The starting dose for an... Agent: Williams Mullen

20100086567 - Botulinum toxin therapy for prevention of anastamotic thrombosis in free tissue transfer: An effective, long lasting, non-systemic drug administration protocol for preventing vascular vasospasm and vessel thrombosis in free tissue transplantation. In a free flap procedure, after the recipient vein and artery (vascular pedicle) are divided, the recipient artery and vein are pretreated with a local injection of botulinum toxin. The vein... Agent: Ober / Kaler A Professional Corporation

20100086568 - Modification of allergens: The invention relates to a process for modifying allergens to enhance their suitability in immunotherapy. The invention further relates to the modified allergens and pharmaceutical compositions thereof, as well as to their use in immunotherapy.... Agent: Morrison & Foerster LLP

20100086569 - Use of a first house dust mite group 2 allergen for treating allergy to a second house dust mite group 2 allergen: The present invention relates to the use of a Der f 2 allergen composition for the manufacture of a vaccine for preventing or treating allergy to Der p 2, as well as to the use of a Der p 2 allergen composition for the manufacture of a vaccine for treating... Agent: Birch Stewart Kolasch & Birch

20100086570 - Cancer immunotherapy predictive parameters: The invention relates to a method for predicting the efficacy of a cancer immunotherapy of an individual with respect to clinical benefit, which comprises the following steps: —providing a blood sample of said individual, —(a1) determining the number of lymphocytes in the blood of said individual, and/or (a2) determining the... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100086571 - Methods to decrease the risk of metabolic syndrome post immunization: This invention contemplates (I) assessing the risk of metabolic syndrome and or one of its component diseases/disorders which is associated with an immunization schedule against one or more infectious diseases, or one or more immunogens which induce protective immunity against infectious diseases, (II) screening one or more potential recipients and... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100086572 - Rational ppi dosage forms: The invention herein provides for a continuous release dosage form (which is referred to as “dosage forms”) comprising a continuous release dosage form, which releases PPI in a first release portion directly to the gastric mucosa and a second release portion to provide for sustained plasma levels resulting in increased... Agent: Lisa Mueller C/o Polsinelli Shugart PC

20100086575 - Benefit agent containing delivery particle: The present invention relates to benefit agent containing delivery particles, compositions comprising said particles, and processes for making and using the aforementioned particles and compositions. When employed in compositions, for example, cleaning or fabric care compositions, such particles increase the efficiency of benefit agent delivery, there by allowing reduced amounts... Agent: The Procter & Gamble Company Global Legal Department - Ip

20100086573 - Composition and method for preparing stable unilamellar liposomal suspension: Compositions and methods for producing and using stable transparent to translucent unilamellar liposomal suspensions are described. The suspensions include a liposome preparation having a uniform plurality of unilamellar liposomal particles with a mean particle size between about 50 nm to about 290 nm. The particles are suspended in an external... Agent: In Re: 28533 Brinks, Hofer, Gilson & Lione

20100086574 - Use of aqueous emulsions in the form of foam for the reloading of textiles: The invention relates to the use of aqueous emulsions and/or dispersions in the form of foam for the reloading of textiles. These aqueous emulsions and/or dispersions contain (a) 0-25% by weight of one or several skin-protecting oils, (b) 0-25% by weight of microcapsules loaded with active ingredients, (c) 0-20% by... Agent: Fox Rothschild LLP

20100086576 - Antimicrobial composition and methods of making and using same: An aqueous composition adapted to kill bacteria in both planktonic and biofilm states is lethal toward a wide spectrum of gram positive and gram negative bacteria as well as other microbes. The composition, which is slightly to moderately acidic, includes a significant amount of one or more surfactants and large... Agent: Zollinger & Burleson Ltd.

20100086577 - Method and device for destruction of lice and lice eggs: A method for treating and killing lice and lice eggs in hair of a person includes the steps of: combing and ironing the hair of the person using a hand-held flat-iron device. The flat-iron device includes a handle having a first arm and a second arm that is pivotally coupled... Agent: Leason Ellis LLP

20100086578 - Fistula plug comprising ecm: The present invention relates to a temporary composite scaffold comprising discrete ECM particles formed as a fistula plug. We demonstrate that when using scaffolds containing ECM material, higher concentrations of ECM surprisingly do not give better cell morphology. Concentrations lower than 60% (w/w) are sufficient to obtain the best cell... Agent: Jacobson Holman PLLC

20100086579 - Macrocyclic lactone compounds and methods for their use: The present invention provides a device for intracorporeal use including an implant or a temporary device and at least one source of a compound myolimus, or a derivative thereof. The present invention also provides a method of inhibiting cell proliferation by local administration of a therapeutically effective amount of a... Agent: Townsend And Townsend And Crew, LLP

20100086580 - Medical device with controllably releasable antibacterial agent: There is disclosed a medical device, such as a urinary catheter, comprising a substrate material, a hydrophilic surface coating, e.g. comprising polyvinylpyrrolidone (PVP), arranged on at least a part of the surface of said substrate material, and an antibacterial layer comprising oligodynamic metal arranged between the substrate material and the... Agent: Birch Stewart Kolasch & Birch

20100086582 - Amorphous rotigotine transdermal system: The present invention refers to a transdermal delivery device comprising a backing layer, an adhesive matrix layer comprising a supersaturated concentration of rotigotine substantially in amorphous form within the adhesive matrix, and a release liner. The present invention also refers to a method of preparing an adhesive matrix containing a... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20100086581 - Method for purpura reduction and prevention: A method for reducing or eliminating skin discoloration caused by purpura or similar conditions uses corticosteroids, particularly glucocorticoids, in a long term cutaneous treatment. A cream, ointment, spray or other means is used to apply a glucocorticoid, for example, hydrocortisone to warmed skin having a red or purple discoloration. Application... Agent: Christopher & Weisberg, P.A.

20100086585 - Antinuclear antibody utilized as a targeting agent for pharmaceutical compounds used in the treatment of cancer and other diseases: This invention describes a method whereby autoimmune antinuclear antibodies are used as a targeting agent to deliver drug nanoparticles or drug liposomes to the tumor or disease site. The antinuclear antibodies have the propensity to localize in areas of tissue necrosis where dead cells have released their nuclear material into... Agent: Henry J. Smith

20100086583 - Lipid-analogous phosphoric triesters: The present invention relates to novel phosphoric triesters which comprise apolar lipid structures.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100086584 - Vaccine compositions of m2e, ha0 and bm2 multiple antigenic peptides: The present disclosure generally relates to a composition comprising one or more peptides selected from influenza virus antigenic peptides M2e, HA0, BM2 and a M2e-BM2 fusion peptide in a composition with a cationic liposome delivery vehicle, and the use of these compositions as a universal vaccine against influenza A and/or... Agent: Dla Piper LLP (us)

20100086586 - Pharmaceutical composition: A pharmaceutical composition comprising eplerenone having a D90 particle size of between 15-25 microns and further comprising one or more pharmaceutically acceptable excipients.... Agent: Summa, Additon & Ashe, P.A.

20100086587 - Hard shell capsule formulations: Hard shell capsules filled with a normally hygroscopic formulation and a method for producing the same is described. The hard shell capsules are filled with a normally hygroscopic formulation including, for example, an excipient, and optionally an active compound. The water content of the formulation and the hard shell capsule... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20100086588 - Compositions and methods for treatment of bowel diseases with granulated mesalamine: Disclosed are methods for treating gastrointestinal disorders, e.g., Crohn's disease, ulcerative colitis, and diverticular disease, with a granulated mesalamine formulation. Some formulations use granulated mesalamine in capsule form. Also included are methods to extend remission of ulcerative colitis by administration of a once-daily dosage of granulated mesalamine.... Agent: Edwards Angell Palmer & Dodge LLP

20100086589 - Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof: An extended release pellet comprising an active ingredient selected from pramipexole and the pharmaceutically acceptable salts thereof, and at least one release-modifying excipient.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100086590 - Novel stable pharmaceutical compositions of clopidogrel bisulfate and process of preparation thereof: The present invention discloses novel stable oral pharmaceutical compositions comprising the active ingredient Clopidogrel bisulfate and hydrophilic polymers along with pharmaceutically acceptable excipients. Particularly, the said Clopidogrel bisulfate is crystalline Form 1 and the composition additionally comprises of one or more chelating agents and antioxidants. Further the invention relates to... Agent: Schwegman, Lundberg & Woessner, P.A.

20100086591 - Rapidly disintegrating dosage form: The invention provides a rapidly disintegrating dosage form comprising a partially-coated tablet having at least one elongated groove along its surface, such that a portion of the at least one elongated groove extends beneath the coating.... Agent: Pfizer Inc Mary J Hosley

20100086592 - Modified dosage forms of tacrolimus: The present invention provides a modified release dosage form of tacrolimus that releases two or more amount of tacrolimus upon oral administration, the first amount of tacrolimus releases from the immediate release dosage unit substantially immediately within 0-2 hours followed by a time interval ranging from about 1-10 hours during... Agent: Ladas & Parry LLP

20100086593 - Dosage forms of bisphosphonates: Oral dosage forms of a bisphosphonate comprised of a safe and effective amount of a pharmaceutical composition comprising a bisphosphonate, a chelating agent, and, means for effecting delayed release of the bisphosphonate and the chelating agent in the lower gastrointestinal tract provide delivery of the pharmaceutical composition to the lower... Agent: Fitzpatrick Cella Harper & Scinto

20100086595 - Non-ionizable hydrophobic galenical system: The present invention concerns a novel hydrophobic galenic system allowing improved masking of the taste of the active ingredients it contains, the stability of said active ingredients and, when applicable, sustained release thereof. The galenic system of the invention consists of lipid particles with no surfactants or emulsifiers, comprising a... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100086594 - Water soluble reactive derivatives of carboxy polysaccharides and fibrinogen conjugates thereof: The present invention provides water-soluble reactive esters of carboxy polysaccharides and derivatives thereof. The reactive carboxy polysaccharide derivatives are useful per se in aqueous solutions or specifically for the formation of water-soluble covalent fibrinogen conjugates. A preferred conjugate is a hyaluronic acid-fibrinogen conjugate and fibrin adhesive, clot or matrix derived... Agent: Winston & Strawn LLP Patent Department

20100086596 - Microspheres for releasing an octreotide compound without an initial time lag: Microspheres for releasing an octreotide compound without an initial time lag include a poly(D,L-lactide-co-glycolide) polymer (PLGA polymer) matrix having a ratio of lactide to glycolide ranging from 80:20 to 90:10 mol %. The polymer has a molecular weight ranging from about 6000 to 16000. The octreotide compound is dispersed in... Agent: Pearne & Gordon LLP

20100086597 - Microspheres for the sustained release of octreotide with a low initial burst: This disclosure features microspheres and a method of making them. The microspheres are for sustained release of an octreotide compound with a low initial burst, comprising a poly(D,L-lactide-co-glycolide) polymer matrix and an octreotide compound dispersed in the polymer matrix. The microspheres release less than 1% of a total amount of... Agent: Pearne & Gordon LLP

20100086598 - Traversal of nucleic acid molecules through a fluid space and expression in repair cells: Disclosed are methods for use in transferring nucleic acids into cells at a wound site associated with a fluid space. These gene transfer protocols are suitable for use in transferring various nucleic acids into cartilage, cardiac muscle, and other tissues, and have many uses including treating diseases such as arthritis... Agent: Seed Intellectual Property Law Group PLLC

20100086599 - Oral modified release formulations: This invention is directed to an oral modified release formulation of the phytoestrogen 8-Prenylnaringenin in combination with a progestin, preferably with Drospirenone, and several uses thereof. In another aspect of the invention an oral modified formulation of 8-Prenylnaringenin with an immediately releasing progestin, like Drospirenone, is provided as well as... Agent: Millen, White, Zelano & Branigan, P.C.

20100086600 - Flowable carrier matrix: A carrier matrix may be delivered to a target position within a patient in a minimally invasive manner by first cutting a collagen sponge sheet into a plurality of relatively small pieces. These pieces are sized so that, when wet, they are capable of flowing through a cannula and/or reduced-diameter... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20100086604 - Absorbant superhydrophobic materials, and methods of preparation and use thereof: The present invention relates to coated, absorbent, freestanding assemblies comprising inorganic nanowires, articles of manufacture comprising the same, processes of producing the same and methods of use thereof. The assemblies of this invention are useful in various applications, including removal of organics or hydrophobic materials, and waterproofing applications.... Agent: Pearl Cohen Zedek Latzer, LLP

20100086606 - Active agent loaded uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same: Uniform, rigid, spherical nanoporous calcium phosphate particles that define an internal space and an amount of active agent present in the internal space are provided. Also provided are topical delivery compositions that include the active agent loaded particles, as well as methods of making the particles and topical compositions. The... Agent: Bozicevic, Field & Francis LLP

20100086603 - Composition for photoprotection: The present invention relates to a method for improving the lifetime of compounds that are prone to photo-degradation by containing the compounds in microcapsules, which have light protecting particles bonded chemically to the capsule walls. In particular, the present invention relates to a microcapsule comprising a biologically active compound inside... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100086605 - Material, item and products comprising a composition having anti-microbial properties: A coating product composition has the general formula AOx-(L-Men+)i, wherein AOx is a metal or metalloid oxide in which x indicates the number of the Oxygen atom(s) (O) bonded to the metal (A) atom, Men+ is a metal ion, L is a bifunctional molecule that could bind both metal oxide... Agent: Laubscher & Laubscher, P.C.

20100086609 - Methods and compositions for delivering peptides: Methods are provided for purifying peptides and proteins by incorporating the peptide or protein into a diketopiperazine or competitive complexing agent to facilitate removal one or more impurities, from the peptide or protein. Formulations and methods also are provided for the improved transport of active agents across biological membranes, resulting... Agent: K&l Gates LLP

20100086608 - Methods and devices for detecting binding events via zeta-potential and pharmacologically active compounds and delivery systems identified thereby: Methods, devices and arrays for measuring a change in zeta-potential of a surface indicative of a binding event are provided. Pharmacologically active compounds and delivery systems for active pharmaceutical ingredients determined to be pharmacologically active or optimized for pharmacological activity or determined to be useful for delivery of the active... Agent: Licata & Tyrrell P.C.

20100086601 - Modified calcium phosphate nanoparticle formation: The present disclosure relates to non-aggregating nanoparticles and their associated methods of preparation. The nanoparticles may have a surface and a size range of 1 nm to 999 nm, along with a zeta potential of −50 to 50 millivolts. A polycation and/or polyanion may be disposed on the nanoparticle surface.... Agent: Grossman, Tucker, Perreault & Pfleger, PLLC

20100086602 - Pharmaceutical composition containing statin-encapsulated nanoparticle: The present invention provides a novel nanotechnology-based strategy for therapeutic neovascularization. Said statin-loaded nanoparticle allows local delivery of statin and thus improves therapeutic efficacy of several kind of diseases which may treated by statin such as ischemic neovascularization.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100086607 - Self-assembled biodegradable nanoparticles for medical and biological applications: A method for forming a biodegradable composition that self-assembles into nanoparticles is provided. The method includes reacting N,N′-Disuccinimidyl carbonate with hydroxyl end-groups of poly(lactide-co-fumarate) to form a composition comprising succinimide-terminated poly(lactide-co-fumarate).... Agent: Dority & Manning, P.A.

20100086612 - Coated carriers: The present invention relates to substantially free flowing powder products as well as preparation thereof. The powder product comprises coated carriers with excellent functional properties. The powder products can be produced in a simple and cost efficient way.... Agent: Merchant & Gould PC

20100086611 - Method for treating infectious organisms normally considered to be resistant to an antimicrobial drug: The present invention relates to compositions of submicron- to micron-size particles of antimicrobial agents. More particularly the invention relates to a composition of an antimicrobial agent that renders the agent potent against organisms normally considered to be resistant to the agent. The composition comprises an aqueous suspension of submicron- to... Agent: Marshall, Gerstein & Borun (baxter)

20100086610 - Vault and vault-like carrier molecules: A method of using vaults as carrier molecules to deliver one or more than one substance to an organism, or to a specific tissue or to specific cells, or to an environmental medium. A vault-like particle. A method of preventing damage by one or more than one substance to an... Agent: Fenwick & West LLP

20100086613 - Chitosan vehicle and method for making same: The invention relates to chitosan (CS) vehicles with chitosan nanoparticles, as well as methods for making such chitosan vehicles and for using them to carry a DNA or proteins by forming CS-DNA or CS-protein complexes. The present invention also relates to CS-DNA or CS-protein complexes being useful for transdermal delivery... Agent: Law Offices Of Khalilian Sira, LLC

20100086615 - Agent for treatment of pulmonary disease: e

20100086614 - Nanoparticulated anesthetic composition for topic use: The present invention relates to a nanoparticulated anaesthetic composition for topical use in which at least one local anaesthetic agent is encapsulated in polymeric nanoparticles. The present invention also relates to the use of such polymeric nanoparticles comprising at least one local anaesthetic agent in the preparation of an anaesthetic... Agent: Arent Fox LLP

20100086616 - Breast milk ethanol screening system and method: A test kit detects the presence of a target analyte in a fluid sample. In particular, the test kit includes reagents capable of detecting the target analyte of interest in breast milk. More particularly, the test kit is capable of detecting the presence of alcohol, caffeine, nicotine, drugs of abuse,... Agent: Townsend And Townsend And Crew, LLP

20100086617 - Antiviral fiber, process for producing the fiber, and textile product comprising the fiber: A fiber which has an excellent effect of inhibiting virus multiplication or eradication (deactivation); a process for producing the fiber; and a textile product comprising the fiber are provided. The method for producing an antiviral fiber comprises bonding a metal ion of a metal having deactivation effect to a virus... Agent: Kenyon & Kenyon LLP

20100086618 - Methods and systems for mineralization of demineralized tissue: Disclosed are systems, methods, compositions and kits for mineralizing tissue, particularly dental tissue. The methods, compositions and kits may be used to strengthen and prevent weakening of the tissue. For example, the methods, compositions and kits may be used for treating and filling cavities in teeth caused by tooth decay.... Agent: Kilpatrick Stockton LLP - M0351

20100086620 - Bone cement composition and method of making the same: Disclosed herein is a composition suitable for use in spinal surgery. The composition generally includes a reaction product or settable mixture of first and second components, the first component including a spray-dried inorganic filler, a radical donor, and a pre-polymerized vinyl polymer, and the second component including a radical scavenger,... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20100086619 - Dietary supplement containing strontium (m) ascorbate, compositions containing same, method for making same and method for using same: A formulation including a compound of formula (ascorbate)2Sr:(M+a)x(ascorbate)y, or ascorbate)2Sr:Ca(ascorbate)2, together with calcium phosphate, vitamin D, D-Glucosamine, protein, fiber, flavoring agents, and optionally chondroitin is provided. A method for making the same together with a method of administering the same is also provided.... Agent: Ajay Pathak

20100086621 - Multi-component peracid generation system: Disclosed herein are multi-component peroxycarboxylic acid generation systems for enzymatically producing aqueous formulations of peroxycarboxylic acids suitable for use in, e.g., disinfectant and/or bleaching applications. The multi-component peroxycarboxylic acid generation systems comprise at least one carbohydrate esterase family 7 enzyme having perhydrolytic activity.... Agent: Potter Anderson & Corroon LLP Attn: Janet E. Reed, Ph.d.

20100086622 - Method of treating or preventing tissue deterioration, injury or damage due to disease of mucosa: An immunomodulatory compound is utilized to treat mucosa disease.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100086623 - Chemical combination for the generation of disinfectant and heat: This invention comprises a lightweight, portable chemical combination of reagents for sterilizing or disinfecting objects in the absence of electrical power or fire. The chemical combination includes a chemical oxidant with the capacity to liberate a biocidal intermediate, a chemical reductant of the oxidant with the capacity to react with... Agent: U.s. Army Soldier Systems Center Legal Office, A306

20100086624 - Colon cleansing compositions and methods: A composition comprising, per litre of aqueous solution, from 30 to 350 g polyethylene glycol, from 3 to 20 g of an ascorbic acid component selected form the group consisting of ascorbic acid, a salt of ascorbic acid, or a mixture thereof, an alkali metal or alkaline earth metal sulphate,... Agent: Leon R. Yankwich

20100086625 - Methods for treating skin lesions: The present invention relates to the treatment of skin lesions such as cold sores and other complications resulting from disorders such as herpes and the like. The invention relates to the use of a composition comprising one or more aluminum salts for treatment purposes.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20100086626 - Capsaicinoid decontamination compositions and methods of use: A therapeutic composition for inhibiting physiological responses elicited by exposure of skin to an irritant can be used to treat exposure to capsaicinoids or other chemical irritants. The therapeutic composition can include a carrier being present in an effective amount and form sufficient to be applied to skin and deliver... Agent: Workman Nydegger 1000 Eagle Gate Tower

20100086627 - Methods and formulations for treating chronic liver disease: An anti-inflammatory and anti-fibrotic antioxidant formulation for treatment of hepatic oxidative stress and cirrhosis is disclosed. The antioxidant formulation can further include at least one of a hepatitis C virus-specific or a non-alcoholic steatohepatitis-specific formulation comprising one or more compounds to retard the progression of liver fibrosis and possibly reverse... Agent: Alston & Bird LLP

20100080756 - Methods for protecting and regenerating bone marrow using cxcr3 agonists and antagonists: CXCR3 agonists, including natural CXCR3 ligands, promote bone marrow regeneration, increase peripheral white blood cells, and increase survival if administered prior to treatment of a subject with chemotherapy or radiotherapy. Similar effects are obtained by administering an CXCR3 antagonists following chemotherapy radiotherapy. Compositions and methods are presented for the treatment... Agent: Foley & Lardner LLP

20100080757 - Method of detecting abnormal tissue: A method for detecting abnormal biological tissue includes administering a vasoactive agent and determining the rate of blood flow in a tissue of interest.... Agent: Tarolli, Sundheim, Covell & Tummino, LLP

20100080759 - Method for forming nano-bubble: The present invention discloses a method for forming a nano-bubble. The forming method is different from the oil-water emulsion reaction in the prior art. The method comprises: taking an inorganic particle as a nucleus and performing a polymer coating process to coat at least one first polymer on the surface... Agent: Wpat, PC Intellectual Property Attorneys

20100080758 - Optical fluorescent imaging: Compounds and methods are disclosed that are useful for noninvasive imaging in the near-infrared (NIR) spectral range. The NIR is highly sensitive for tumor detection and tracking. The application discloses targeting a tumor-enriched cell surface receptor with a ligand-conjugated fluorescent probe, which specifically allows detection of the tumor relative to... Agent: Townsend And Townsend And Crew, LLP

20100080761 - Extracts of isochrysis sp.: The present invention relates to extracts of Isochrysis sp., preferably Tahitian Isochrysis, its cosmetic, dermatological and/or therapeutic uses and compositions and cosmetic, dermatological or therapeutic products comprising such an extract of Isochrysis sp., preferably Tahitian Isochrysis.... Agent: Connolly Bove Lodge & Hutz LLP

20100080760 - Method, device, and system to control ph in pulmonary tissue of a subject: Methods, devices, and systems are provided which include an aerosol generator and a pharmaceutical composition including a membrane selective for a charged ion configured to achieve a selected pH of a pulmonary tissue in a subject. The methods, devices, or systems which include the membrane may be configured to alter... Agent: Searete LLC Clarence T. Tegreene

20100080763 - Acrylic-based copolymer compositions for cosmetic and personal care: A composition for nails, skin and hair in the form of an aqueous emulsion or dispersion is provided. The composition comprises: (a) at least one copolymer comprising (i) about 10 to 85 weight percent of (meth)acrylate ester of C4 to C18 straight and/or branched chain alkyl alcohol, (ii) about 10... Agent: 3m Innovative Properties Company

20100080762 - Skin care composition: The present invention relates to an oral composition containing an optimal combination of nutritional ingredients at high concentrations and at optimal ratios in order to maintain and/or achieve health and/or beautiful look of the skin.... Agent: Nixon & Vanderhye, PC

20100080764 - Skin treatment systems: A basic facial and body treatment cosmetic formulation is a combination of a cationic emulsifying agent, an oil soluble liquid polymer and a naturally occurring lactate buffer system. The basic formulation is a starter system that can be specialized to skin moisturizers, skin lighteners, skin pigmenting agents, sunscreens, antioxidants, line... Agent: Lerner Greenberg Stemer LLP

20100080766 - Eyelash makeup composition and process comprising the application of two compositions: Composition containing a continuous aqueous phase, at least one silicone surfactant and at least one crosslinked polyelectrolyte. Process for making up or caring for keratin fibres, by applying to keratin fibres the noted composition and a second composition different from the first.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100080767 - Compounds: The present invention relates to compounds according to Formula 1; wherein R represents a hydrocarbon group, Z represents an oxyethylene group, B represents an alkyl chain comprising 1 to 5 carbon atoms, Y represents 0 or 1, X represents a number greater than zero, and their use as surfactants, and... Agent: Jones Day

20100080765 - Eyelash makeup composition and conditioning kit: A composition for making up or caring for keratin fibres, containing a continuous oily phase, at least one compound chosen from copolymers of an alkene and of vinyl acetate, and at least one polar wax.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100080768 - Compositions and methods for the treatment of inflammatory dermatosis and other pathological conditions of the skin: The present invention relates to a composition used as a vehicle for percutaneous absorption of Pharmaceutical and Cosmaceutical active agents that comprises Dimethiconol (hydroxyl-terminated polydimethydimethylsiloxane), dimethicone-350 (polydimethylsiloxane-350), cyclomethicone-5 nf (decamethylcyclopentasiloxane), alkymeth siloxane copolyol-lauryl peg/ppg 18/18 methicone (alkymethyl siloxane copolyol), cyclopentasiloxane and dimethicone Crosspolymer (silicone elastomer and decamethylcyclopentasiloxane), stearoxytrimethylsilane and stearyl... Agent: Mayback & Hoffman, P.A.

20100080769 - Treatment of chronic lymphocytic leukemia using anti-cd20 antibodies: Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen.... Agent: Sidley Austin LLP Attn: Dc Patent Docketing

20100080770 - Hepatitis c virus inhibitors: r

20100080771 - Hepatitis c virus inhibitors:

20100080772 - Hepatitis c virus inhibitors: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.... Agent: Louis J. Wille Bristol-myers Squibb Company

20100080773 - Orally bioavailable lipid-based constructs: The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapetuic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes.... Agent: Kathryn Doyle, Ph.d., J.d. Drinker Biddle & Reath LLP

20100080774 - Lactococcus promoters and uses thereof: The invention is in the field of molecular biology, and relates to recombinant engineering and protein expression. More in particular, the invention relates to nucleic acids for recombinant expression of proteins comprising sequences derived from Lactococcus and useful as promoters. The invention further relates to vectors comprising the said nucleic... Agent: Knobbe Martens Olson & Bear LLP

20100080775 - Recombinant adenoviruses encoding the specific iodine transporter (nis): The present invention relates to the field of gene therapy and the treatment of tumors.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100080783 - Microbial feed additive: A microbial feed additive comprising lactic acid bacteria, silicate such as bentonite, and a yeast culture. The animal feed additive of this invention results in more piglets born alive, reduced mortality in nursery pigs, improved growth performance in pregrower, growing and finishing pigs, improved utilization of dietary protein in pregrower... Agent: Thomte Law Office, L.L.C.

20100080782 - Use of probiotic lactic acid bacteria for balancing the skin's immune system: The present invention pertains to the use of probiotics for the preparation of a carrier for balancing the skin's immune function. In particular, the present invention pertains to the use of probiotic micro-organisms for balancing the skin's immune function under stress conditions, such as a exposure to ultraviolet radiation, specifically... Agent: K&l Gates LLP

20100080776 - Method of enhancing an immune response: A method of enhancing an immune response to an antigen is provided. The method involves augmenting the level of a TAP molecule in a target cell bearing the antigen. Preferably, the TAP molecules enhanced by administering a nucleic acid sequence encoding a TAP-1 and/or TAP-2 molecule. The method is useful... Agent: Rissman Hendricks & Oliverio, LLP

20100080777 - Composition containing autologous mononuclear cells and pig collagen scaffold in paste form and its use in the preparation of a medicament for surgical treatment: Composition including autologous mononuclear cells supported on scaffold chosen from the group including lyophilized scaffold or pre-constituted scaffold in the form of membrane or tissue, with possible addition of platelet gel, as well as use of said composition for the preparation of medicaments for surgical treatments.... Agent: Lucas & Mercanti, LLP

20100080779 - Methods related to wound healing: The invention is directed to methods for the treatment of wounds. Such methods utilize novel compositions, including but not limited to amnion-derived multipotent cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine suspension or ACCS), cell lysates derived therefrom, cell products... Agent: Linda O. Palladino

20100080780 - Pluripotent autologous stem cells from oral mucosa and methods of use: The present invention provides a new readily accessible source of adult somatic stem cells from the gastrointestinal tract in general and oral mucosa in particular, methods for isolating pluripotent stem cells from oral mucosa, cells derived therefrom and uses thereof.... Agent: Fennemore Craig

20100080781 - Preventing transfusion related complications in a recipient of a blood transfusion: e

20100080778 - Stem cell expansion enhancing factor and method of use: The present invention relates to a stem cell expansion factor, and to a method for enhancing hematopoietic stem cell expansion by direct delivery of a protein in the cell and which protein is able to cross cell membrane. The method comprises directly delivering in a HSC an amino acid sequence... Agent: Goudreau Gage Dubuc

20100080784 - Methods for treating cachexia and lymphopenia: Disappearance of a cell population, designated CD4+ CD44v.low, has been shown to be associated with cachexia and lymphopenia, and those conditions can be treated or delayed by administering those cells to a patient. In addition, disclosed are assays for those cells for diagnosing or prognosticating cachexia and/or lymphopenia and the... Agent: Knobbe Martens Olson & Bear LLP

20100080785 - Dried formulations: The present invention provides novel formulations with improved bioavailability for substances such as ubiquinone, ubiquinol and omega-3 fatty acid. The present invention provides methods and compositions for drying formulations of such substances, wherein those dried formulations can readily be dissolved in water. The compositions and methods of the invention are... Agent: Morgan, Lewis & Bockius LLP (sf)

20100080786 - Phenyl or pyridinyl substituted indazoles derivatives: e

20100080787 - Cosmetic or dermopharmaceutical composition comprising an enzyme which is insoluble in an aqueous medium as well as its uses:

20100080788 - Alginate and alginate lyase compositions and methods of use: The invention features alginate and alginate lyase compositions and methods that are useful for the treatment of various conditions and diseases. The invention also provides kits and instructions for use.... Agent: Edwards Angell Palmer & Dodge LLP

20100080789 - Therapeutic ribonucleases: The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.... Agent: Casimir Jones, S.c.

20100080790 - Sterilization using high-pressure carbon dioxide: Disclosed are compositions and methods for the biocompatible sterilization of materials, in particular, of medical devices and implants. Sterilization is achieved by deactivation of microorganisms through treatment of the material with a mixture of at least one microbiocidal additive and a high-pressure or supercritical fluid, for example, high-pressure carbon dioxide... Agent: Ballard Spahr LLP

20100080791 - Composition and method for treating tissue defects: The present invention provides a composition and method for treating tissue defects. The composition includes thrombin and fibrinogen, or sodium alginate and calcium chloride, and also a surfactant, and non-resorbable polymer microparticles dispersed within the composition.... Agent: Philip S. Johnson Johnson & Johnson

20100080795 - Biodegradable thermogelling polymer: There is provided a polymer comprising blocks of at least one polyethylene glycol) block, at least one poly(propylene glycol) block and at least one poly(hydroxybutyrate) block. Also provided is a method of making the polymer and a method of using the polymer.... Agent: Klarquist Sparkman, LLP

20100080793 - Dcr3 polypeptide, a tnfr homolog: A TNFR homolog, identified as DcR3, is provided. Nucleic acid molecules encoding DcR3, chimeric molecules and antibodies to DcR3 are also provided.... Agent: Genentech, Inc.

20100080798 - Kim-1 antagonists and use to modulate immune system: The use of KIM-1 antagonists to inhibit signaling between a T cell and a second cell, e.g., an antigen-presenting cell, is disclosed. Such inhibition is useful for treatment of diseases including various autoimmune diseases and graft-versus-host disease. Also disclosed is the use of a KIM-1 antagonist to inhibit secretion of... Agent: Fish & Richardson

20100080792 - Method for identifying a mhc class ii-dependent tumor-associated t helper cell antigen: The present invention is a method for identifying MHC class II-dependent disease-associated antigens. The instant method involves expressing a library of disease-derived proteins in lytic bacteriophage for subsequent presentation by antigen presenting cells to T helper cells. Disease-associated antigens are provided as are the use of such antigens in vaccines... Agent: Licata & Tyrrell P.C.

20100080794 - Mutant polypeptide having effector function: Mutant polypeptides of the present invention contain an Fc region in which a cysteine residue is substituted for the second amino acid from the glycosylation site to the N terminal side in the Fc region. The Fc region is preferably a human IgG Fc region. The mutant polypeptides of the... Agent: Bozicevic, Field & Francis LLP

20100080796 - Synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders: The instant invention comprises a process for the solid phase synthesis of directed epitope peptide mixtures useful in the treatment and diagnosis of protein conformational disorders, such process defined by a set of rules regarding the identity and the frequency of occurrence of amino acids that substitute a base or... Agent: Ropes & Gray LLP

20100080797 - Therapy procedure for drug delivery for trigeminal pain: The present invention relates to methods for the treatment or prevention of trigeminal nerve-associated pain, in particular chronic, acute and procedural-related pain. The methods comprise administration of analgesic agents to the trigeminal nerve system which results in analgesia to the facial or head region.... Agent: Morrison & Foerster LLP

20100080799 - Wstf regulates the dna damage response of h2a.x via novel tyrosine kinase activity: The present invention relates to methods of detecting and regulating cellular DNA damage as well as methods of screening compounds suitable for modulating cellular DNA damage. The methods of the present invention utilize antibodies that selectively bind to a phosphorylated tyrosine residue in a SQEY tyrosine phosphorylation motif sequence or... Agent: Nixon Peabody LLP - Patent Group

20100080800 - Humanized antibody: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.... Agent: Jones Day

20100080802 - Anti-il-tif antibodies and methods of use: The present invention relates to ZCYTO18 polynucleotide and polypeptide molecules. The ZCYTO18 is a novel cytokine. The polypeptides may be used within methods for stimulating the proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and... Agent: Darby/zymogenetics, Inc.

20100080803 - Labor biomarkers, methods comprising same, and methods targeting same: The present invention provides methods of predicting or detecting labor in a female subject and methods of testing a compound for an ability to delay the onset of labor. The present invention also provides methods of testing a labor marker useful in the diagnostic methods, isolated peptides identified in the... Agent: Pearl Cohen Zedek Latzer, LLP

20100080801 - Lir-9, a novel leukocyte immunoglobulin-like receptor: A new family of immunoreceptor molecules of the immunoglobulin superfamily, (LIR) polypeptides is described. Disclosed are sequences encoding LIR family members and their deduced amino acid sequences, polypeptides encoded by DNA that hybridizes to defined nucleotide sequences, processes for producing polypeptides of the LIR family, and specific antibodies directed against... Agent: Immunex Corporation Law Department

20100080804 - Methods of treating inflammatory disorders of the lungs: 2F1 polypeptides are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing the polypeptides. Soluble 2F1 polypeptides find use in inhibiting prostaglandin synthesis and treating inflammation.... Agent: Immunex Corporation Law Department

20100080805 - Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof: A composition-of-matter comprising an antibody or antibody fragment including an antigen-binding region capable of specifically binding an antigen-presenting portion of a complex composed of a human antigen-presenting molecule and an antigen derived from a pathogen is disclosed.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100080806 - Anti-human trail receptor dr5 monoclonal antibody (ad5-10), method thereof and use of the same: The present invention discloses a monoclonal antibody against the extracellular domain of human tumor necrosis factor-related apoptosis-inducing ligand receptor DR5 (death receptor 5), The present invention also provides a method of producing the monoclonal antibody, amino acid sequences of the variable regions of the monoclonal antibody's heavy chain and light... Agent: Fulbright & Jaworski, LLP

20100080808 - Anti-notch2 antibodies and methods of use: The invention provides anti-Notch antibodies, and in particular, antibodies that bind Notch2 NRR, and methods of using the same.... Agent: Genentech, Inc.

20100080807 - Methods and compositions for treating viral hemorrhagic fever: Disclosed herein are methods and compositions for treating viral hemorrhagic fever in a subject by use of at least one inhibitor or suppressor of oxidase, inducible nitric oxide synthase (iNOS) and apoptosis pathway.... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20100080809 - Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof: The present invention provides novel isolated and purified polynucleotides and polypeptides related to a novel ligand for glucocorticoid-induced TNF receptor (GITR). The invention also provides antibodies to the GITR ligand (GITRL). The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating disorders... Agent: Fitzpatrick Cella Harper & Scinto

20100080810 - Methods of treating diseases with anti-vegf antibodies: The present invention provides monoclonal antibodies, and portions thereof, which are capable of specifically binding to human vascular endothelial cell growth factor (hVEGF) or hVEGF-related protein. The invention also provides hybridoma cell lines that produce such monoclonal antibodies. The monoclonal antibodies of the invention are useful as therapeutic agents either... Agent: Genentech, Inc.

20100080811 - Anti-myostatin antibodies: Anti-myostatin antibodies are identified that are characterized as having high affinity and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or for the treatment of various disorders in... Agent: Eli Lilly & Company

20100080812 - Antibodies against human il17 and uses thereof: An antibody binding to IL-17 characterized by binding to the same IL-17 epitope to which monoclonal antibody 3C1 binds, and being of human IgG1 isotype modified in the hinge region at amino acid position 216-240, preferably at amino acid position 220-240, between CH1 and CH2 and/or in the second inter-domain... Agent: Grant D. Green Roche Palo Alto LLC

20100080813 - Neutralizing anti-influenza a virus antibodies and uses thereof: The invention relates to antibodies, and antigen binding fragments thereof, that bind to hemagglutinin and neutralize a group 1 subtype and a group 2 subtype of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and cultured single plasma cells that produce, and to... Agent: Global Patent Group - Hmb

20100080814 - Novel compositions and methods for treating ige-mediated disorders: The present invention relates to immunoglobulins that bind IgE and FcγRIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.... Agent: Morgan, Lewis & Bockius, LLP (sf)

20100080815 - Mn gene and protein: A new gene—MN—and proteins/polypeptides encoded therefrom are disclosed. Recombinant nucleic acid molecules for expressing MN proteins/polypeptides and recombinant proteins are provided. Expression of the MN gene is disclosed as being associated with tumorigenicity, and the invention concerns methods and compositions for detecting and/or quantitating MN antigen and/or MN-specific antibodies in... Agent: Leona L. Lauder

20100080816 - Tolerogenic populations of dendritic cells: Tolerogenic populations of dendritic cells are provided, where the dendritic cells are characterized by expression of select tissue-specific homing receptors including the chemokine receptors CCR9; or CMKLR1; or the integrin CD103. The dendritic cells may be conventional/myeloid or plasmacytoid dendritic cells. The cells may be isolated from lymphoid tissue, from... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20100080817 - Human papillomavirus / ii-key hybrids and methods of use: The present invention is directed towards compositions comprising Ii-Key/HPV hybrid peptides. The hybrid peptides of the present invention are effective in the generation of CD4+ helper T cell immune responses directed towards the specific HPV epitopes encoded in the hybrid peptide. The inclusion of the Ii-key peptide in the hybrid... Agent: Kevin Farrell Pierce Atwood

20100080818 - Expression and characterization of hiv-1 envelope protein associated with broadly cross reactive neutralizing antibody response: The present invention relates to HIV-1 envelope proteins from a donor with non-progressive HIV-1 infection whose serum contains broadly cross-reactive, primary virus neutralizing antibody. The invention also relates to isolated or purified proteins and protein fragments that share certain amino acids at particular positions with the foregoing HIV-1 proteins.... Agent: Morgan Lewis & Bockius LLP

20100080819 - Modulators of p-selectin glycoprotein ligand 1: Multimeric compounds that bind to P-Selectin Glycoprotein 1 (PSGL-1) on the surface of T cells or natural killer (NK) cells can be used to induce T cell or NK cell depletion and/or to induce T cell or NK cell apoptosis. The multimeric compounds and methods of the invention can be... Agent: Wolf Greenfield & Sacks, P.C.

20100080820 - Preparation of a therapeutic composition: Product R, a novel therapeutic composition for treating viral infections and stimulating the immune system comprises a unique peptide having 31 amino acids and another unique peptide having 21 amino acids and connected with an oligo-nucleotide through a diphosphodiester or diphosphodithioate ester linkage. The composition has a light absorption spectrum... Agent: Downs Rachlin Martin PLLC

20100080822 - Cinnamomi and poria composition, method to prepare same and uses thereof: This invention provides a method for identifying a composition of Cinnamomi and Poria. This invention further provides a composition comprising: Ramulus Cinnamomi, Poria Cortex, Moutan Radicis, Radix Paeonize Alba, and Semen Persicae. This invention provides various uses of these compositions.... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20100080821 - Energy compositions: Described herein are caffeine-free compositions that provide a sense of energy and well-being. In one aspect, the compositions include a blend of natural herbs or herbal extracts such as at least one Schizandra, at least one Rhodiola, an eleutheroside, at least one Cordyceps, at least one Lycium (genus of goji),... Agent: Marc Van Dyke

20100080823 - Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants: Compositions are provided which include hyaluronic acid derivatives in combination with vaccine antigens, and optionally adjuvants, for mucosal delivery. Also provided are methods of making the compositions, as well as methods of immunization using the same.... Agent: Robins & Pasternak

20100080825 - Filovirus vectors and noninfectious filovirus-based particles: Cloned filovirus genomic cDNA and methods of using the cDNA are provided. Further provided are noninfectious lipid encapsulated filovirus-based particles.... Agent: Schwegman, Lundberg & Woessner, P.A.

20100080824 - Human virus causing severe acute respiratory syndrome (sars) and uses thereof: The present invention relates to an isolated novel virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). The hSARS virus is identified to be morphologically and phylogenetically similar to known member of Coronaviridae. The present invention provides the complete genomic sequence of the hSARS virus. Furthermore, the invention... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100080826 - Process for treatment of amyotrophic lateral sclerosis, rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis and non-viral based cancers: The present invention provides a composition and method for treating diseases associated with demyelination of the nerves, such as ALS, RA, Tremors/Parkinson's Disease, and MS, and for treating non-viral based cancers. By administering measured doses of an immunity-provoking agent and a bacterial antigen activator, patients suffering from ALS, RA, MS,... Agent: Dergosits & Noah LLP

20100080827 - Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents: The present invention relates to the engineering of recombinant influenza viruses that express tumor-associated antigens. Expression of tumor-associated antigens by these viruses can be achieved by engineering specific epitopes into influenza virus proteins, or by engineering viral genes that encode a viral protein and the specific antigen as independent polypeptides.... Agent: Jones Day

20100080828 - Immunogenic sequences: The application relates to nucleic acids which encode enzymes responsible for the production of the O-antigen of Francisella tularensis, and their use as or in the production of vaccines and in diagnosis.... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20100080829 - Lyophilized pharmaceutical compositions and methods of making and using same: The present invention relates to a new lyophilized pharmaceutical composition capable of adhering to oral mucosal tissue for an extended period of time for delivering active pharmaceutical ingredient through the oral mucosal tissue using transmucosal absorption.... Agent: Ross J. Oehler Cephalon, Inc.

20100080830 - Systemic delivery of antiviral agents: The systems and methods disclosed herein provide sustained delivery of a therapeutic agent for treating a patient, e.g., human, to obtain a desired local or systemic physiological or pharmacological effect. Method includes positioning the sustained released drug delivery system at an area wherein release of the agent is desired and... Agent: Ropes & Gray LLP

20100080831 - Composition comprising microcapsules: A liquid composition having a microcapsule, the microcapsule having an aldehyde-containing resin, and one or more formaldehyde scavenger which reacts with formaldehyde to achieve more than about 60% reaction completeness in about 15 minutes time at pH 8 and at about 21° C. A liquid composition having a microcapsule, the... Agent: The Procter & Gamble Company Global Legal Department - Ip

20100080833 - Stable, concentrated and dilute, oil-in-water emulsions, their processes of preparation, and formulation process employing these emulsions: A stable oil-in-water emulsion, a process for the preparing such emulsion, and a formulation process employing the emulsion. The stable oil-in-water emulsion is obtained from an air-in-water preemulsion to which a simple or complex fatty substance is added by moderate mixing, preferably without exerting a shear force. The air-in-water preemulsion... Agent: Young & Thompson

20100080832 - Vesicle-containing composition and production method thereof: To provide a vesicle-containing composition wherein a perfume component is stably incorporated in the vesicle bilayer membrane composed of a silicone surfactant and to provide a simple production method of the vesicle-containing composition wherein a perfume component is stably incorporated. A vesicle-containing composition comprising; (A) a perfume, (B) a silicone... Agent: Rankin, Hill & Clark LLP

20100080834 - Film material with antimicrobial and/or odor-absorbing coating and sanitary article: A film material (1) is disclosed herein, particularly a polyolefin-based film material, coated on one side with a water resoluble resin-containing skin (2), and containing antimicrobial and/or odor-absorbing agents susceptible of being activated by organic liquids and blood liquids, such film material is particularly designed to form a disposable sanitary... Agent: Saltamar Innovations

20100080837 - Compositions and methods for reducing the likelihood of implantation failure or spontaneous abortion in recipients of assisted reproduction: Methods and kits for preventing or reducing the likelihood of implantation failure or spontaneous abortion in a recipient of FET, ICSI, GIFT or ZIFT are provided. The methods include administering into a recipient of FET, ICSI, GIFT or ZIFT in need of such treatment an effective amount of granulocyte colony... Agent: Morris Manning Martin LLP

20100080835 - Implantable device for the delivery of risperidone and methods of use thereof: This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active risperidone at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients... Agent: Foley And Lardner LLP Suite 500

20100080836 - Method and means for culturing osteoblastic cells: A method of culturing human or mammalian mesenchymal stem cells (MSC) or osteoblastic cells to form corresponding cell aggregates evenly distributed in the culturing medium having a reduced content of cells with fibroblast morphology comprises contacting MSC or OC with a water-soluble cellulose derivative over a period of from 1... Agent: Dickstein Shapiro LLP

20100080838 - Reactive surgical implant: Biocompatible implants including a polymer substrate and a reactive component for implant fixation in situ. The reactive component in combination with the substrate creates a reactive implant which bonds to a tissue surface in situ.... Agent: Tyco Healthcare Group Lp

20100080839 - Parenteral formulation: The present invention relates to a kinetic implant comprising (a) biodegradable material comprising opened starch, destructurised starch or a mixture of opened starch and destructurised starch, (b) a biologically or pharmaceutically active substance; and (c) a stabilising component stabilising the biologically or pharmaceutically active substance. The biodegradable material comprises about... Agent: Foley And Lardner LLP Suite 500

20100080840 - Hybrid superporous hydrogel scaffold for cornea regeneration: The present invention features a hybrid superporous hydrogel scaffold for cornea regeneration and a method for producing the same. The hybrid hydrogel is composed of a superporous hydrogen matrix with collagen and cells embedded within the pores of the matrix.... Agent: Licata & Tyrrell P.C.

20100080841 - Fibrous articles with one or more polyelectrolyte layers thereon and methods for making the same: Fibrous articles having fibers coated with one or more polyelectrolyte layers are disclosed. Methods of making and using the fibrous articles are also disclosed.... Agent: 3m Innovative Properties Company

20100080842 - Transdermal extended-delivery donepezil compositions and methods for using the same: A transdermal extended-delivery donepezil active agent composition is provided. Aspects of the compositions of the invention include a donepezil active agent layer that is formulated to provide for multi-day delivery of a therapeutically effective amount of a donepezil active agent to a subject when the composition is topically applied to... Agent: Bozicevic, Field & Francis LLP

20100080845 - Cosmetic methods and compositions for repairing human skin: The present invention relates to methods and compositions for repairing adverse effects of the environment, daily stress, sun exposure, or pre-mature aging on human skin, comprising applying to the skin, prior to a period of bodily rest, a topical composition that contains resveratrol or a derivative thereof and at least... Agent: The Estee Lauder Cos, Inc

20100080844 - Method to enhance an immune response of nucleic acid vaccination: A composition comprising liposomes associated with a nucleic acid operatively encoding an antigenic protein and with an assistor protein, wherein the assistor protein shares at least one epitope with the antigenic protein, and wherein the nucleic acid and said assistor protein are associated with the same liposomes is described. The... Agent: Morrison & Foerster LLP

20100080843 - Natural and synthetic sulfur and selenium analogs and polymer conjugated forms thereof for the modulation of angiogenesis: The present invention relates to inhibiting angiogenesis with sulfur- or selenium-containing compounds, and polymeric forms thereof, in mammals including animals and humans. Sulfur- or selenium-containing compounds, and polymeric forms thereof, can be used alone or in combination with standard therapies to inhibit angiogenesis-mediated disorders. The present invention also relates to... Agent: Heslin Rothenberg Farley & Mesiti PC

20100080846 - Dipyridamole and acetylsalicylic acid formulations and process for preparing same: The present invention provides pharmaceutical formulations of dipyridamole and acetylsalicylic acid, methods of making thereof, and methods of using thereof.... Agent: Kenyon & Kenyon LLP

20100080847 - Medicinal compositions quickly disintegrating in the oral cavity and process for producing the same: This invention relates to a medicinal composition, which rapidly disintegrates when taken in the oral cavity and shows sufficient hardness upon production, distribution and use in usual manner, can be obtained by adding, to a sugar alcohol and/or saccharide, a sugar alcohol and/or saccharide having a lower melting point than... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100080848 - Recombinant lubricin molecules and uses thereof: Recombinant lubricin molecules and uses thereof. Novel recombinant lubricin molecules and their uses as lubricants, anti-adhesive agents and/or intra-articular supplements for, e.g., synovial joints, meniscus, tendon, peritoneum, pericardium and pleura, are provided.... Agent: Fish & Richardson P.C.

20100080849 - Pellets containing a pharmaceutical substance, method for the production thereof and use of the same: The invention relates to pellets containing a pharmaceutical substance with a breaking strength of more than 0.001 newton, method of production thereof and pharmaceutical preparations based on said pellets.... Agent: Hedman & Costigan P.C.

20100080850 - Polypeptide ligands for targeting cartilage and methods of use thereof: Ligands that specifically bind to articular cartilage tissues are disclosed, including uses for targeting therapeutics towards articular cartilage tissue and new materials for articular cartilage. The ligands are effective in vivo to target therapeutic materials to articular cartilage.... Agent: Dardi & Herbert, PLLC

20100080851 - Method of preparing a microcapsule containing unsaturated fatty acids, the microcapsule prepared by the method, and articles containing the microcapsule: g

20100080852 - Phamaceutical composition comprising nanoparticles and casein: A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug and a poorly aqueous soluble non-ionizable polymer, and casein.... Agent: Chernoff, Vilhauer, Mcclung & Stenzel, LLP

20100080853 - Use of spongilla spicules as a dermabrasion device or resurfacing modality: Dermabrasive compositions for skin resurfacing are disclosed. Therapeutic compositions disclosed are derived from Porifera species, specifically sponges, and more specifically fresh water sponges. One disclosed embodiment is derived from Spongilla species and is formulated with pharmaceutically acceptable excipients.... Agent: K&l Gates LLP

20100080854 - Atopic dermatitis inducer: An atopic dermatitis inducer binding to a human own IgE antibody and activating mast cells and basophiles, which includes a purified human secretion fraction, or an antigenic molecule or an antigenic determinant in the purified fraction, and obtained through the following steps of: filtering a human secretion, removing insoluble matters... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100080855 - Hedgehog signaling and cancer stem cells in hematopoietic cell malignancies: The present disclosure relates generally to methods of treating hematopoietic cell malignancy in a subject by administering to the subject a Hedgehog (Hh) pathway antagonist, such as a Smoothen (Smo) antagonist alone or in combination with an ABL-kinase antagonist. Specifically, the disclosure relates to a method of treating hematopoietic cell... Agent: Dla Piper LLP (us)

20100080856 - Method and composition for postoperative wound healing: A composition and a method for administering the composition to a patient in order to accelerate wound healing, particularly postoperative wound healing. The composition, which essentially comprises ornithine α-ketoglutarate, is water-soluble and formulated for oral administration in single-dose packets. The method for using the composition for promoting wound healing includes... Agent: Michael G. Petit

20100080857 - Halogen-containing sanitizing composition: Compositions comprising a mixture of (a) a major amount of solid halogen-containing sanitizer material and (b) a minor amount of calcium oxide modified particulate boric acid, the amount of calcium oxide modified particulate boric acid being sufficient to enable the composition to be classified as a class 1 or class... Agent: Ppg Industries Inc Intellectual Property Dept

20100080858 - Anti-hypothermia composition: An anti-hypothermia composition is provided, in particular an anti-hypothermia composition that prevents hypothermia caused by general anesthesia during surgical operations. The composition prevents hypothermia by preventing the decrease in the biological function of patients and correcting acidosis. Specifically, the anti-hypothermia composition is a preparation containing a bicarbonate ion and provided... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100080859 - Method for attenuating free radical formation resulting from a bodily insult: A method is provided for attenuating free radical formation resulting from a bodily insult. The method includes administering bicarbonate to the body of a subject at a dosage ranging from 1.5 mEq/kg of body weight to 5.0 mEq/kg of body weight within a 24-hour period.... Agent: Schwartz Law Firm, P.C. Southpark Towers

20100080860 - Application of short-chain monocarboxylic acids for crop protection: The present invention relates to the agricultural use of hexanoic acid and monocarboxylic acids with similar chain structure having from 5 to 8 carbon atoms, their derivatives, their salts, and aqueous mixtures thereof containing modified hexoses and/or amines. These compounds are useful as plant growth stimulants, anti-senescents, and as resistance... Agent: Berenbaum Weinshienk PC

20100080862 - Compositions and foods for improving lipid metabolism: It is intended to provide compositions and foods for use in the treatment, prophylaxis, or amelioration of diseases or symptoms which can be treated, prevented or ameliorated by activating PPAR, in particular, insulin resistant diabetes and hyperlipidemia. Namely, medicinal compositions usable in treating, preventing or improving diseases or symptoms which... Agent: Foley And Lardner LLP Suite 500

20100080861 - Cosmetic or dermatological compositions comprising a mixture of essential oils, and its uses thereof, particularly for the care of sensitive or sensitized skin: The present invention relates to cosmetic or dermatological compositions comprising a combination of a cannabis essential oil substantially free of cannabinoids and a helichrysum essential oil, and to their uses thereof, particularly for the care of sensitive or sensitized skin.... Agent: Woodcock Washburn LLP

20100080863 - Dietary composition and method of using the same: According to one aspect of the present invention, a dietary composition is provided. In at least one embodiment, the dietary composition comprises a therapeutically effective amount of an admixture including a caffeine ingredient and a vasodilator ingredient. In at least another embodiment, the admixture further includes an additive selected from... Agent: Brooks Kushman P.C.

20100080864 - Treatment and composition for achieving skin anti-aging benefits by corneum protease activation: Novel methods and compositions for treating aged and environmentally damaged skin are disclosed which provide improvements in the skin's visual appearance, function and clinical/biophysical properties by activating at least one proteolytic enzyme in the skin's stratum corneum. The disclosed treatment methods involve topical application of a novel cosmetic composition containing... Agent: Fulbright & Jaworski L.L.P.